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                            ABSTRACT 
 
 
 
Ryanodine receptors are intracellular Ca
2+
 release channels located in the membrane of 
the Endoplasmatic/Sarcoplasmatic Reticulum. Ryanodine receptor 1 isoform is 
preferentially expressed in skeletal muscle where it is responsible for release of Ca
2+
 
from the SR, an event that leads to muscle contraction. Point mutations in the gene 
encoding ryanodine receptor 1 have been linked to disease such as Malignant 
Hyperthermia, Central core disease and Multi-minicore disease.  
Malignant Hyperthermia is a pharmacogenetic disorder with autosomal dominant 
inheritance and abnormal Ca
2+ 
homeostasis in skeletal muscle in response to triggering 
agents. In susceptible individuals, a malignant hyperthermia crisis may be triggered by 
commonly used halogenated anaesthetics (halothane, isoflurane) or muscle relaxants 
(succhinylcholine). The main symptoms are hypermetabolism and muscle rigidity. 
Without treatment, death would occur in more than 80% of cases. Although a genetic-
chip based diagnostic approach is under development, the invasive in vitro contracture 
test remains the “gold standard” to diagnose this disorder.  
Central core disease is a slowly progressive myopathy characterized by muscle weakness 
and hypotonia. Central core disease is characterized histologically by the presence of 
central cores running along longitudinal axis of the muscle fiber.  
Multi-minicore disease disease is a more severe, rare, autosomal recessive myopathy 
characterized histologically by the presence of multi-minicores in only a small number of 
sarcomeres. So far, no effective therapy has been developed to treat muscle weakness in 
central core disease and multi-minicore disease patients and their diagnosis is difficult on 
the basis of clinical findings alone. Histological examination of muscle tissue in these 
diseases is essential.  
Recent data has shown that ryanodine receptor 1 is also expressed in some areas of the 
central nervous system as well as in cells of the immune system, specifically B-
lymphocytes and dendritic cells.  
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The first part of my thesis focuses on the role of the ryanodine receptor 1 in dendritic cell. 
We first show that both immature and mature in vitro derived dendritic cells as well as 
circulating plasmocytoid cells express the ryanodine receptor 1 Ca
2+
 release channel 
within the endoplasmatic reticulum. Pharmacological activation of the ryanodine receptor 
1 leads to the rapid release of Ca
2+
 from intracellular stores, and in the presence of sub-
optimal concentrations of microbial stimuli, provides synergistic signals resulting in 
dendritic cell maturation and stimulation of T cell function. Furthermore, we were 
interested in unravelling more direct roles of this receptor in dendritic cells function. 
Interestingly, ryanodine receptor 1 activation in dendritic cells causes a very rapid 
increase in surface expression of major histocompatibility complex II molecules. In order 
to dissect the physiological route of ryanodine receptor 1 activation in vivo we 
hypothesized that a possible functional partner of ryanodine receptor 1 in dendritic cells 
could be, an L-type Ca
2+
 channel. We were able to show that human dendritic cells 
express the cardiac isoform of the L-type Ca
2+
 channel, which acts as a ryanodine 
receptor 1 functional partner on the plasma membrane of dendritic cells. We show that 
depolarization of dendritic cells by the addition of potassium chloride activates L-type 
Ca
2+ 
channels initiating Ca
2+ 
influx and activation of Ca
2+ 
release via ryanodine receptor 1 
and that this process could be prevented by nifedipine or ryanodine. Physiologically 
potassium could be released from dying cells within an inflamed tissue or from T- cells 
into immunological synapse during dendritic cell T-cell engagement and these events 
could be possible routes for activation of L-type Ca
2+
 channel- ryanodine receptor 1 
signalling in dendritic cells in vivo. Thus, in vivo, activation of the ryanodine receptor 1 
signalling cascade may be important during the early stages of infection, providing the 
immune system with rapid mechanisms to initiate an early response, facilitating the 
presentation of antigens to T cells. 
While continuing our investigation on Ca
2+
 homeostasis in dendritic cells we noticed that 
spontaneous Ca
2+
 oscillations occur in immature dendritic cells but not in dendritic cells 
stimulated to undergo maturation with lipopolysaccharide or other toll like-receptor 
agonists. We investigated the mechanism and role of spontaneous Ca
2+
 oscillations in 
immature dendritic cells and found that they are mediated by the inositol-1,4,5-
trisphosphate receptor since they were blocked by pre-treatment of cells with the inositol-
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1,4,5-trisphosphate receptor antagonist Xestospongin C and 2-Aminoethoxydiphenyl 
borate. A component of the Ca
2+
 signal is also due to influx from the extracellular 
environment. As to the biological function of these high frequency oscillations, our 
results indicate that they are associated with the translocation of a Ca
2+
 dependent 
transcription factor (nuclear factor of activated T-cells) into the nucleus of immature 
dendritic cells. In fact, once the Ca
2+
 oscillations are blocked with the 2-
aminoethoxydiphenyl borate or by treating cells with lipopolysaccharide, nuclear factor 
of activated T-cells remains cytoplasmic. 
The results from the first part of my thesis provide novel insights into the physiology of 
dendritic cells, role of ryanodine receptor 1 signaling and Ca
2+ 
as an important second 
messenger in these cells. 
The second aim of my thesis deals with functional properties of ryanodine receptor 1 
carrying mutations linked to neuromuscular disorders, which is important from diagnostic 
point of view but also to understand the basic pathophysiological mechanism leading to 
these different diseases. 
Since functional ryanodine receptors 1 are expressed in B-lymphocytes we investigated 
Ca
2+
 homeostasis in B-lymphocytes transformed with Epstein Barr virus from patients 
carrying the mutation linked to malignant hyperthermia and healthy donors. 
In the first study from the Swiss population we investigated four novel mutations found 
in malignant hyperthermia susceptible pedigrees: (p.D544Y, p.R2336H, p.E2404K and 
p.D2730G). We found that the resting Ca
2+
 levels were significantly higher in cells from 
all four mutations bearing individuals compared to controls. These four mutations were 
also found to significantly affect either 4-chloro-m-cresol or caffeine dose response 
curves suggesting higher sensitivity of ryanodine receptor 1 to pharmacological 
activation in patients carrying these mutations. 
In the second study we examined patients from the Swedish population carrying five 
different novel mutations (p.E1058K, p.R1679H, p.H382N, p.K1393R and p.R2508G). 
The first 4 patients had serious malignant hyperthermia clinical reactions and thereafter 
have tested by the in vitro contracture test and classified as malignant hyperthermia 
susceptible; the patient with the fifth mutation, p.Arg2508Gly, had been diagnosed as a 
central core disease. In this study as well functional studies were performed on Epstein 
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Barr virus transformed B-lymphocytes from patients carrying mutations and healthy 
donors. Our results from the Swedish population suggest that ryanodine receptor 1 
mutations also lead to abnormal Ca
2+
 homeostasis. Results from these and other studies 
support the use of Epstein Barr virus transformed -B-lymphocytes as an alternative, non-
invasive, protocol for the diagnosis and the functional proof that a mutation in the 
ryanodine receptor causes alterations in Ca
2+
 homeostasis. This is a pre-requisite for the 
molecular diagnosis of malignant hyperthermia. These results also provide new concepts 
for the treatment of muscular pathologies involving mutations in ryanodine receptor 1. 
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             CHAPTER 1: INTRODUCTION 
 
 
 
I. Dendritic cells and their role in innate immunity 
 
I.1 Initiate immunity and pattern recognition; general 
introduction 
 
Vertebrates display two main kinds of immunity, innate immunity and adaptive 
immunity. The first line and evolutionary ancient part of host defence is innate immunity. 
On the other hand the evolutionary younger adaptive immune response that comes in the 
second stage of host defence provides specific recognition of foreign antigens and allows 
generation of “immunological memory”, which in a subsequent encounter with the same 
antigen, generates a more efficient immune response.  
Many cells participate in innate immune response such as macrophages, dendritic cells 
(DCs), mast cells, neutrophils, eosinophils, and NK cells. These cells express pattern-
recognition receptors, which are germ line encoded and recognize conserved repetitive 
antigenic structures called PAMPs (pathogen-associated molecular patterns) (Janeway 
and Medzhitov, 2002). 
  
The innate immune response recognizes foreign antigens by way of a variety of pattern 
recognition receptors (PRR). PRR are expressed on the cells surface, in intracellular 
compartments or secreted into the bloodstream and tissue fluids. The principal functions 
of PRR include opsonisation, activation of the complement and coagulation cascades, 
phagocytosis, activation of proinflammatory signalling pathways, and induction of 
apoptosis. Antigen presenting cells also use pattern recognition receptors to become 
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activated and efficiently present antigens to antigen specific lymphocytes and 
successfully connect innate and adaptive immune responses. Janeway proposed that 
antigen-presenting cells of the innate immune system perform their own self-nonself 
discrimination. This is based on their ability to innately recognize the signatures of 
bacterial presence, through these receptors. This hypothesis of contribution of innate 
immunity to self-nonself distinction is still not completely elaborated and does not 
explain for example the lack of response to symbiotic bacteria of gut flora that also 
posses PAMPs. Contrary to this hypothesis Matzinger introduced the “danger theory”. 
This theory suggests that the immune system is controlled by the detection of damage to 
the body, not detection of antigen or bacterial products. Matzinger proposed the existence 
of endogenous mediators produced by damaged or stressed cells, which activate the 
immune system through cells of the innate immune system. On the other hand in the 
absence of “danger signals” the cells of the innate immune system can actively suppress 
an immune response. This dynamic process is known as the mechanism of peripheral 
tolerance (Germain, 2004; Janeway and Medzhitov, 2002; Matzinger, 1994; Matzinger, 
2002). 
The Toll-like receptor (TLR) family is the best characterized class of PRRs in 
mammalian species. Most mammalian species express about 10 to 15 different TLRs 
which are encoded by a yet to be defined number of genes. Different TLRs recognize 
different PAMPs. Lipopolysaharide (LPS) is detected by TLR4 and mice with a targeted 
deletion of TLR4 gene are unresponsive to LPS (Hoshino et al., 1999). Ligands for TLR2 
constitute a large list and include lipoproteins and lipoteichoic acids. TLR5 recognize 
flagellin, the protein subunits that make up bacterial flagella (Hayashi et al., 2001). The 
unmethylated CpG DNA of bacteria and viruses are detected by TLR9, double stranded 
RNA by TLR3 and single stranded viral RNA detected by TLR7 (Diebold et al., 2004; 
Heil et al., 2004; Lund et al., 2004)  
Innate recognition of PAMPs trough TLRs initiates an inflammatory response 
characterized by the recruitment of cells to the sites of infection to induced killing of 
pathogens and to stop their spread (Iwasaki and Medzhitov, 2004). Upon recognition of 
their ligands, TLRs induced the expression of many different host defence genes. These 
include inflammatory cytokines and chemokynes, antimicrobial peptides, costimulatory 
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molecules, MHC molecules and other effectors necessary for successful activation of 
immune response and finally host defence. 
Different TLRs direct different types of adaptive immune responses and probably 
activate different intracellular signalling pathways. The canonical signalling pathway for 
TLRs following PAMP ligation involves the interaction of the adaptor molecule MyD88, 
with TLR. MyD88 has both a TIR (Toll/Interleukin-1 receptor) domain and death 
domain, and the recruitment of MyD88 to a TLR occurs via a TIR-TIR homotypic 
interaction. The death domain of MyD88 then binds to the death domain of a 
serine/threonine kinase, usually interleukin-1-receptor-associated kinase (IRAK), and the 
signal is propagated via a specific member of the TNF-receptor-associated factor (TRAF) 
family, TRAF6, ultimately leading to the activation of NF-kB mitogen activated protein 
(MAP) kinases, and the transcription of genes connected with activation of the immune 
response. There are other signalling pathways downstream of TLRs that do not require 
IRAK-4. Activation of TIRF pathway, for example, leads to the production of antiviral 
gene products via the transcription factor, IRF3, suggesting signalling specificity that 
may be relevant to the type of infection (Kopp and Medzhitov, 2003). In order to protect 
the host against a highly diverse microbial world the innate immune system is very 
complex and has diversities to recognize through different TLRs the different products of 
microbial infection. DCs are the key cell type that couples TLR-mediated innate immune 
recognition to the initiation of the specific immune response by activating T- and B-
lymphocytes.  
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 I.2 Dendritic cells and antigen sampling and processing 
 
 
 
 
Figure 1-1: Two Dendritic cells. The nucleus is shown in green while the cell body is in 
red. At certain development stages dendritic cells grow branched projections, the 
dendrites, which give the cell its name.  
http://www.wehi.edu.au/faculty_members/research_projects/what_dendritic_cells_do) 
 
DCs are the most potent, professional, antigen presenting cells (Fig 1-1). They play an 
essential role in connecting innate and adaptive immune responses. Due to their 
efficiency in antigen-presentation and their unique migration behaviour, dendritic cells 
are the cells responsible for the activation of naive T-lymphocytes. 
DCs were first discovered by Paul Langerhans in 1868 during experiments to characterize 
the cellular constituents of skin (Jolles, 2002; Kimber et al., 2009). The term “dendritic” 
cell was coined by Steiman and Cohn in 1973 (Steinman and Cohn, 1973).  
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In general DCs exist in two forms immature DCs (iDCs) and mature DCs (mDCs). 
Immature DCs reside in the peripheral tissues, where they actively and constantly sample 
their environment by endocytosis for the presence of foreign antigens. After capturing 
antigens and being stimulated by cytokines, bacterial compounds and “danger” signals, 
they become activated and migrate to lymphoid tissues. During migration, DCs undergo 
profound phenotypical changes and convert into professional antigen-presenting cells, the 
so-called mDC. This maturation process is followed by downregulation of endocytic 
activity, upregulation of co-stimulatory molecules and increase of surface expression of 
major histocompatibility complex molecules that are involved in antigen presentation to 
T cells (Banchereau and Steinman, 1998; Lanzavecchia, 1996; Trombetta and Mellman, 
2005). 
 
 
 
Ag-sampling: 
 
 
 
Immature DCs have the capacity to internalize a broad range of antigens using specific 
and non-specific uptake modes.  
There are three general types of endocytic routs that can be distinguished in antigen 
presenting cells (Fig 1-2):  
 
 
 
1.receptor mediated endocytosis  
2.macropinocytosis 
3.phagocytosis 
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Figure 1-2: Endocytosis. (1) phagocytosis is the process by which cells ingest large 
objects, such as bacteria, or the remnants of cells, which have undergone apoptosis. The 
membrane invaginates enclosing the wanted particles in a pocket, then engulfs the object 
by pinching it off, and the object is sealed off into a large vacuole known as a 
phagosome. (2) pinocytosis is the process responsible for the uptake of soluble and single 
molecules such as proteins. (3) receptor mediated endocytosis is a more specific active 
event where the cytoplasm membrane folds inward to form coated pits. In this case, 
proteins lock into receptors/ ligands in the cell‟s plasma membrane and than get engulfed. 
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1.Receptor mediated endocytosis 
 
Receptor mediated endocytosis allows the efficient internalization of antigens, which 
enables the APCs to present antigens also in the case of their low concentration 
(Lanzavecchia, 1990). 
Antigen presenting cells express a broad range of surface receptors that mediate 
endocytosis including: C-type lectin receptors, which function as PRRs, like the 
macrophage mannose receptor and DEC205 expressed on DCs. In addition Fc receptors 
can also mediate endocytosis and provide delivery of captured antigens to the 
intracellular compartment of APCs. There is one important difference between mannose 
receptors and FcR in terms of recycling, FcR are degraded together with their cargo 
whereas mannose receptors release their ligand at endosomal pH and get recycled, thus 
allowing uptake and accumulation of many ligands by a small number of receptors 
(Fig.1-2) (Banchereau and Steinman, 1998; Jiang et al., 1995; Sallusto and Lanzavecchia, 
1994; Sallusto et al., 1995). 
 
 
2.Macropinocytosis 
 
 
Macropinocytosis is a cytoskeleton dependent type of fluid phase endocytosis mediated 
by membrane ruffling and the formation of large vesicles (1-3 µm). In iDCs this process 
is constitutive and enables a single cell to take up a very large volume of fluid (half of the 
cell‟s volume per hour) on the other hand in macrophages and epithelial cells 
macropinocytosis is stimulated by growth factors (Lanzavecchia, 1996; Sallusto et al., 
1995). Macropinosome formation starts at the cell periphery by extension of a large 
planar membrane ruffle that folds back to form the vesicle (Araki et al., 1996). 
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3.Phagocytosis 
 
Phagocytosis is the process by which cells ingest large particles, such as apoptotic cells, 
bacteria, yeasts or parasites. The membrane invaginates enclosing the ingested particle in 
a pocket, then engulfs the object by pinching it off, and the object is sealed off into a 
large vacuole known as a phagosome. Phagocytosis serves uptake of antigens in the 
process of antigen sampling but more importantly represents an innate host defence 
mechanism. Besides killing of microbes the phagosomal contents represent a major 
source of exogenous antigens. A number of the endocytic receptors that can recognize 
ligands free in solution also contribute to the phagocytic process by recognizing their 
ligands on the surface of microbes. These include FcγRs, complement receptors, and a 
variety of lectins (Fig.1-2) (Trombetta and Mellman, 2005).  
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Antigen processing: 
 
Internalized antigens need to be further processed to generate peptide ligands for surface 
presentation on MHC molecules. There are two pathways for antigen processing (Fig.1-
3): 
 
 
 
 
Figure 1-3: Ag-processing pathways. MHC class I molecules present peptides that are 
derived from proteins degraded mainly in the cytosol, whereas MHC class II molecules 
present exogenous antigens generated by proteolytic degradation in endosomal 
compartments and also endogenous components, such as plasma membrane proteins, 
components of the endocytic pathway and cytosolic proteins that access the endosomes 
by autophagy. Cross-presentation pathway represents possibility that exogenous antigens 
get delivered to MHC class I pathway. (José A. Villadangos & Petra Schnorrer, Nature 
Reviews Immunology 7, 543-555 (July 2007). 
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1. The MHC class I pathway 
 
 
MHC class I molecules are found on every nucleated cell of the body (and thus not on red 
blood cells and platelets). They are heterodimers consisting of a membrane-spanning 
heavy chain, which is non-covalently associated with a ß-chain, called microglobulin. 
The peptides bind in a cleft generated by the folding of alpha 1 and alpha 2 domains of 
the heavy chain (Bjorkman et al., 1987). MHC I ligands are derived from endogenous 
cytosolic proteins. Proteasome, a cytosolic multy-enzyme complex (Baumeister et al., 
1998), plays a critical role in cleaving the ubiquitinated proteins into peptides of 10-20 aa 
length. Peptides presented on MHC class I molecules are recognized by CD8
+
 T-cells. 
  
 
 
2. The MHC class II pathway 
 
 
MHC class II molecules are normally expressed only on professional APCs 
(macrophages, DCs and B cells). They are composed of two transmembrane 
glycoproteins, the alpha and beta chain. MHC-II ligands are exogenous, encountering 
MHC-II molecules following endocytosis. For proteolitic processing proteins are 
transported into the acidic lysosomal compartment where they are cleaved into shorter 
peptides by proteases, which include cystein proteases, the cathepsins as well as 
asparaginyl endopeptidase (Chapman, 1998; Manoury et al., 1998). MHC class II loading 
takes place in a specialized endocytic compartment called MHC class II compartment 
(MIIC) and once loaded the peptide –MHC class II complexes are transported to the 
surface of APC where they are recognized by CD4
+
T cells. 
 
, MHC-I can present peptides derived from exogenous antigens, and MHC-II can present 
intracellular antigens that do not come from the extracellular space; these events are 
called “cross-presentation.”  (Bevan, 1976; Trombetta and Mellman, 2005). 
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Process of DCs maturation: 
 
 
One of the most important yet at the same time most complex processes concerning DCs 
is maturation. It is clear that maturation of DCs is crucial for the initiation of immunity 
and the critical link between innate and many forms of adaptive immunity. Immature 
DCs begin to mature during the antigen collection stage immediately after receiving 
adequate stimuli, such as microbial and inflammatory products. In vitro DC maturation 
can be stimulated by TLR ligands such as LPS. Different cytokines such as IL1, GM-CSF 
and TNF-alpha are also responsible for DCs maturation but other factors recognized as 
“danger” signals such as different factors released from dead cells as well. Upon 
activation DCs travel to lymphoid tissues such as spleen and lymph nodes. There, DCs 
may complete their maturation process under the influence of signals (e.g. CD40 ligand) 
received from T cells to which they present antigens. During activation and migration 
DCs drastically change their phenotype. First there is induction in surface expression of 
MHC-II, co-stimulatory and MHC-I molecules. Activation of TLRs induces the 
expression of selectin, and chemokine receptor genes that regulate cell migration to the 
sites of inflammation (Huang et al., 2001). Secondly there are also drastic morphological 
changes of iDCs; they develop extensions and membrane folds that give them increased 
surface area and this further increases the probability of binding to T cells (Mosmann and 
Livingstone, 2004). An increase in surface area makes the mDC more suitable for antigen 
presentation rather than collection, maximizing the chance of binding with a T-cell 
receptive to the specific structures of the presented antigen. Function versus phenotype of 
mDCs is further complicated by the fact that different maturation stimuli may produce 
qualitatively different DCs that can produce distinct ways of immunstimulation, 
selectively polarizing Th1 versus Th2 responses (Lanzavecchia and Sallusto, 2001). 
Furthermore certain types of stimuli responsible for production of DCs with 
“intermediate” phenotypes (high MHC-II, low or moderate CD86) may produce 
tolerogenic effect (Inaba et al., 1997; Steinman et al., 1997). 
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Different DCs subsets: 
 
 
In both humans and mouse, distinct DCs subsets occupy special niches defined by their 
anatomical location and their ability to respond to certain types of pathogens (Iwasaki 
and Medzhitov, 2004). In humans two main DCs subsets have been identified: CD11c+ 
myeloid DCs (MDC) and CD11c- CD123+ plasmacytoid cells (PDC). MDC include 
Langerhans cells, dermal DCs and interstitial DCs, and populations widely distributed 
throughout the body. PDC are primarily located in the blood and secondary lymphoid 
organs, but they can be recruited to sites of inflammation. Besides location, the difference 
between MDC and PDC is manifested by cytokine secretion and TLR expression pattern. 
MDC secrete high levels of interleukin-12 (IL-12), whereas PDC are thought to play an 
important role in the innate immune response to different viruses by producing interferon 
alpha (IFNα) (Asselin-Paturel and Trinchieri, 2005; Colonna et al., 2004). 
In vitro monocyte derived dendritic cells, produced by culturing monocytes with 
granulocyte-macrophage colony-stimulating factor (GM-SCF) and interleukin 4 (IL4), 
are phenotypically equivalent to iDCs residing in peripheral tissues. They can undergo 
maturation when stimulated by agonist such as LPS and reach the mature stage exhibiting 
all phenotypic characteristics of mDCs found in secondary lymphoid tissues. 
Research on DCs was enhanced since the discovery that DCs could be produce in-vitro 
from monocytes in the presence of cytokines such as IL4 and GM-CSF (Sallusto et al., 
1995). 
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I.3 Formation of immunological synapse and T cell activation: 
 
A critical event in the initiation of the adaptive immune response is the activation of T 
lymphocytes. This is mediated by the interaction of T cell antigen receptors (TCRs) with 
their ligands, major histocompatibility molecule-peptide complexes (MHC-peptide). 
Signaling via the TCR results in the intracellular activation of transcription factors such 
as NFκB, AP-1 and NF-AT (Cantrell, 1996). Together these factors promote transcription 
and secretion of the T-cell growth factor IL-2 and other cytokines, leading to T-cell 
proliferation, differentiation and induction of its effector functions. 
The signals generated via TCR are not sufficient for full T cell activation. Some other 
signals are also triggered by activation of accessory molecules present on the surface of 
the antigen-presenting cells (APC). Efficient T cell activation and initiation of immune 
response require TCR engagement and signalling for many minutes or hours. To fulfil 
this requirement T cells and APCs form special structures at the contact site, the 
immunological synapse, which allows them to be in close contact for a long enough 
period of time (fig.1-4).  In the center of the synapse, the so-called centralized 
supramolecular activation cluster (cSMAC), TCR/CD3 complex and CD28 accumulate. 
A second group of molecules including the adhesion receptor LFA-1 which interacts with 
ICAM-1 on the opposing APC form a ring around the cSMAC, termed peripheral SMAC 
(Bromley et al., 2001). The interaction between T cells and DCs in immunological 
synapses is a dialog rather than a monolog in which DCs also respond to signals from T 
cells through different surface molecules but also via release of cytokines and other 
molecules from activated T cells. During this communication DCs conclude their 
maturation process and undergo further changes, which make antigen presentation even 
more efficient.  
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Figure 1-4: Immunological synapse formed between DC and T cell. The key 
interaction is driven by the recognition of antigenic peptide–major histocompatibility 
complex (MHC) dimers by T cells bearing T-cell receptors (TCRs) with high affinity for 
the complex. However, this signal alone is not sufficient for initiation and amplification 
of specific T-cell responses. Co-stimulatory signals (that is, CD28 recognition of 
CD80/CD86) and the production of pro-inflammatory cytokines, provide the 'infectious 
context' by which the full activation of antigen-specific T cells is achieved. 
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II. Calcium homeostasis and the role of calcium as a 
second messenger in muscle and immune cells 
 
 
Calcium was established very early on as a possible second messenger when Ringer 
demonstrated for the first time its importance for contraction of the heart (Ringer, 1883). 
Changes in the intracellular free Ca
2+
 concentration regulate a variety of functions in 
eukaryotic cells from muscle contraction and neuronal excitability to gene expression, 
cell proliferation, secretion, metabolism and apoptosis (Berridge et al., 1998). 
Genome-wide screens have identified over 300 different genes (Feske et al., 2001; 
Lanahan and Worley, 1998) and approximately 30 transcription factors that are regulated 
by the concentration of intracellular calcium. The processes regulated by changes in Ca
2+
 
concentration are within extremely different time frames, from microseconds 
(exocytosis), minutes and hours (gene expression) to months and years (memory 
processes) (Petersen et al., 2005). 
 
Unlike many others second messenger molecules calcium cannot be metabolized so cells 
are enforced to create specific calcium stores and tightly regulate intracellular levels of 
Ca
2+
 through numerous binding and specialized extrusion proteins (Clapham, 1995). 
Under resting conditions, eukaryotic cells maintain the cytoplasmatic calcium 
concentration at very low levels (about 100nM) in comparison with the extracellular 
concentration which is 1-2mM, but upon stimulation its concentration raises dramatically 
(more than 1000-fold) in just a few milliseconds and both the amplitude and the 
frequency of the Ca
2+
 signal can be sensed by specific proteins allowing a cell to respond 
appropriately to specific signals. One of the most important questions in Ca
2+
 signalling 
is, how cells interpret these diverse Ca
2+
 signals and convert them into specific responses. 
To efficiently utilize Ca
2+
 as second messenger, cells are equipped with an essential 
toolbox kit composed of a variety of proteins that allow Ca
2+
 ions to flow into the 
cytoplasm and be removed from the cytoplasm, proteins that store/buffer Ca
2+
 and 
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proteins acting as a sensor after Ca
2+
 binding as well as Ca
2+
 regulated enzyme. Calcium 
is stored in special compartments, organelles (or subregions of organelles) inside of cell 
and at the same time these stores represent Ca
2+
 reservoirs that could be used when 
necessary. These cellular compartments are: endoplasmatic/sarcoplasmatic reticulum 
(ER/SR), the Golgy apparatus (Hu et al., 2000), mitochondria, secretory granules, and the 
nuclear envelope. In order to keep the free Ca
2+
 concentration low in the cytoplasm 
during the resting phase, cells use also different buffer proteins, exchangers and pumps. 
Since Ca
2+
 concentration in the cell is not static, but, on the contrary dynamic, we can 
divide Ca
2+
 homeostasis into several functional units: 
1. Signalling that is triggered by a stimulus that generates various Ca
2+
 mobilizing 
signals. 
2.”On” phase that feed Ca2+ into the cytoplasm. 
3. Effector phase where Ca
2+
 binds to numerous Ca
2+
 sensors, which produce specific 
cellular effects. 
4. “Off” phase where cells using different tools such as pumps, exchangers, or organelles 
(such as mitochondria) remove Ca
2+
 from the cytoplasm to restore the resting state 
(Berridge et al., 2000). 
During the “on” phase previously received stimuli induce both entry of external Ca2+ and 
formation of second messengers that lead to the release of Ca
2+
 from intracellular stores. 
 
 
II.1 Ca2+ entry mechanisms 
 
Entry of Ca
2+
 is driven by the presence of a large electrochemical gradient across the 
plasma membrane. 
Two different categories of plasma membrane Ca
2+
 channels, which allow Ca
2+
 entry, can 
be distinguished: voltage-operated Ca
2+
 channels (VOCs) and voltage independent 
channels. Thus, plasma membranes Ca
2+
 channels can be activated by voltage or 
extracellular and intracellular signals and stretch (Chakrabarti and Chakrabarti, 2006). 
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II.1.1 Voltage Gated Ca
2+
 cannels 
 
 
In excitable cells, such neurons and muscle cells Ca
2+
 entry mostly occurs through 
voltage-operated channels (VOCs). These mediate calcium influx in response to 
membrane depolarization and regulate intracellular processes such as muscle contraction, 
secretion, neurotransmission, and gene expression. The Ca2+ channels that have been 
characterized biochemically are complex proteins composed of four or five distinct 
subunits, which are encoded by multiple genes. The α1 subunit of 190–250 kDa is the 
largest subunit, and it encompasses the conduction pore, the voltage sensor and gating 
apparatus, and the known sites of channel regulation by second messengers, drugs, and 
toxins. Mammalian α1 subunits are encoded by at least ten distinct genes. Six families of 
VOCs have been identified L-, P-, Q-, N-, R-, T-type, however as new Ca
2+
 channel 
genes are cloned, it seems that this alphabetical nomenclatures is too simple and that Ca
2+
 
channels should be renamed using the chemical symbol of the principal permeating ion 
(Ca) with the principal physiological regulator (voltage) indicated as a subscript (CaV). 
The numerical identifier would correspond to the CaV channel α1 subunit gene family (1 
through 3 at present) and the order of discovery of the α1 subunit within that family (1 
through m). According to this nomenclature, the CaV1 family (CaV1.1 through CaV1.4) 
includes channels containing α1S, α1C, α1D, and α1F, which mediate L-type Ca2+ 
currents. The CaV2 family (CaV2.1 through CaV2.3) includes channels containing α1A, 
α1B, and α1E, which mediate P/Q-type, N-type, and R-type Ca2+ currents, respectively. 
The CaV3 family (CaV3.1 through CaV3.3) includes channels containing α1G, α1H, and 
α1I, which mediate T-type Ca2+ currents (Fig.1-5) (Ertel et al., 2000). 
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Figure 1-5: Ca
2+
 channel structure and nomenclature. These are formed as a complex 
of several different subunits: α1, α2δ, β1-4, and γ. The α1 subunit forms the ion- 
conducting pore while the associated subunits have several functions including 
modulation of gating. α1 subunit possesses main characteristics of the channel and is 
encoded by CACNA1 gene family consisting of 10 genes represented by nomenclature in 
this figure. 
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L-Type calcium cannels: 
 
 
L-type Ca
2+
 currents require a strong depolarization for activation, are long lasting, and 
are blocked by organic L-type Ca
2+
 channel antagonists, including dihydropyridines, 
phenylalkylamines, and benzodiazepines. These cannels are called also dihydropyridine 
receptors (DHPRs) according to one of their antagonists. L-type Ca2+ channels are 
composed of a α1 subunit (Cav), which spans the membrane and contains the pore 
region, and four additional subunits β1, α2, γ, and δ. There are at least four genes 
encoding α1 subunits (Cav1.1-Cav1.4), and all mediate L-type Ca2+ currents, although 
their products are preferentially expressed in different tissues/subcellular locations 
(Catterall, 2000; Catterall et al., 2005).  
Cav1.1 is localized in the transverse tubules and is involved in skeletal muscle excitation-
contraction coupling; Cav1.2 is expressed in cardiac and smooth muscle cells, endocrine 
cells, and pancreatic β cells as well as in neuronal cell bodies and is involved in cardiac 
excitation-contraction coupling, hormone release, transcription regulation, and synaptic 
integration. Cav1.3 and Cav1.4 have a more widespread distribution, including neuronal 
cell bodies, dendrites, pancreatic β cells, cochlear hair cells, adrenal gland, and mast cells 
where they are involved in hormone/neurotransmitter release, regulation of transcription, 
and synaptic regulation (Catterall et al., 2005). 
Recently, new form of store operated Ca
2+
 entry in muscle cells called excitation coupled 
Ca
2+
 entry (ECCE) has been demonstrated. Physiological stimuli that do not produce 
substantial depletion of stores, rapidly activate Ca
2+
 entry trough channels having 
properties corresponding to those of store operated Ca
2+
 cannels (Cherednichenko et al., 
2004). This Ca
2+
 influx channel has pharmacological properties identical to those of the 
CAV1.1 (Bannister et al., 2009). 
 
 
 
 
 27 
 II.1.2 Store-operated channels (SOCs)  
 
 
There are many others Ca
2+
 entry channels that open in response to different external 
signals, such as receptor-operated channels (ROCs), second messenger operated channels 
(SMOCs) or store-operated channels (SOCs). In this section, only store-operated 
channels will be described. 
SOCs are Ca
2+
 permeable channels located on the plasma membrane that are activated in 
response to depletion of intracellular Ca
2+
 stores. Giving rise to the phenomenon of store 
operated calcium entry also known as capacitative Ca
2+
 entry. The concept of store-
operated Ca
2+
 entry was proposed in 1986 by Putney (Putney, 1986). The idea originated 
from a series of experiments in parotid acinar cells aimed at investigating the relationship 
between Ca
2+
 release from internal stores, Ca
2+
 entry, and store refilling. On the basis of 
this work, and a few eclectic observations in the literature, it was suggested that the 
amount of Ca
2+
 in the stores controlled the extent of Ca
2+
 influx in nonexcitable cells. 
When stores are full, Ca
2+
 influx did not occur but as the stores emptied, Ca
2+
 entry 
developed. The first time SOC currents were characterized, was in mast cells where they 
were identified as the Ca
2+
 release-activated Ca
2+
(CRAC) current (Hoth and Penner, 
1992). This current had been previously identified by Lewis and Cahalan in T-cells, but 
at the time it was not recognized as a store operated current (Lewis and Cahalan, 1989). 
The existence of SOC current in T cells was confirmed later (Zweifach and Lewis, 1993). 
Other groups demonstrated the existence of capacitative Ca
2+
 entry in excitable cells, first 
in skeletal myotubes cultured in vitro (Hopf et al., 1996) and later in adult skeletal muscle 
fibers (Kurebayashi and Ogawa, 2001). 
However, the molecular mechanism remained undefined until recently. The key 
breakthroughs came from RNAi screening experiments, which first identified STIM 
proteins as the molecular link from ER Ca
2+
 store depletion to Store Operated Calcium 
Entry (SOCE) and CRAC channel activation in the plasma membrane, and then identified 
Orai proteins that comprise the CRAC channel pore-forming subunit.  
Almost simultaneously, two laboratories discovered the role of STIM1 (initially 
Drosophila Stim) in capacitative Ca
2+
 entry by use of limited RNAi screens for 
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modulators of thapsigargin-activated Ca
2+
 entry in Drosophila S2 cells (Roos et al., 2005) 
and in mammalian HeLa cells (Liou et al., 2005). Drosophila has a single STIM gene, 
whereas mammals have two, STIM1 and STIM2. STIM1 and STIM2 are both single-pass 
transmembrane proteins with paired N-terminal EF-hands located in the ER lumen and 
protein interaction domains located both in the ER lumen and in the cytoplasm 
(Stathopulos et al., 2008). Both STIM1 and STIM2 are functional ER Ca
2+
 sensors that 
can trigger store-operated Ca
2+
 entry through CRAC channels in activated (store-
depleted) cells (Fig.1-6). STIM1 activates SOCE upon Ca
2+
 store depletion, whereas its 
homolog STIM2 seems to be more implicated in the control of basal cytosolic and ER 
Ca
2+
 levels, presumably because the affinity of STIM2 EF-hands for Ca
2+
 is two-fold 
lower than that of STIM1 EF-hands (Brandman et al., 2007; Oh-Hora et al., 2008). 
Orai1 was first reported (and named) by Feske et al. through a combination of gene 
mapping in a family with an immunodeficiency attributed to loss of CRAC and a whole-
genome screen of Drosophila S2 cells (Feske et al., 2006). 
Orai1 has since been demonstrated to be the pore subunit of the prototypic store-operated 
CRAC channel of blood cells (Prakriya et al., 2006; Vig et al., 2006; Yeromin et al., 
2006). Co-expression of STIM1 and Orai1 generates robust CRAC currents in a number 
of expression systems (Peinelt et al., 2006). 
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Figure 1-6: Local activation of CRAC channels by STIM1 at ER–plasma membrane  
junctions. Store depletion causes STIM1 to accumulate in pre-existing and newly formed 
regions of ER, whereas Orai1 accumulates in apposed regions of the plasma membrane. 
CRAC channels open only in the close vicinity of the STIM1 puncta. The convergence of 
STIM1 and Orai1 at ER–plasma membrane junctions creates the elementary unit of 
SOCE. (Luik R. M. et.al. J. Cell Biol. 2008:174:815-825) 
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II.2 Ca
2+
 release from internal stores 
 
Aside the Ca
2+
 entry pathways, the main source of Ca
2+
 utilized for signalling, are the 
internal stores that are located primarily in the ER/SR, of which Ins(1,4,5)P3Rs and RyRs 
are the main intracellular Ca
2+
 release channels. These two channels are sensitive to Ca
2+
 
and this phenomenon of Ca
2+
 induces Ca
2+
 release (CICR) is thought to contribute to the 
rapid rise of Ca
2+
 levels during the “on” reaction. In addition to Ca2+, these channels are 
regulated by a variety of factors that operate on both the luminal and cytosolic surface of 
the channels. 
In the case of Ins(1,4,5)P3Rs, the primary agonists are Ins(1,4,5)P3 and Ca
2+
. The binding 
of Ins(1,4,5)P3 increases the sensitivity of the receptor to Ca
2+
, which has a biphasic 
action, it activates at low concentrations, but inhibits at high concentrations. This Ca
2+
 
regulation is mediated by the direct action of Ca
2+
 on the receptor as well as indirectly 
through calmodulin (CaM) (Nadif Kasri et al., 2002; Taylor and Laude, 2002). A variety 
of ligands activate receptors coupled to phospholipase C (PLC) to generate Ins(1,4,5)P3 
which in turn releases Ca
2+
 from the internal stores. There are several PLC isoforms that 
are activated by different mechanisms, such as G-protein-coupled receptors (PLCß), 
tyrosine-kinase-coupled receptors (PLCγ), Ca2+ activated (PLCδ) or Ras activated 
(PLCɛ ).  
Excitable cells, which need to respond to signals within milliseconds, are equipped with 
RyR calcium channels (Berridge et al., 2000). Regulation of the latter class of proteins is 
not mediated by the generation of a second messenger but rather through direct coupling 
with the L-type Ca
2+
 channel present on the plasma membrane (Catterall, 2000). In fact, 
in cardiac and skeletal muscles, signalling to the RyR is coupled to the dihydropyridine 
receptor (DHPR), L-type Ca
2+
 channels, which sense changes in membrane potential 
thereby activating Ca
2+
 release from the sarcoplasmic reticulum. 
During the “on” phase Ca2+ flows into the cytoplasm increasing drastically the 
intracellular concentration. Of the cytoplasmic calcium however, only a small amount 
stays free, because most of it is rapidly bound to the different calcium binding proteins. 
There are around 200 genes in the human genome, which encode either for Ca
2+
 buffer or 
effectors (Carafoli et al., 2001). The buffers, which become loaded with Ca
2+
 during the 
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“on” phase and unload during the “off “phase, function to fine-tune the spatial and 
temporal properties of Ca
2+
 signals. They can alter both the amplitude and the recovery 
time of individual Ca
2+
 transients. These buffers have different properties and expression 
patterns. For example, calbindin D-28 (CB) and calretinin (CR) are fast buffers, whereas 
parvalbumin (PV) has much slower binding kinetics and a high affinity for Ca
2+
. These 
are mobile buffers that increase the diffusional range of Ca
2+
 (John et al., 2001). Once the 
“On” mechanisms have generated a Ca2+ signal, various Ca2+ sensitive processes translate 
this into a cellular response. Several different Ca
2+
 effectors (sensors) have been 
described and classified into 4 categories: (1) Ca
2+
 -binding proteins (calmodulin, 
troponin C, etc.), (2) Ca
2+
-sensitive enzymes (kinases, phosphatases, proteases, nitric 
oxide syntases, calcineurin, etc.), (3) ion channels (potassium channels such as SK, IK 
and BK and chloride channels) and (4) Ca
2+
 -sensitive transcription factors (NFATc, 
CREB, DREAM and CREB-binding protein) (Berridge et al., 2003). In the case of 
transcription factors, Ca
2+
 itself or Ca
2+
-dependent intracellular pathways activate or 
inhibit the transcription factors and consequently regulate the expression of certain genes. 
Activation of the nuclear factor of activated T cells (NFAT), a well characterized Ca
2+
 
dependent transcription factor requires, Ca
2+
 elevation. NFAT translocates from the 
cytoplasm into the nucleus in response to dephosphorylation of several of its serins by the 
Ca
2+ 
Calmodulin (CaM) phosphatase calcineurin (Clipstone and Crabtree, 1992; 
Okamura and Rao, 2001). Calcineurin binds some NFAT isoforms and translocates into 
the nucleus as a complex with NFAT, where it maintains NFAT in the dephosphorylated 
state as long as Ca
2+
 remains elevated. As soon as Ca
2+
 signalling stops, kinases in the 
nucleus rapidly phosphorylate NFAT, which then leaves the nucleus and transcription of 
NFAT responsive genes ceases (Fig.1-7) (Shibasaki et al., 1996). Calcineurin is a serine- 
and threonine-specific protein phosphatase that is conserved in all eukaryotes and is 
unique among phosphatases for its ability to sense Ca
2+
 through its activation by 
calmodulin. Identified and characterized in pioneering work by Claude Klee and Philip 
Cohen in the late 1970s, calcineurin catapulted to center stage when the groups of Stuart 
Schreiber and Irving Weissman discovered that it is the target of the immunosuppressants 
cyclosporin A and FK506 (Aramburu et al., 2004). Thus explaining its action as an 
immunosuppressant drug and leading to its wide spread use in transplanted patients. 
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Nuclear factor kappa B (NFB) is another transcription factor that is regulated by Ca2+. 
NFB translocates into the nucleus after phosphorylation and degradation of an 
inhibitory subunit IB (Stancovski and Baltimore, 1997). A single spike of Ca2+ is 
sufficient to trigger IB degradation and NFB translocation into the nucleus, where it 
persists for at least 30 min until IB is replenished (Dolmetsch et al., 1997). 
 
 
Figure 1-7: The Calcineurin-NFAT signalling pathway. An increase of intracellular 
calcium levels activates the cellular phosphatase Calcineurin (CN) through its interaction 
with Calmodulin (CaM). Activated CN is able to dephosphorylate NFAT (Nuclear Factor 
of Activated T-cells), and allows the nuclear translocation of this transcription factor. In 
the nucleus, NFAT binds to specific DNA motifs within the promoter of numerous genes 
and induce their transcription. (http://www.angiobodies.com/figuras/uam_fig2.gif)  
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During the “off” phase various pumps and exchangers are activated in order to decrease 
the levels of cytosolic Ca
2+
 and to terminate the signal. There are four different pumping 
mechanisms that are responsible for maintaining or bringing back the Ca
2+
levels at 
approximately 100nM and ensure that the internal stores are loaded. The plasma 
membrane Ca
2+ 
-ATPase (PMCA) pumps and Na
+
/ Ca
2+
 exchangers extrude Ca
2+ 
to the 
outside whereas the sarco-endoplasmatic reticulum ATPase (SERCA) pumps return Ca
2+ 
to the internal stores. These pumps use energy from ATP hydrolysis and from the Na
+
 
electrochemical gradient to transport Ca
2+
 against its electrochemical gradient.  
The forth component of this machinery is the mitochondrial uniporter. Mitochondria 
extrude protons to create an electrochemical gradient that allows ATP synthesis and the 
same gradient is used to drive Ca
2+
 uptake through a uniporter that has a low sensitivity 
to Ca
2+ 
(half–maximal activation around 15µM). This low sensitivity means that 
mitochondria accumulate Ca
2+ 
more effectively when they are close to Ca
2+ 
release 
channels (Rizzuto et al., 1993). The mitochondrion has an enormous capacity to 
accumulate Ca
2+ 
and the mitochondrial matrix contains buffers that prevent its 
concentration from rising too high. Once the cytosolic Ca
2+ 
has returned to its resting 
level, a mitochondrial Na
+
/ Ca
2+ 
exchanger pumps the large load of Ca2+ back into the 
cytoplasm, from which it is either returned to the ER or removed from the cell. Ca
2+ 
can 
also leave the mitochondrion through a permeability transition pore (PTP) (Bernardi, 
1999; Duchen, 1999), which has all the elements of Ca
2+ 
-induced Ca
2+ 
release because it 
is activated by the build up of Ca
2+ 
within the mitochondrial matrix (Ichas et al., 1997). 
On the other hand, PMCA and SERCA pumps have lower transport rates but high 
affinities, which means that they can respond to modest elevations in Ca
2+ 
levels and set 
basal Ca
2+ 
levels.  
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II.3 Role of Ca
2+
 as a second messenger in skeletal and cardiac    
       muscle excitation-contraction coupling 
 
 
One of the main roles of Ca
2+ 
as a second messenger in muscle cells is to promote 
contraction. The release of Ca
2+ 
from the SR and generation of Ca
2+ 
signal responsible for 
muscle contraction differ between skeletal and cardiac muscles. To accomplished this 
special function and generate Ca
2+ 
signals skeletal muscle cells are equipped with 
specialized proteins, namely L-type VOC (alpha1S/CaV1.1), the dihydropyridine 
receptor (DHPR) located on the plasma membrane and RyR1 located on the SR terminal 
cisternae junctional face membrane. The DHPR interacts directly with the large 
cytoplasmic head of the RyR1. Membrane depolarization induces a conformational 
change in alpha1S subunit of DHPR that is transmitted directly to the RyR1, causing it to 
release Ca
2+ 
from the SR (Fig.1-8) (Ikemoto et al., 1994; Marty et al., 1994). Ca
2+
 
conductance trough DHPRs in skeletal muscle is not essential for excitation-contraction 
coupling. The Ca
2+
 released from the SR mediates the interaction between thick and thin 
filaments resulting in muscle contraction. At the same time Ca
2+
 is pumped back into the 
SR by SR Ca
2+
 -ATPases (SERCA) (Ebashi et al., 1969; Hasselbach, 1964; Sandow, 
1965). 
Electron microscopy investigations have demonstrated that skeletal muscle DHPRs are 
arranged in tetrads, clusters of four receptors, corresponding to the homotetratmeric 
structure of RyR1. Experimental evidence supports a physical interaction between the 
two proteins and activation of DHPR by membrane depolarization elicits opening of RyR 
(Bers and Stiffel, 1993; Franzini-Armstrong et al., 1998). The coupling is bidirectional, in 
addition to orthograde signal transmitted from skeletal DHPR to the RyR1, the DHPR 
also receives a retrograde signal from the RyR enhancing L-type Ca
2+
 currents. 
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Figure 1-8: Neuromuscular junction and skeletal muscle type of EC coupling  
Action potential from a motor neuron results in local depolarization of the sarcolema and 
activation of DHPR (Cav1.1), that cause conformational changes of the channel and 
direct interaction with RyR1, opening of RyR1 and release SR Ca
2+
 
(http://www.bio.miami.edu/~cmallery/150/neuro/neuromuscular-sml.jpg) 
 
 
 
 
In contrast to skeletal muscle cells, cardiac muscle cells are equipped with different 
isoforms of L-type Ca
2+
channels and RyRs: They express alpha1C/ CaV1.2 L-type VOC 
and RyR2 isoforms. The nature of the coupling between these two players in cardiac cells 
is different. In heart, the action potential depolarizes the membrane, opens the DHPR and 
causes entry of extracellular Ca
2+ 
that diffuses across the junctional zone to stimulate 
RyR2 to release Ca
2+
from the SR. The process is named calcium-induce calcium-release 
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(CICR) (Bers, 2002). As the Ca
2+ 
entry activates a cluster of 4-6 RyR2s Ca
2+ 
release from 
the SR is much larger and results in a considerable amplification of the initial Ca
2+ 
influx. 
After its release from the SR, Ca
2+ 
then diffuses from the junctional zone to induce 
muscle contraction by activating sarcomeres that are situated in the immediate vicinity 
(Fig. 1-9). Calcium homeostasis is particularly important in cardiac cells, since during 
every heart beat there is a large circulation of Ca
2+
. Thus the same amount of Ca
2+ 
that is 
released by the RyRs2 is returned to the SR by the SERCA pump.  
The force of contraction can be adjusted by varying the amount of Ca
2+
 that circulates 
during each on/off cycle. The positive inotropic response that is produced by ß-
adrenergic stimulation is mediated by cyclic AMP/PKA, which has three main actions on 
Ca
2+ 
signalling. First, it stimulates the L-type VOCs to increase the amount of Ca
2+ 
that 
enters during each action potential. Second, it phosphorylates phospholamban to reduce 
its inhibitory effect on the SERCA pump, which is then able to increase the luminal Ca
2+
 
concentration so that more Ca
2+
 is released from the SR and an increase in the activity of 
the SERCA pump is also enhanced by cADPR (Lukyanenko et al., 2001). Third, 
cAMP/PKA phosphorylates the RyR2, thereby enhancing their ability to release Ca
2+
 
(Marx et al., 2000). In contrast to skeletal muscle, dihydropyridine receptors in cardiac 
muscle are located randomly relative to the RyR2 tetramers (Berridge et al., 2003).  
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Figure 1-9: EC coupling in cardiac muscle Ca
2+
 induce Ca
2+
 release mechanism 
Calcium realize from RyR2 is triggered by Ca
2+
 entry through the nearby L-type Ca
2+
 
channel (CaV1.2 isoform). Ca
2+
 that flows into the cell activates RyR2 channels and 
amplify Ca
2+
 signal. (http://calcium.ion.ucl.ac.uk/images/contraction-heart.gif). 
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II.4 Role of Ca2+ signalling in immune cells 
 
In the cells of the immune system calcium signals are essential for diverse cellular 
functions including differentiation, migration, effector functions and gene transcription. 
An increase in intracellular calcium concentration occurs after the engagement of 
immunoreceptors, such as B-cell and T-cell receptors and Fc receptors on mast cells, 
natural killer (NK) cells, DCs or macrophages as well as chemokine receptors. Many 
important immune receptors initiate Ca
2+
 signals trough the production and accumulation 
of the soluble second messenger InsP3. InsP3 is produced by the hydrolysis of the 
membrane lipid phosphatidylinositol-4,-5-bisphosphate (PtdIns(4,5)P2; also known as 
PIP2), a process that also produces the lipid second messenger diacylglycerol (DAG) 
(Brose et al., 2004). PIP2 hydrolysis is mediated by members of the PLC enzyme family, 
which is constituted of several differentially regulated isoforms (Rhee, 2001). An 
important distinction among the various PLC isoforms is that 7-transmembrane spanning 
G-protein-coupled receptors (GPCRs) activate PLCβ isoform through the heterotrimeric 
G-protein Gq and related subunits, whereas tyrosine-kinase-linked receptors, including 
many growth factor receptors, the T-cell receptor (TCR), the BCR and activating Fc 
receptors (FcRs), activate PLCγ isoform through tyrosine phosphorylation. 
InsP3 binds to the IP3Rs on the ER membrane and causes the release of Ca
2+
 from ER-
bound intracellular stores. The reduced ER Ca
2+
 concentration is sensed by STIM 
molecules, which are located on the ER membrane, and its conformational change leads 
to activation of Orai1 and CRAC channels on the plasma membrane and consequently to 
sustained Ca
2+
 influx into the cell. As a result, several Ca
2+
-dependent signalling proteins 
and their target transcription factors are activated, including the phosphatase calcineurin 
and its target NFAT (nuclear factor of activated T cells), CaMK (Ca
2+
- calmodulin-
dependent kinase) and its target CREB (cyclic-AMP-responsive-element-binding protein) 
MEF2 (myocyte enhancer factor 2) which is activated by both the calcineurin and CaMK 
pathways, and NFκB (nuclear factor κB). Simultaneously, DAG production activates the 
Ras-mitogen activated protein kinase (MAPK) and protein kinase C (PKC) pathways, 
which in turn lead to activation of the transcription factors AP-1 (a transcriptional 
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complex formed by c-Jun and c-Fos) and NFκB (Karin and Gallagher, 2005; Schulze-
Luehrmann and Ghosh, 2006). 
Beside SOCE, which is the most studied Ca
2+ 
entry pathway in immune cells, the 
existence of other Ca
2+ 
entry pathways has been reported, such as L-type voltage-gated 
Ca
2+ 
channels (CaV channels), TRP (transient receptor potential) and ATP-responsive 
purinergic (P2X) receptors (Oh-hora, 2009). Several studies have shown that CD4+ and 
CD8+ T cells express high levels of the Cav1 pore-forming subunit subfamily (α1S, α1C, 
α1D, and α1F) at levels comparable to those in excitable cells in which these channels are 
critical for Ca
2+
 entry (Badou et al., 2006; Gomes et al., 2004; Kotturi et al., 2003; Matza 
and Flavell, 2009). Other studies have also shown that these channels are widely 
expressed in various immune cell types, such as dendritic cells (DCs), B-lymphocytes, 
and monocytes (Grafton et al., 2003; Vukcevic et al., 2008). It has been shown that CaV 
channels are required for T cell functions in vitro and in vivo. The DHP antagonist, 
nifedipine and related compounds, clearly reduce in vitro T cell proliferation, IL2 
secretion, and Ca
2+
entry (Colucci et al., 2009; Gomes et al., 2004; Grafton and Thwaite, 
2001). In DCs CaV1.2 activation influences process of maturation and the mechanisms 
that lead to fast induction in surface expression of MHC class II molecules (Vukcevic et 
al., 2008). Although InsP3 is a key messenger regulating Ca
2+
concentration, some studies 
have postulated the possibility that the ryanodine receptor (RyR) contributes to the InsP3-
insensitive component of Ca
2+
 signalling in immune cells (Sei et al., 1999). Particularly 
in B-lymphocytes and DCs pharmacological activation gives rise to a rapid and transient 
increase in the intracellular Ca
2+
concentration. Furthermore in freshly isolated B-
lymphocytes, activation of the RyR1 leads to the rapid release of the proinflamatory 
cytokine IL1ß (Bracci et al., 2007; Ducreux et al., 2006; Girard et al., 2001; Goth et al., 
2006; O'Connell et al., 2002). Interestingly in some cells the Ca
2+
 signal is also encoded 
by high frequency oscillations of the cytosolic Ca
2+
 concentration. This is an interesting 
mechanism through which decoding of both the amplitude and the frequency of the 
oscillations can convey different messages leading to activation of different cell 
functions. 
For some functions of immune cells such as activation of T-lymphocytes by antigen, 
repetitive oscillation of the intracellular Ca
2+
 concentration are the result of the activation 
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of the phosphoinositide signalling pathway trough cell-surface receptors (Lewis, 2003). 
Furthermore positive selection of T cells has been shown to depend on Ca
2+
 oscillations 
in thymocytes. Thus immune cells are equipped with a variety of components to handle 
Ca
2+
 homeostasis and decode messages underlining specific Ca
2+
 signals. The close 
coordination of CRAC channels and PMCA pumps allows the PMCA pumps to respond 
rapidly to local changes in Ca
2+
 concentration and thereby to significantly influence the 
frequency and amplitude of intracellular Ca
2+
 oscillations and/or the peak cytosolic Ca
2+
 
concentration triggered by CRAC channel activation.  
 
Thus Ca
2+
 signalling is integrated with other signalling pathways and the integration 
occurs at the level of the binding of transcription factors to DNA response elements, 
resulting in cell proliferation and cytokine gene expression. The functional consequences 
of Ca
2+
entry have been very well documented in T cells and mast cells where differences 
between short term and long term increases in intracellular Ca
2+
 levels have been 
observed. 
 
Short-term functions of Ca
2+
 signals: 
 
The regulation of lymphocyte motility and immunological synapse formation are Ca
2+
 
dependent processes. Several studies using in vitro and in vivo imaging of T cells have 
shown that an increase in the intracellular Ca
2+
 concentration results in reduced mobility 
and rounding of otherwise polymorphic T cells (Delon et al., 1998; Negulescu et al., 
1996). This “stop” signal seems to sustain the interaction between a CD4+ T cells and 
APCs and favour the formation of the immunological synapse. An immunological 
synapse is also formed between CTLs and their target cells, such as virus-infected cells 
and tumor cells. Synapse formation is accompanied by a rise in the intracellular Ca
2+
 
concentration of CTLs, which is required for granule exocytosis and target-cell killing 
(Lyubchenko et al., 2001; Poenie et al., 1987; Treves et al., 1987). Similarly, mast cell 
degranulation also involves granule exocytosis triggered by Ca
2+
 entry, in this case 
degranulation is initiated by binding of antigen –immunoglobulin E (IgE) complexes to 
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the mast cell Fc receptor, and leads to the release of variety of mediators including 
histamine and leukotrienes (Perrimon and Mathey-Prevot, 2007).  
 
Long-term functions of Ca2+ signals: 
 
The long-term responses involve transcriptional programs initiated by sustained Ca
2+
 
signalling. They include proliferation, differentiation and acquisition of effector function 
by “naive” T and B lymphocytes following their first encounter with antigen, as well as 
transcription of cytokine, chemokine and other activation-associated genes by 
differentiated “effector” T cells upon secondary exposure to antigen. 
It also has been known that increases in the intracellular Ca
2+
 concentration participate in 
the regulation and maturation of dendritic cells (Czerniecki et al., 1997; Koski et al., 
1999). Probably the best studied Ca
2+
-responsive signalling pathway in T cells involves 
the phosphatase calcineurin, which dephosphorylates NFAT proteins following an 
increase in intracellular Ca
2+
 concentration and leads to its nuclear translocation. NFAT 
is regulated in a highly dynamic manner by Ca
2+
 levels because a decrease in intracellular 
Ca
2+
 level results in the almost instantaneous phosphorylation and export of NFAT from 
the nucleus. As a consequence, NFAT-dependent gene transcription is only poorly 
activated in response to a single pulse of high intracellular Ca
2+ 
levels but requires 
prolonged elevation of Ca
2+ 
levels (Dolmetsch et al., 1997). This is in contrast to another 
transcription factor, nuclear factor-B (NF-kB), for which a transient increase in 
intracellular Ca
2+ 
concentration is sufficient for activation and subsequent target gene 
expression. Calcineurin–NFAT signalling pathway is responsible for activation of 
transcription of diverse cytokines and several hundreds other genes (Cristillo and Bierer, 
2002; Feske et al., 2001). These studies also indicated that Ca2+ signals exert both 
stimulatory and inhibitory effects on gene expression. As to the long term functions of 
Ca
2+ 
signals in DCs there are reports of CRAC activity in DCs. Its activation in these 
cells has been reported to be linked to the induction of maturation (Hsu et al., 2001).  
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                    III. RYANODINE RECEPTORS AND 
                    NEUROMUSCULAR DISORDERS 
 
 
          III.1. The Ryanodine receptor calcium channels 
 
 
III.1.1. Isoforms of ryanodine receptor and their structure   
 
Ryanodine receptors are intracellular Ca
2+
 release channels of which at least three 
different isoforms that have been identified and extensively characterized biochemically, 
functionally and at the molecular level (Bers, 2004; Franzini-Armstrong and Protasi, 
1997; Sutko and Airey, 1996). The three isoforms share an overall amino acid identity of 
approximately 60% and experimental evidence suggests that they are structurally similar, 
with a large hydrophilic NH2-terminal domain and a hydrophobic C-terminal domain 
containing several transmembrane domains as well as the channel pore (Samso et al., 
2005; Serysheva et al., 2005). Type 1 RyR, also called skeletal type RyR because it was 
identified for the first time in skeletal muscles (Takeshima et al., 1989; Zorzato et al., 
1990) is encoded by a gene on human chromosome 19 and is mainly expressed in skeletal 
muscle where it mediates Ca
2+
 release from the sarcoplasmic reticulum, following 
depolarization of the plasmalemma. RyR1 is also expressed to a lower extent in Purkinje 
cells and recent reports have demonstrated its expression in some cells of the immune 
system (Hosoi et al., 2001) particularly B-lymphocytes and DCs. Mutations in this gene 
are associated with the rare neuromuscular disorders malignant hyperthermia, central 
core disease, and some forms of multi-minicore disease, Centronuclear myopathy and 
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King Denborough syndrome (Robinson et al., 2006; Treves et al., 2005). Type 2 RyR 
encoded by a gene located on chromosome 1 is mainly expressed in cardiac muscle and 
in certain areas of the cerebellum and is activated trough a Ca
2+
 induce Ca
2+
 release 
mechanism (McPherson and Campbell, 1993; Otsu et al., 1990). Mutations in its gene are 
associated with genetic variants of congestive heart failure, namely catecholaminergic 
polymorphic ventricular tachycardia and arrhythmogenic right ventricular dysplasia 
(George et al., 2007; Wehrens and Marks, 2003). 
Type 3 RyR encoded by a gene located on a chromosome 15 is expressed in a variety of 
excitable tissues, including central nervous system, as well as in developing muscle cells. 
Its expression in some tissues appears to be developmentally regulated (Sorrentino et al., 
1993; Tarroni et al., 1997). 
RyRs are large homotetramers made up of four subunits with a mass of around 560kD, 
each composed of about 5000 amino acids. Each subunit can bind one molecule of the 
12KDa protein FKBP12. Accessory proteins, including CaM, calcineurin and S100 
(MacKrill, 1999; Meissner, 1994) have been shown to form a complex with RyRs giving 
rise to a huge macromolecular complexes with a total molecular mass greater than 2 
million Da making the RyR the largest known ion channel. The RyR protomer contains a 
large hydrophilic domain and a relatively small hydrophobic COOH-terminal domain 
containing several transmembrane (TM) segments. Depending on the model, the exact 
number of TM segments ranges between 4 and 12. Primary sequence and hydropathy plot 
analysis by Takeshima et al. (1989) suggest an arrangement of four transmembrane 
spanning α-helices and a final tail facing the SR lumen. In a second model, Zorzato et al., 
proposed 10 transmembrane domains (Takeshima et al., 1989; Zorzato et al., 1990).  
More recently a model consisting of 6-8 TM domains was proposed (Fig. 1-10) (Du et al., 
2002). This arrangement places both the N-terminal and C-terminal domain of RyR in the 
cytoplasm. However, determination of the exact number TM segments will require 
further investigations at high EM resolution. The transmembrane sequences from each of 
the four monomers interact to form the ion–conducting pore (Lai et al., 1989) whereas the 
large cytoplasmic region regulates gating via interaction with a variety of intracellular 
messengers. Many of the mutations that produce human disease are located in the 
cytoplasmic region (Du et al., 2002). 
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Figure 1-10: Model for the transmembrane regions of RyR1. Proposal for the 
transmembrane topology of rabbit skeletal muscle RYR1 according to the model of Du. 
Model shows eight transmembrane sequences with cytosolic N- and C-terminal domain. 
 
 
Over the last 10 years, single-particle cryoelectron microscopy (cryo-EM) was the 
method of choice to unravel the structure of the RyRs and recently reconstructions of 
RyR1 have reached subnanometer resolution (Fig. 1-11). RyRs have a mushroom shape 
with 4-fold symmetry (Ludtke et al., 2005). Image analyses revealed a quatrefoil or 
coverleaf-shaped channel with a large square cytoplasmic domain (29x29x12nm) and a 
narrower transmembrane domain spanning 7nm from the center of the cytoplasmic 
domain. A 2-3nm cylindrical hole, which could be occluded by a “plug” mass, in the 
center of the channel, may correspond to the transmembrane Ca
2+
 conducting pathway.  
Single-particle cryo-EM has been used to generate images of RyR1 in different 
conformational states to explore the structural transitions associated with RyR gating. 
Such studies have shown the existence of conformation changes between open and closed 
states of the channel (Ikemoto and el-Hayek, 1998; Samso and Wagenknecht, 1998). 
Global conformational changes associated with the closed-open transition of the RyR 
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channel were detected in both the cytoplasmic region and the transmembrane region. 
Channel opening was proposed to be similar to the opening-closing of the iris in a camera 
diaphragm (Hamilton and Serysheva, 2009). 
 
 
 
 
 
Figure 1-11: Three-dimensional structure of RyR1 at 14 A resolution. (from I.I. 
Serysheva, S.L. Hamilton, W. Chiu and S.J. Ludtke, J. Mol. Biol. 345 (2005) 
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III.1.2.RyR modulators 
 
The activities of all three RyR isoforms are modulated by a large number of substances. 
These compounds can act as activators or inhibitors and most of them bind to the 
cytoplasmic domain of the RyRs and allosterically regulate the opening of the Ca
2+ 
conduction pathway in the transmembrane region. RyR activity can also be modulated by 
post-translational modifications such as phosporylation, oxidation and S-nitrosylation. To 
address the mechanisms and nature of the channel regulation by individual modulators it 
is important to identify sites of interaction on the primary/secondary sequence of the RyR 
as well as their location in the three-dimensional structure of RyR. Single-particle cryo-
EM has been used to analyze macromolecular interactions between the RyR and some of 
its larger modulators, such as FKBP12 and calmoduline (Wagenknecht et al., 1996; 
Zorzato et al., 1990). 
 
Endogenous modulators: 
 
1. Calcium:  
 
All RyR isoforms are activated by Ca
2+
: RyR1 shows a bell-shaped Ca
2+
-dependent 
activation curve with low Ca
2+
 concentrations (1-10 M range) activating the channel and 
higher concentrations (500 M to 10 mM range) inhibiting channel activity (Meissner et 
al., 1997). Interestingly RyR2 show a small inactivation at high Ca
2+
 concentrations (over 
100 mM). This biphasic Ca
2+
 dependent behavior of RyR1 suggests the existence of at 
least two different Ca
2+
 binding sites: high affinity sites, which stimulate Ca
2+
 release and 
low affinity binding sites, which are less selective and inhibit Ca
2+
 release. In RyR1 
potential Ca
2+
 binding sites have been identified between residues 1861 and 2094 and 
between 3657 and 3776 (Chen and MacLennan, 1994). In another study Treves et al. 
generated an antibody to a peptide encoded by sequence from amino acid 4380-4625 and 
found that this antibody could block Ca
2+
 dependent RyR1 activation.  They speculated 
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that this could be the Ca
2+
 activating site. Interestingly several motifs within the primary 
sequence of RyRs have been suggested to act like Ca
2+
 binding EF hand motifs. Two 
such putative sites are located at amino acids 4079-4092 and at 4115-4126 (Xiong et al., 
1998). On the other hand little is known about the inactivation low affinity site. Both 
Zorzato et al. and Hayek et al. suggested that the low affinity inhibitory Ca
2+
 binding site 
falls within the negatively charged region between residues 1872 and 1923 (Hayek et al., 
2000; Zorzato et al., 1990). 
 
2. Magnesium:  
 
Mg
2+
 is a key regulator of RyRs function and in general of normal skeletal and cardiac 
muscle contraction. Mg
2+
 is believed to inhibit RyRs by two mechanisms: it can inhibit 
RyRs by competiting with Ca
2+
 for the activation sites (Dunnett and Nayler, 1978; 
Meissner, 1986) or it can bind to the low affinity Ca
2+
 binding site and close the RyRs 
(Laver et al., 1997; Soler et al., 1992). There is a difference between RyR1 and RyR2 in 
their sensitivity to inhibition by Mg
2+
since the low affinity Ca
2+
 binding sites have a 10 
fold lower affinity for Mg
2+
 in RyR2 than in RyR1. This is translated into differences in 
Mg
2+
 inhibition of RyR1 and RyR2 at elevated cytoplasmatic Ca
2+
 levels (Laver et al., 
1997; Laver et al., 1995). In resting skeletal muscle, where the free Mg
2+
 concentration is 
approximately 1mM, Mg
2+
 is the primary inhibitor of Ca
2+
 release from the SR 
preventing CICR and uncontrolled contraction of resting muscles. This concept was 
highlighted in experiments by Lamb and Stephenson (Lamb and Stephenson, 1994; Owen 
et al., 1997) which showed that a reduction of cytoplasmic free Mg
2+
 from physiological 
levels (approximately 1 mM) to 0.2 mM or lower in skinned muscle preparations, 
released Ca
2+
 from the SR. Furthermore during t-tubule depolarization and activation of 
the RyR by the DHPR, the sensitivity of RyRs to inhibition by Mg
2+
 is reduced by more 
than ten fold (Lamb and Stephenson, 1991). Thus during EC coupling, DHPRs somehow 
relieve Mg
2+
`s inhibition and thus permit RyR activation by ATP and Ca
2+
 (the Mg2+ de-
repression hypothesis) (Lamb and Stephenson, 1992). 
Cytosolic Mg
2+
 may also be involved in the regulation of RyR1 by SR luminal Ca
2+
. 
Recent work suggests that luminal Ca
2+
 influences RyR gating indirectly, by decreasing 
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the affinity of the cytosolic Ca
2+ 
activation site for Mg
2+
 (Laver et al., 2004). Thus, 
pharmacological activators of the RyR must overcome Mg
2+
 inhibition to produce Ca
2+
 
release from the SR. Interestingly, increasing evidence suggests that defects in the 
regulation of RyR by Mg
2+
 may be connected with MH susceptibility (Laver et al., 1997; 
Owen et al., 1997). 
 
 
3. Adenine nucleotides 
 
Adenine nucleotides including ATP and ADP are RyR activators (Galione and Churchill, 
2000; Pessah et al., 1987). ATP strongly activates RyR1 at resting (nM) cytoplasmic Ca
2+
 
concentration and in conjunction with Ca
2+
, can cause almost full activation. The cardiac 
isoform RyR2 is not appreciably activated by ATP in the absence of Ca
2+
, but ATP 
enhances its activation by Ca
2+ 
(Kermode et al., 1998; Meissner et al., 1988). RyR3 also 
appears to be less sensitive to ATP. 
 
 
 
 
4. Redox modifications of RyR: 
 
RyR channels have been proposed to act as intracellular redox sensors (Eu et al., 2000; 
Hidalgo et al., 2005). Each RyR monomer has 100 cystein residues (Liu et al., 1994) and 
about half of them are free. This large number of free thiol groups makes RyRs sensitive 
to modification by reactive oxygen intermediates. In particular, many recent studies have 
reported modifications of RyR cysteines by non-physiological redox compounds 
(Hamilton and Reid, 2000; Hidalgo et al., 2002; Pessah et al., 2002). For example 
thimerosal enhances single RyR channel activity in lipid bilayers (Marengo et al., 1998). 
Thimerosal also stimulates CICR from SR vesicles isolated from mammalian skeletal 
muscle (Donoso et al., 2000; Hidalgo et al., 2000). Endogenous redox components 
include the free radicals nitric oxide (NO) and superoxide anion, which through 
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enzymatic or non-enzymatic chemical reactions can be readily converted into non-radical 
species of lower reactivity but longer half-life such as S-nitrosoglutathione (GSNO) or 
hydrogen peroxide (H2O2). These endogenous redox components can modify RyR 
function (Hidalgo et al., 2004) and both skeletal and cardiac RyR isoforms have been 
shown to be endogenously S- nitrosylated (Eu et al., 2000; Xu et al., 1998b; 
Zahradnikova et al., 1997), suggesting that nitric oxide (NO) and NO-adducts are 
physiological effectors of excitation contraction- coupling. Incubation with NO or NO 
donors also modifies RyR channel activity (Salama et al., 2000; Suko et al., 1999; Xu et 
al., 1998a). Additionally, RyR channels are highly susceptible to modification by other 
endogenous redox agents, including glutathione (GSH), glutathione disulphide (GSSG), 
NADH, and by changes in the GSH/GSSG ratio (Hidalgo et al., 2004). 
 
 
5. Phosporylation of RyRs: 
 
Endogenous kinases and phosphatases which modulate RyRs include cAMP-dependent 
protein kinase (PKA), cGMP-dependent protein kinase (PKG), protein kinase C (PKC), 
and calmodulin-dependent proteinkinase II (CaMK). According to sequence analysis, 
several serine and threonine residues have been identified as possible phosphorylation 
sites on the RyR1. Phosphorylation of Ser2843 by endogenous kinase (Varsanyi and 
Meyer, 1995) and in vitro phosporylation of Ser2843 by cAMP-, cGMP- and CaM- 
dependent protein kinases (Suko et al., 1993) have been reported. In addition 
phosphorylation of Ser2809 by PKA and Ser2815 by CaMKII of cardiac isoform RyR2 
are thought to be involved in activation of channel gating (Bers, 2006).  In failing human 
hearts PKA phosphorylation of RyR2 is significantly elevated. Since PKA 
phosphorylation of RyR2 inhibits FKBP12.6 binding, which is normally bound to the 
RyR complex and stabilizes the channel, hyperphosphorylated RyR2 in failing heart 
results in increased Ca2+ sensitivity for activation and elevated channel activity 
associated with destabilization of the tetrameric channel complex. These modifications of 
the channel lead to defective channel functions and possibly underline the pathological 
mechanism in failing heart (Marx et al., 2000).  
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Exogenous modulators: 
 
1. Ryanodine: 
 
 In 1948, Rogers purified ryanodine, a plant alkaloid, from Ryania speciosa. Ryanodine 
specifically binds to RyRs and gives the receptor its name. Ryanodine has two opposite 
effects on Ca
2+
 release: at submicromolar concentrations it increases the channel‟s 
activity whereas at high micromolar concentrations it decreases SR Ca
2+
 release. 
Consequently, ryanodine has been proposed to bind at multiple (high- and low- affinity) 
sites on the ryanodine receptor but the number and exact location of these sites are still 
unknown. The high-affinity site may be located on the carboxy-terminal domain of the 
channel and since RyR monomers do not able to bind ryanodine, it has been assumed that 
the tetrameric structure is necessary for ligand binding where binding of ryanodine 
favours the open RyR conformation and modifies the conductance properties of the 
channel (Fill and Copello, 2002; Fryer et al., 1989).  
 
2. Caffeine:  
 
Caffeine a methylxanthine, promotes Ca
2+
 release and CICR at millimolar concentrations 
(Pessah et al., 1987). By an allosteric interaction, caffeine appears to increase the 
sensitivity of the Ca
2+
 activator site for Ca
2+
 and even to reverse Mg
2+
 inhibition. RyR2 is 
more sensitive to caffeine than RyR1. Caffeine and adenosine nucleotides seem to have a 
synergistic effect, suggesting that their respective binding sites are in close proximity or 
even overlap with each other. 
 
3. Volatile anaesthetics: 
  
In skeletal muscle, at a concentration of 0.002-3.8% gas, halothane increases Ca
2+
 efflux 
via the RyR by increasing the open probability of the channel (Kim et al., 1984). The 
response of the channel to halothane stimulation is pH and Ca
2+
-dependent but adenosine 
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nucleotide independent. Effects similar to those of halothane have been observed with 
other volatile anaesthetics such as isoflurane and enflurane (2.5 to 4%).  
  
4. 4-chloro-m-cresol: 
 
It is a specific RyR1 activator (Herrmann-Frank et al., 1996; Zorzato et al., 1993). It 
seems to have a similar effect to that of caffeine but opens the channel at lower 
concentrations (micromolar versus millimolar concentrations). It is a more potent and 
specific drug than halothane and caffeine.  
 
5. Ruthenium red: 
 
It is an inorganic polyamine and a polycationic dye. It has been demonstrated to inhibit 
the SR- Ca
2+
 release in both skeletal and cardiac muscles.  Ruthenium red blocks the 
channel in an asymmetrical and voltage-dependent mode. In particular it completely 
blocks CICR and therefore is often used to verify RyR-dependent leakage from the SR 
(Chamberlain et al., 1984; Chiesi et al., 1988).  
 
6. Dantrolene  
 
It is a highly lipophilic hydantoin (anticonvulsant) derivate. It is classified as a direct-
acting skeletal muscle relaxant. It is currently the only specific and effective treatment for 
malignant hyperthermia. The therapeutic concentration is about 10µM (Flewellen et al., 
1983). Dantrolene depresses excitation-contraction coupling in skeletal muscle by 
binding to the ryanodine receptor 1. In vivo, dantrolene may target RyR1 and RyR3 but 
not RyR2 (Zhao et al., 2001). 
 
7. Doxorubicin: 
  
Doxorubicin also known as Adriamycin, was first described to induce Ca
2+
-release from 
isolated skeletal muscle SR vesicles and from skinned muscle fibres (Zorzato et al., 
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1985). The same behavior was also found in cardiac muscle, where doxorubicin increases 
the [3H] ryanodine– binding to the ryanodine receptor. Doxorubicin, an anthraquinone, is 
a widely used antineoplastic and chemotherapeutic agent. Although its acute effects are 
completely reversible, chronic clinical treatment may cause cardiotoxicity, possibly due 
to the long term sensitization of RyRs to Ca
2+
 (Abramson et al., 1988; Pessah et al., 
1990).  
 
 
III.2. Genetic linkage and functional effects of RYR1 mutations  
 
The RyR1 is encoded by a gene composed of 106 exons, which produces one of the 
largest known proteins (5038 amino acids). The first 4000 amino acids are predicted to 
from the hydrophilic domain while the last 1000 residues encode the hydrophobic 
COOH-terminal domain containing the transmembrane segments and the pore region. 
Mutations in the RYR1 gene have been linked to several neuromuscular disorders such as 
MH, CCD, MmD, CNM and King Denborough syndrome (D'Arcy et al., 2008; Jungbluth 
et al., 2007; Robinson et al., 2006; Treves et al., 2005; Wu et al., 2006; Zhou et al., 
2007).  
To date over 100 mutations (substitutions or small deletions) in the RYR1 have been 
associated with MH susceptibility and CCD/MmD phenotypes while a few with CNM 
(Ghassemi et al., 2009; Jungbluth et al., 2007). Most MH and CCD causing mutations are 
located in one of the three “hot spot” regions. The first hotspot is clustered between 
amino acid residues 35 and 614 (MH/CCD region 1), the second region between amino 
acid residues 2129 and 2458 (MH/CCD region 2) and the third between amino acid 
residues 3916 and 4942 (MH/CCD region 3)(Fig. 1-12) (Robinson et al., 2006; Treves et 
al., 2005). The majority of MH-linked mutations are present in the heterozygous state, 
within the myoplasmic foot regions 1 and 2, while in most CCD-affected individuals 
mutations are also in heterozygous state, but appear to be concentrated in the 
transmenbrane/luminal domain. Though some patients affected by CCD have also been 
phenotyped as MHS, these results must be interpreted with caution, particularly since (i) 
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any underlying muscular disorder can potentially influence the outcome of the in vitro 
contracture test and (ii) the threshold values for caffeine and halothane sensitivity in the 
in vitro contracture test have been defined for the “general population”, unaffected by 
neuromuscular disorders. Since both MH and CCD are due to a dysregulation of Ca
2+
 
homeostasis it appears risky to classify CCD patients as MHN or MHS. For those MmD 
patients harbouring RYR1 mutations, these appear to be evenly distributed along the gene 
and present either in homozygous state at the genomic level, or homozygously expressed 
in muscle due to imprinting of the mutated allele (Zhou et al., 2007).  
 
 
 
 
 
 
Figure 1-12: Cartoon depicting the ryanodine receptor tetramer inserted into a lipid 
bilayer. The mutations identified in the different domains as well as their association with 
MH and CCD are indicated (from Treves et al., 2005) 
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Functional effects of RYR1 mutations: 
 
It appears that RYR1 mutations result in four different channel defects (Treves et al., 
2008): (i) one class of mutations (mostly associated with the MHS phenotype) cause Ca
2+
 
channels to become hypersensitive to membrane depolarization and pharmacological 
activation; (ii) a second class of mutations causes the RyR1 channels to become leaky 
(iii) a third class of mutations renders the Ca
2+ 
channel unable to conduct Ca
2+
 and/or 
uncouples RyR1 from the voltage sensor (Xu et al., 2008) (mutation class 2 and 3 are 
mostly associated to CCD); (iv) the fourth class of mutations found in MmD patients 
where only one allele is expressed (hemyzygous) results in protein Ca
2+
 channel 
instability which ultimately leads to a decrease of the expression level within muscle 
(Monnier et al., 2008; Zhou et al., 2006b). In order to elucidate possible 
pathophysiological mechanisms of neuromuscular disorders linked to RYR1 mutations it 
is essential to define the mutation class by studying the functional properties of channels 
harbouring clinically relevant amino acid substitutions. 
Functional studies have revealed that most Malignant Hyperthermia causing mutations 
disturb normal calcium homeostasis by shifting the sensitivity to pharmacological 
activation to lower agonist concentrations and/or by causing an increase in the resting 
Ca
2+
 concentration (Ducreux et al., 2004; Girard et al., 2001; Lopez et al., 2000). A 
recent model proposed by Kobayashi et al. (Shimamoto et al., 2008) concerning channel 
regulation suggests inter-domain interactions between the N-terminal and the central 
domain of RyR1 serving as “domain switches” for calcium regulation. In the resting 
state, these domains make close contacts within several subdomain regions and any 
mutation in these regions could cause partial unzipping or weakening of domain switches 
resulting in the hypersensitivity of the RyR1 to agonists. The existence of such inter-
domain interactions between N-terminal and central RyR1 domains has been 
experimentally confirmed (Zorzato et al., 1996). The recently hypothesized flip-state 
theory (Steinbach, 2008) could further explain the increased sensitivity of mutated RyR1 
to agonists. Flip-state was recently proposed for the acetylcholine receptor but could also 
be applied to the RyR1. “Flip” is an intermediate state between an initial inert drug-
effector complex and the receptor with the channel open. MH-causing mutations could 
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promote the entry of the RyR channel into the flip-state; as a consequence, after binding 
the agonist, the mutated receptors are more able to “flip” and therefore pass into the 
“open” state. Alternatively, Malignant hyperthermia causing mutations might increase the 
stability of the flip-state. The flip-state theory is attractive for ion channels which are 
large proteins composed of several subunits and whose activation involves a considerable 
conformational change that probably takes place in a series of steps. 
 
Two hypotheses have been suggested to explain the functional effect of CCD-linked 
RYR1 mutations: the first one, leaky channel hypothesis, suggests that these mutations 
lead to leaky channels, depletion of SR Ca
2+
 stores and consequently muscle weakness 
(Lynch et al., 1999; Rossi and Dirksen, 2006; Tilgen et al., 2001; Treves et al., 2005; 
Zorzato et al., 2003). According to the second hypothesis, the “EC uncoupling 
hypothesis” CCD mutations in the hot spot domain 3 lead to functional uncoupling of 
sarcolemma depolarization from release of Ca
2+
 from the SR Ca
2+
 stores (Dirksen and 
Avila, 2004; Rossi and Dirksen, 2006). The main difference between these two 
hypothesis concerns the Ca
2+
 load in the lumen of the SR (Treves et al., 2005). In the case 
of the uncompensated Ca
2+
 leak hypothesis, a decrease of the SR is present, while the EC 
uncoupling hypothesis predicts that the muscle weakness does not result from major 
changes in the SR Ca
2+
 levels, but rather is due to a defect in excitation contraction 
coupling mechanism (Rios et al., 2006). 
In MmD patients harbouring RYR1 mutations the situation is more complicated in terms 
of alterations of RyR1 function. The first functional study of MmD-related RYR1 
mutations demonstrated that the p.P3527S and p.V4849I substitutions are associated with 
a slightly elevated resting Ca
2+
 concentration, but not depleted intracellular stores 
(Ducreux et al., 2006). Interestingly, cells carrying the homozygous P3527S RYR1 
mutation were found to release significantly less Ca
2+
after pharmacological activation. In 
another study it was shown that RyR macromolecular complexes carrying the p.N2283H 
heterozygous mutations increased the sensitivity of the RyR1 activation by KCl and 
caffeine but this is probably caused by its MHS linkage phenotype. The same study 
however, a patient with the compound heterozygous p.N2283H + p.S71Y mutations lead 
to “unstable” channels which lost their activity during purification. Other compound 
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heterozygous mutations such as p.A1577T + p.G2060C and p.R109W + p.M485V lead to 
a decrease in the amount of RyR1 expressed in skeletal muscle, to a decrease of Ca
2+
 
release as well as [
3
H]ryanodine binding (Zhou et al., 2006b). Finally in some MmD 
patients, particularly those with ophthalmoplegia, the clinical phenotype may be at least 
partly explained by a decrease of the RyR1 channel density in the junctional sarcoplasmic 
reticulum membrane, as demonstrated by Western blot analysis with anti-RyR Ab (Zhou 
et al., 2006a; Zhou et al., 2006b; Zhou et al., 2007) (Monnier et al., 2003). 
 
 
 
                       III.3. Neuromuscular disorders  
 
 
 
Ca
2+ 
is an important second messenger and in skeletal muscle is a key player in the 
development of contractile force. The intracellular Ca
2+
 concentration is finely regulated 
and any alteration in the proteins involved in Ca
2+
 handling can potential lead to 
pathological condition. Thus defects in genes encoding proteins of the SR have been 
found to cause several pathologies (MacLennan, 2000) including Brody disease (BD) the 
first described disorder of skeletal muscle. That is due to a dysfunctional in SERCA1a 
(Brody, 1969; Odermatt et al., 1996).Furthermore Malignant Hyperthermia (MH; 
MIM#145600), Central Core Disease (CCD; MIM#11700), specific forms of multi-
minicore (MmD; MIM#255320) disease and centronuclear myopathy (CNM) associated 
with RYR1 mutation.  
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III.3.1 Malignant Hyperthermia 
 
Malignant hyperthermia (called also Malignant hyperpyrexia) is an autosomal dominant, 
potentially lethal, pharmacogenetic disorder manifesting itself as a hypermetabolic 
response triggered by volatile halogenated anaesthetics such as halothane, sevoflurane, 
desflurane, isoflurane, enflurane and/or depolarizing muscle relaxant succinylcholine and 
rarely, in humans, by stress, vigorous exercise and heat. MH is a classical example of a 
pharmacological disease since almost all patients who are MH susceptible have no 
phenotypic changes without anaesthesia. Numerous publications in the anaesthesia 
literature have reported that also patients with disorders leading to Ca
2+
 dysregulation 
such as Duchenne muscular dystrophy (DMD) (Brownell et al., 1983) and Becker 
dystrophy (BD) can experience a variety of life-threatening complications during and 
after general anaesthesia and are at an increased risk of developing a MH episode. 
Furthermore patients with diseases connected with RYR1 mutation such as CCD 
(Denborough et al., 1973) and MmD are also at risk of developing an MH reaction. MH 
like crisis may also develop after administration of some drugs such as neuroleptics.  
 
Epidemiology: 
 
The first time an MH reaction was clearly identified in a patient, was at the beginning of 
the 20
th
 Century by Denborough and Lovell in1960. Since than the number of 
publications reporting MH reactions has grown exponentially and it is now established 
that the incidence of MH episode is about 1 in 5000 to 1 in 15000 anaesthesias in 
children and about 1 in 50000 to 1 in 100000 in adults (Loke and MacLennan, 1998; 
Rosenberg et al., 2007). MH episodes are a major cause of anaesthetic related deaths in 
young, fit individuals (Kaus and Rockoff, 1994). Reactions develop more frequently in 
males than females with males having a greater fatality rate (Brady et al., 2009; Strazis 
and Fox, 1993). It is so far unclear why age and sex differences influence the incidence of 
MH. It has been suggested that young males are more likely candidates for general 
anaesthesia and surgical interventions such as orthopaedic, eye, dental operations, ear, 
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nose and throat trauma in which triggering drugs are frequently used, compared to 
females. All ethnic groups are affected in all parts of the world. It should be mentioned 
however that the reported incidences are probably underestimated because of the 
difficulty in defining mild reactions and since many MH susceptible individuals are never 
anesthetized and also since many individuals who develop an MH reaction do so after 
being subjected to other general anaesthesias without developing a reaction (Loke and 
MacLennan, 1998). MH crises develop not only in humans but also in other species 
particularly pigs, which have been a valuable source for research. Reactions have also 
been described in horses, dogs and other animals (Britt, 1985). Over the years mortality 
in humans has been reduced from 80% to 10% and even 0% in developed countries. This 
is possible under present-day standard anaesthetic practice where heart rate, blood 
pressure, body temperature and other parameters are closely monitored during 
anaesthesia and if necessary the antidote dantrolene is available (Harrison, 1975). 
Nevertheless neurological, muscle and kidney damage still contribute to the morbidity 
resulting from an MH reaction. 
 
 
Clinical description: 
 
MH may occur at any time during anaesthesia and in the early postoperative period. The 
earliest signs are tachycardia, rise in end-expired carbon dioxide concentration despite 
increased minute ventilation, accompanied by muscle rigidity, especially following 
succinylcholine administration. Body temperature elevation is a dramatic but often late 
sign of MH. Other signs include acidosis, tachypnea and hyperkalemia. The progression 
of the syndrome may be very rapid. Uncontrolled hypermetabolism leads to cellular 
hypoxia that is manifested by a progressive and worsening metabolic acidosis. If 
untreated, continuing myocyte death and rhabdomyolysis result in life-threatening 
hyperkalemia. Thus muscle damage brings about electrolyte imbalance, with early 
elevation of serum K
+
 and Ca
2+
 and later elevation of muscle proteins such as creatine 
kinase and myoglobin in the blood and urine myoglobinuria may lead to acute renal 
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failure. Additional life-threatening complications include disseminated intravascular 
coagulation, congestive heart failure, bowel ischemia, and compartment syndrome of the 
limbs secondary to profound muscle swelling, and renal failure from rhabdomyolysis. 
Indeed, when body temperature exceeds approximately 41°C, disseminated intravascular 
coagulation is the usual cause of death. 
For patients known or suspected of being MHS or even for patients with other 
myopathies, anaesthetic management should be changed to avoid contact with trigger 
agents. All inhalation anaesthetics except nitrous oxide (NO) act as trigger agents for 
MH. Thus in patients at risk for developing a MH reaction a combination of non-
triggering anaesthetics such as barbiturates, tranquilizers, narcotics, propofol, ketamin, 
NO, and local anaesthetics should be used. 
 
Laboratory diagnostic methods:  
 
The “gold standard” for diagnosis of MH is currently the in-vitro contracture test (IVCT), 
which is based on contracture of muscle fibres in the presence of halothane or caffeine. 
This test was developed and standardize by the European Malignant Hyperthermia Group 
(EMGH, www.emgh.org) to exclude the MH risk of family members who had a MH 
reaction. The test is invasive because for each test muscle fibres from biopsied skeletal 
muscle need to be removed. In Switzerland, phenotypic assessment by the IVCT has been 
performed since 1986 in the MH laboratory of the Departments of Anaesthesia and 
Research, Kantonsspital Basel. 
 
Summarized protocol: 
 
The biopsy is preferably performed from the quadriceps muscle (vastis medialis or vastis 
lateralis) under regional anaesthesia. The patient fully recovers from the biopsy within 8 
to 11 days. After excision, muscle bundles are immediately placed in precarboxygenated 
Krebs-Ringer solution at room temperature at a pH of 7.4. The muscle should be 
transported to the lab with minimal delay between the surgical removal of the muscle 
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strip and the IVCT performance; this time should not exceed 5 hours. The muscle biopsy 
is dissected into strips (15-25mm length x 2-3mm thickness) free of connective tissues. A 
strip is suspended in a bath of Krebs-Ringer solution at 37°C. It is stretched to its optimal 
length and allowed to equilibrate in order to develop a stable resting tension; viability is 
demonstrated by recording twitches elicited by electrical stimulation. Once the baseline 
tension is obtained, muscle strips are tested successively for their sensitivity to increasing 
concentrations of caffeine and halothane. The threshold of positivity is an increase of ≥ 
2mN in the resting tension to caffeine concentration ≤ 2mM and to halothane 
concentration ≤ 0.44mM (2% vol) (Fig 1-13). According to the European guidelines, 
patients are diagnosed as MHS if results are positive for both substances, MHN if results 
are negative for both substance and MHE when only one test is positive. For research, 
MHE patients are treated separately, while for clinical purposes they are considered as 
MHS. 
 
 
 
 
 
 
Figure 1-13: In Vitro Contracture Test. (A) set up for IVCT. (B) Original traces with 
resting tension and absolute twitch tension. The test with halothane in a normal and a 
MHS individual is shown. The increase of resting tension of MHS reflects the 
development of a contracture.  
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The IVCT carries a good sensitivity (99%) and specificity (93.6%) (Ording et al., 1997). 
A slightly different protocol for testing MH susceptibility evolved in North America and 
is referred as the caffeine-halothane contracture test (CHCT). The test is associated with a 
lower specificity (78%) and sensitivity (97%) than the European protocol (Allen et al., 
1998). Japan also has a different standard protocol for testing MH susceptibility. It relies 
on the detection of an accelerates rate of calcium-induce calcium-release (CICR) from SR 
of skinned muscle fibres in comparison to reference values previously measured in 
healthy controls. In this test, the sarcolemma of skeletal muscle fibres is chemically 
destroyed, thus allowing the stimulation of calcium release from sarcoplasmic reticulum 
using external calcium solutions of five different concentrations. If the patient's CICR 
values are 1.5 SD above the normal average values at two or more calcium 
concentrations in two or more skinned fibres, the CICR rate is defined as being clearly 
enhanced. Otherwise, CICR test results are reported as abnormally enhanced or not 
enhanced (Ibarra et al., 2006). Nevertheless, all test procedures carry the potential risk of 
false-positives and false-negatives. Moreover, people with other neuromuscular disorders 
can have a positive IVCT. The major drawbacks of the IVCT are false positive and false 
negative results, the invasiveness of the test since surgical procedure is required, the test 
is expensive and commitment of a specialized testing center. 
Modifications of EMHG protocol include the use of ryanodine (Bendahan et al., 2004) 
which binds selectively to the calcium release channel, 4-chloro-m-cresol (Rueffert et al., 
2002) but to date these agents have not been included in the standard protocol. 
Further problems arising from the presently used diagnostic method are linked to the fact 
that supplies of halothane are becoming limited. Possible alternative trigger agents are the 
fluorinated ether and sevoflurane. Even if the IVCT is the “gold standard” research is 
focusing on the development of less invasive but equally sensitive tests for MH 
diagnosis. 
Measurements of other physiologic parameters potentially associated with MH pathology 
such as abnormal lymphocyte or hepatocytes intracellular calcium mobilization in 
response to anaesthetics have not been proven as sufficiently useful for clinical diagnosis 
of MH (Fletcher et al., 1990; Klip et al., 1987; Klip et al., 1986; Ording et al., 1990) 
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(Iaizzo et al., 1991). DNA analysis, however, offers an alternative to IVCT, requiring 
only a blood sample, which can be sent to specialized testing laboratories. Since about 
50% of MH cases have been linked to mutations in the RYR1 gene and over 100 different 
point mutations have been identified in MH families, genetic identification of a proven 
RYR1 causing mutation can theoretically substitute the IVCT, however, patients with 
negative genetic tests still require an IVCT. 
 
 
 
 
 
 III.3.2 Central Core Disease 
 
 
Central core disease (CCD) is a rare, nonprogresive, or slowly progressing myopathy, 
presenting in infancy, with main clinical symptoms such as hypotonia and proximal 
muscle weakness. CCD is usually inherited as an autosomal dominant (AD) trait 
(Jungbluth, 2007) but recessive inheritance has been recently described in few families 
(Kossugue et al., 2007; Wu et al., 2006; Zhou et al., 2006b; Zhou et al., 2007). Marked 
clinical variability, often within the same family, has been recognized. Orthopaedic 
complications such as congenital dislocation of the hips (Ramsey and Hensinger, 1975), 
scoliosis which may be present from birth (Merlini et al., 1987) and foot deformities 
including talipes equinovarus and pes planus (Gamble et al., 1988) are common in CCD.  
Almost all patients with CCD achieve the ability to walk independently, except the most 
severe neonatal cases and those with congenital dislocation of the hips. 
More severe presentations within the range of the foetal akinesia syndrome (Romero et 
al., 2003) have been reported associated with recessive inheritance or de novo dominant 
mutations. Inability to bury eyelashes completely may be the only manifestation of some 
patients presenting with mild symptoms. Bulbar involvement is untypical in the dominant 
form and extra-ocular muscle involvement has been considered a clinical exclusion 
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criterion by some authors however, both features may be observed in the most severely 
affected neonates due to recessive inheritance (Romero et al., 2003).  
Beside the clinical diagnosis by a neurologist, pathological examination of a muscle 
biopsy from CCD patients shows muscle fibre, with areas of reduced or absent oxidative 
enzyme activity running along the longitudinal axis (Dubowitz and Pearse, 1960). These 
areas are called cores and they are observed upon histological staining of the muscle 
biopsies from patients. Type I fibre predominance is common in CCD. Electron 
microscopy shows variable degrees of disintegration of the contractile apparatus within 
the core region, from Z line streaming to total loss of myofibrillar structure  
Many patients with CCD are positive for the malignant hyperthermia susceptibility 
(MHS) trait on IVST (Robinson et al., 2002; Shuaib et al., 1987)  and should therefore be 
considered at risk for MH episode during anaesthesia. An association between CCD and 
MHS had been suspected early, as individuals with MHS may have central cores on 
muscle biopsy (Denborough et al., 1973)  and patients with CCD may be prone to 
malignant hyperthermia episodes (Eng et al., 1978; Frank et al., 1980; Shuaib et al., 
1987). In most cases, patients with dominant CCD carry mutations in RYR1 gene and 
with few exceptions these are clustered in the hydrophobic COOH-terminal pore-forming 
region of the molecule (domain 3) (Robinson et al., 2006; Treves et al., 2005; Wu et al., 
2006). 
 
 
 
III.3.3 Multi-minicore disease 
 
 
MmD disease is an autosomal recessive early onset congenital myopathy (Engel et al., 
1971). The diagnosis of MmD is based on the presence, in most muscle fibres, of 
multiple mini-cores, which occur in both type 1 and type 2 fibres and typically run to a 
limited extent along the longitudinal muscle fibre axis. By electron microscopy mini-
cores appear as unstructured lesions with amorphous material, misalignment of 
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myofibrils and absence of mitochondria. The most common phenotype of MmD or 
“classical” MmD form is characterized by the axial predominance of muscle weakness, 
scoliosis with spinal rigidity and respiratory insufficiency; because of early respiratory 
failure, most patients require mechanical ventilation. A second group of patients shows 
moderate phenotype with generalized muscle weakness predominantly in the hip girdle 
region, amyotrophy and hyperlaxity. In this group of patients, scoliosis and respiratory 
impairments are mild or absent. Other patients may also have partial or complete 
ophthalmoplegia. The clinical heterogeneity of MmD is reflected in its genetic 
heterogeneity having been linked to recessive mutations both in the selenoprotein 1 
(SEPN1) gene and the skeletal muscle RYR1 gene (Ferreiro et al., 2002; Godfrey et al., 
2006; Jungbluth et al., 2002; Moghadaszadeh et al., 2001). Although genotype-phenotype 
correlations have not been fully established, it appears that extra-ocular muscle 
involvement is more common in the RYR1-related form of MmD, while severe scoliosis 
and respiratory impairment requiring ventilatory support are more prevalent in SEPN1-
related „classical‟ MmD (Ferreiro et al., 2002; Jungbluth et al., 2002; Monnier et al., 
2003). The association with malignant hyperthermia (MH) is not as well documented as 
in CCD due to dominant RYR1 mutations (Denborough et al., 1973), but clinical MH 
episodes have been recognized in a few cases of MmD (Koch et al., 1985; Osada et al., 
2004); Mini-cores have also been noted in muscle biopsies from families with MH 
susceptibility due to RYR1 mutations but no other clinical features of a congenital 
myopathy (Barone et al., 1999; Guis et al., 2004). Precautions during general anaesthesia 
are necessary especially in the cases of MmD with RYR1 mutation.  
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  III.3.4 Centronuclear myopathy (CNM) 
 
 
Centronuclear myopathy is a rare and genetically heterogeneous congenital myopathy. 
On examination of muscle biopsies from CNM patients, the nuclear material is located 
predominantly in the center of the muscle cells with a central aggregation of oxidative 
enzymes and type 1 fibre predominance. Mutations in the myotubularin (MTM1) gene on 
chromosome Xq28 are implicated in the X-linked variant of disease and mutation in the 
dynamin 2 (DNM2) gene on chromosome 19p13 have been recently associated with a 
dominant form of CNM (Bitoun et al., 2005; Laporte et al., 1996; Laporte et al., 1997). 
Interestingly a de novo dominant RYR1 mutation has been reported in a sporadic case of 
CNM. The latest findings between RYR1 missense mutations (c.12335C > T; 
Ser4112Leu) and CNM clinical manifestations indicate that RYR1 screening should be 
considered in CNM patients without MTM1 or DNM2 mutations (Jungbluth et al., 2007).  
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                   CHAPTER 2: RESULTS 
 
I. Ca
2+
 homeostasis and role of RyR1 in dendritic cells 
 
I.1 Introduction to publications 
 
Recent data has shown that the skeletal muscle isoform of the RyR (RyR1) is express in 
cells of the immune system, specifically B-lymphocytes and DCs.  
In the first publication of our study we confirmed the expression of RyR1 in B-
lymphocytes, immature and mature monocyte derived DCs and Plasmocytoid cells.  
We investigated the role of RyR1 in dendritic cells by following the changes in 
intracellular Ca
2+
 concentration and phenotypical changes of DCs, upon pharmacological 
activation of RyR1. In particular, since previous publications had noticed a role for Ca
2+
 
in maturation, we were interested in investigating the involvement of RyR1 in the 
maturation process of DCs and possible synergy between TLR engagement (LPS induced 
maturation) and RyR1 activation. We evaluated the expression of genes associated with 
DCs maturation as well as the capacity of DCs to stimulate T-cell responses. We also 
investigated the involvement of RyR1 induced Ca
2+
 release in calcineurin 
(Ca
2+
/calmodulin phosphatase) dependent processes. 
We were also interested (paper 2) in identifying the possible physiological routes of 
RyR1 activation in DCs in-vivo and whether in these cells as well, the L-type Ca
2+
 
channel is a functional partner leading to RyR1 induce Ca
2+
 release. The underlining 
hypothesis being that in cardiac and skeletal muscles, signalling to the RyR1 is coupled 
to the L-type Ca
2+
 channel, which senses changes in membrane potential thereby 
activating Ca
2+
 release from the SR.  
 
In the third part of our study (manuscript 3) we further investigated Ca
2+
 homeostasis in 
DCs since we had noticed that immature DCs exhibit unstimulated changes in their 
intracellular Ca
2+
 concentration. In particular our studies show that spontaneous Ca
2+
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oscillations occur in immature human monocyte-derived dendritic cells, but not in 
dendritic cells stimulated to undergo maturation with LPS or other toll like-receptor 
agonists. We investigated the mechanism and role of spontaneous Ca
2+
 oscillations in 
immature dendritic cells. Amplitude and frequency of specific Ca
2+
 signals are precise 
codes that cell is using to decode and take right messages form different stimulus. 
Spontaneous Ca
2+
 oscillations have been observed in a number of excitable and non-
excitable cells, but in most cases their biological role remains elusive.  
 
I.2 publications 
 
1.  Laura Bracci*, Mirko Vukcevic*, Giulio Spagnoli, Sylvie Ducreux, Francesco   
    Zorzato and Susan Treves. Ca2+ signalling through ryanodine receptor 1 enhances  
    maturation and activation of human dendritic cells 
    J Cell Sci. 2007 Jul 1;120(Pt 13):2232-40. Epub 2007 Jun 13. Erratum in: J Cell Sci.    
   2007 Jul 15;120(Pt 14):2468. 
  * These authors contributed equally to this work 
 
2. Mirko Vukcevic, Giulio C. Spagnoli, Giandomenica Iezzi, Francesco Zorzato¶and 
    Susan Treves. Ryanodine Receptor Activation by Cav1.2 Is Involved in Dendritic Cell 
    Major Histocompatibility Complex Class II Surface expression 
    J Biol Chem. 2008 Dec 12;283(50):34913-22. Epub 2008 Oct 16. 
 
3. Mirko Vukcevic, Francesco Zorzato, Giulio Spagnoli and Susan Treves. 
    Frequent calcium oscillations lead to NFAT activation in human immature dendritic        
    cells 
    J. Biol Chem. 2010 May 21;285(21):16003-11. Epub 2010 Mar 26. 
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Ca2+ signaling through ryanodine receptor 1 enhances maturation and
activation of human dendritic cells
Laura Bracci, Mirko Vukcevic, Giulio Spagnoli, Sylvie Ducreux, Francesco Zorzato and Susan Treves
Journal of Cell Science 120, 2468 (2007) doi:10.1242/jcs.017590
There was an error published in J. Cell Sci. 120, 2232-2240.
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Introduction
Ryanodine receptors (RyR) are intracellular Ca2+ channels
mainly found in excitable tissues, mediating Ca2+ release from
intracellular stores (Sutko and Airey, 1996; Franzini-Armstrong
and Protasi, 1997). The functional Ca2+ release channel is
composed of four ryanodine receptor monomers (each of which
has a molecular mass of approximately 560 kDa), which
assemble into a large macromolecular structure with a molecular
mass of more than 2106 Da (Bers, 2004; Serysheva et al., 2005;
Samso et al., 2005). Three isoforms of the RyR have been
identified at the molecular level: they share an overall amino acid
identity of approximately 60% and experimental evidence
suggests that they are structurally similar, with a large
hydrophilic NH2-terminal domain and a hydrophobic C-terminal
domain containing several transmembrane domains as well as
the channel pore (Bers, 2004; Serysheva et al., 2005; Samso et
al., 2005). Type 1 RyR (RyR1), encoded by a gene located on
human chromosome 19, is mainly expressed in skeletal muscle
where it mediates Ca2+ release from the sarcoplasmic reticulum,
following depolarization of the plasmalemma (Phillips et al.,
1996; Takeshima et al., 1989; Zorzato et al., 1990). Type 2 RyR,
encoded by a gene located on chromosome 1, is mainly
expressed in the heart and in certain areas of the cerebellum and
is activated through a Ca2+-induced Ca2+-release mechanism
(Otsu et al., 1990; McPherson and Campbell, 1993). Type 3
RyR, encoded by a gene located on chromosome 15, is
expressed in several tissues, including the central nervous
system; its expression in some tissues appears to be
developmentally regulated (Sorrentino et al., 1993; Tarroni et al.,
1997). In recent years, more detailed investigations have
revealed that this isoform-specific tissue distribution of RyR may
in fact be more complex. Sei et al. (Sei et al., 1999) and Hosoi
et al. (Hosoi et al., 2001) showed that circulating leukocytes, as
well as leukocyte-derived cell lines, express different RyR
transcripts. We have shown that Epstein Barr Virus (EBV)-
immortalized B-lymphocytes express the transcript, the protein
and the functional RyR1 Ca2+-release channel (Girard et al.,
2001), and O’Connell et al. (O’Connell et al., 2002) have
demonstrated that the RyR1 is expressed in immature mouse
dendritic cells (DCs). Immature DCs (iDCs) act as sentinels in
peripheral tissues, continuously sampling the antigenic
environment. Upon Toll-like receptor engagement by microbial
products or tissue debris, DCs undergo maturation and become
the most potent antigen-presenting cells. At this point, Toll-like
receptor-activated DCs upregulate costimulatory and antigen-
presenting molecules and migrate to secondary lymphoid organs
for the interaction with naive T-cells and the priming of immune
responses in vivo (Banchereau and Steinman, 1998). For several
years it has been known that increases in the intracellular
calcium concentration ([Ca2+]i) participate in the regulation and
maturation of DCs (Koski et al., 1999; Czerniecki et al., 1997),
although the mechanism and molecules involved in the early
steps of the Ca2+-release event have not been clearly defined.
As part of an investigation aimed at identifying the role of
RyR1 in cells of the immune system, we showed that in freshly
isolated human B-lymphocytes, activation of the RyR1 leads
Increases in intracellular Ca2+ concentration accompany
many physiological events, including maturation of
dendritic cells, professional antigen-presenting cells
characterized by their ability to migrate to secondary
lymphoid organs where they initiate primary immune
responses. The mechanism and molecules involved in the
early steps of Ca2+ release in dendritic cells have not yet
been defined. Here we show that the concomitant activation
of ryanodine receptor-induced Ca2+ release together with
the activation of Toll-like receptors by suboptimal
concentrations of microbial stimuli provide synergistic
signals, resulting in dendritic cell maturation and
stimulation of T cell functions. Furthermore, our results
show that the initial intracellular signaling cascade
activated by ryanodine receptors is different from that
induced by activation of Toll-like receptors. We propose
that under physiological conditions, especially when low
suboptimal amounts of Toll-like receptor ligands are
present, ryanodine receptor-mediated events cooperate in
bringing about dendritic cell maturation.
Key words: Dendritic cell, Maturation, Ryanodine receptor,
Signaling
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to the rapid release of the proinflammatory cytokine IL1B.
Furthermore, cells from patients with the malignant
hyperthermia susceptible phenotype, a pharmacogenetic
hypermetabolic disease caused by RYR1 mutations (Treves et
al., 2005), released more proinflammatory cytokines than cells
from controls, indicating that one of the downstream effects of
human RyR1 activation is coupled to cytokine release (Girard
et al., 2001). In the present study we investigated the effects of
pharmacological activation of RyR1 in human DCs. Our results
show that treatment of iDCs with RyR1 agonists is
accompanied by an increase in the intracellular calcium
concentration. Furthermore, treatment of iDCs with a
suboptimal concentration of bacterial lipopolysaccharide
(LPS) in the presence of RyR1 agonists induces activation of
cytokine transcription and upregulation of surface markers that
are typically associated with cell maturation as well as with an
increased capacity to stimulate allospecific T-cells. These
effects are specifically associated with RyR1 activation as they
could be blocked by pretreatment with the RyR1 antagonist
dantrolene (Zhao et al., 2001) and could not be induced by
addition of ATP, an agonist releasing calcium through IP3
mobilization (Ralevic and Burnstock, 1998; Schnurr et al.,
2004). These results provide for the first time evidence for the
involvement of RyR1 in DC maturation and indicate a
functional cooperation between RyR1-mediated and Toll-like
receptor-mediated intracellular signaling.
Results
Fig. 1A shows that peripheral blood monocytes cultured for 5
days in the presence of GM-CSF and IL4 differentiate into iDCs
(Sallusto and Lanzavecchia, 1994). These cells display a typical
immature phenotype in as much as they express the surface
markers CD1a, CD80, CD40, CD86 and CD54 and are negative
for CD83 (maturation marker) and CD14 (monocyte marker).
Furthermore, no positivity for CD3 (T-lymphocytes), CD19 (B-
lymphocyte marker) and CD56 (NK cell marker) could be
detected. Immature CD1a-positive DCs can be matured by
treatment with Toll-like receptor agonists, including bacterial
LPS (Sallusto et al., 1998). Fig. 1B shows that, irrespective of
their degree of maturation, DCs express the gene encoding the
skeletal muscle RyR1 but not the other isoforms. This transcript
is not expressed by other peripheral blood leukocyte populations
such as monocytes (which express the RyR2 isoform transcript)
and T-lymphocytes (Fig. 1B), but is expressed by plasmacytoid
DCs, which are natural circulating DCs isolated from peripheral
blood as opposed to cells obtained upon in vitro culture.
Immunofluorescence analysis shows that the intracellular
distribution of the RyR1 in in vitro-derived CD1a-positive DCs
is concentrated in a reticulum extending from the perinuclear
area towards the plasma membrane. Confocal analysis of 1 m
optical slices shows no surface fluorescence, confirming that the
RyR1 is expressed in intracellular membrane compartments,
most likely the endoplasmic reticulum (Fig. 1C).
Fig. 1. Expression of RyR in human DCs. Peripheral blood monocytes were induced to differentiate into iDCs by 5-day culture in IL4 and
GM-CSF. (A) Cells were then washed and incubated in the presence of fluorochrome-labeled monoclonal antibodies (mAbs) recognizing the
indicated surface markers. Specific fluorescence (full histograms) was evaluated by taking advantage of a FACSCalibur flow cytometer
equipped with Cell Quest software (Becton Dickinson) using, as negative controls, isotype-matched irrelevant reagents (empty histograms).
One representative experiment out of five is shown. (B) Total RNA was extracted from immature (iDCs), LPS-matured (mature DCs) and from
other cell types, and the expression of genes encoding the different RYR isoforms was evaluated by RT-PCR. RNA from EBV-transformed
lymphocytes was used as control for RYR1 isoform gene expression. (C) Immunofluorescence analysis of iDCs. Cells were stained with goat
anti-RyR polyclonal Ab followed by Alexa Fluor-555-conjugated anti-goat Ab (a-j), Alexa Fluor-555-conjugated anti-goat Ab alone (k) or with
allophycocyanine-conjugated anti-CD1a (l). Immunofluorescence analysis on acetone:methanol-fixed iDCs reveals strong perinuclear RyR
fluorescence that extends into the endoplasmic reticulum network. Panels a-j show 1 m optical slices from the bottom upwards; bar, 10 m.
Images were acquired with a 100 Plan Neofluar oil immersion objective (NA 1.3) mounted on a Zeiss Axiovert 100 confocal microscope.
Panel l: paraformaldehyde fixed DCs display typical plasma membrane fluorescence for the CD1a marker (bar, 20 m).
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Single-cell intracellular Ca2+ measurements on fura-2-
loaded iDCs show that addition of 10 mM caffeine leads to a
rapid and transient increase in the [Ca2+]i (Fig. 2A). Data
presented in Fig. 2B confirm that the RyR1 can also be
activated pharmacologically with specific agonists such as
caffeine and 4-chloro-m-cresol (Zucchi and Ronca-Testoni,
1997) as well as by KCl. The addition of 100 M ATP, which
induces Ca2+ release through InsP3 receptor activation in many
cell types (Ralevic and Burnstock, 1998; Schnurr et al., 2004),
was also accompanied by an increase in [Ca2+]i in iDCs (Fig.
2C). Interestingly, the peak amplitude induced by ATP was
significantly larger than that observed after RyR1 activation
(compare Fig. 2B and Fig. 2D; P<0.00001). These results
unequivocally demonstrate that increases in intracellular [Ca2+]
in human iDCs can be stimulated both by InsP3 mobilizing
agonists as well as by RyR1 activators. We next investigated
whether the Ca2+ released through RyR1 activation plays a
specific function in DC maturation.
Immature DCs generated by culturing peripheral blood
monocytes for 5 days in the presence of IL4 and GM-CSF were
induced to mature by 18 hours of incubation with increasing
concentrations of LPS (from 1 ng/ml to 1 g/ml) in the
Journal of Cell Science 120 (13)
presence of 10 mM caffeine. The expression of genes
associated with DC maturation and their capacity for
stimulating T-cell responses was then evaluated. Fig. 3 shows
the results obtained in a typical experiment representative of
data obtained with four different donors. Low (sub-optimal)
concentrations (1 ng/ml) of LPS only slightly activated the
transcription of the genes under investigation, whereas the
addition of an optimal LPS concentration (1 g/ml) strongly
stimulated the transcription of genes encoding the maturation
marker CD83 and IFN, IL12B and IL23A, cytokines that are
associated with a high capacity of stimulating T-cell responses.
Importantly, costimulation of DCs for 18 hours with 10 mM
caffeine plus 1 ng/ml LPS stimulated transcription of all the
genes under investigation to extents similar to those obtained
using a 1000-fold higher concentration of LPS alone. The
involvement of RyR1 activation is supported by the fact that
pretreatment of cells with the RyR1 antagonist dantrolene
followed by the addition of caffeine and LPS inhibited the
synergistic effects of caffeine and LPS on gene expression (Fig.
3A). Quantitatively and qualitatively similar results were
obtained when iDCs were treated with 4-chloro-m-cresol and
LPS, but in some cases the presence of the latter RyR1 agonist
was accompanied by apoptosis, resulting in more variable
results (data not shown). Fig. 3B shows that in human DCs
Ca2+ release mediated by the activation of the InsP3-signaling
pathway induced by 100 M ATP in the presence of 1 ng/ml
LPS could only partially activate DCs, as detected by the
expression of the IL23A gene, albeit at a fourfold lower extent
than that observed upon RyR1 activation. By contrast, it was
not potent enough to induce transcription of the genes encoding
CD83, IL12B and IFN. The addition of 10 mM caffeine alone
(i.e. in the absence of LPS) caused an increase in IL23A gene
expression, but did not affect transcription of the other genes
under investigation (Fig. 3B, right panel).
Finally, increasing concentrations of caffeine (from 1-10
mM + 1 ng/ml LPS) resulted in a proportional increase of
IL23A gene transcription, reflecting the calcium-dependent
nature of this activation event (Fig. 3C); this result was further
confirmed by the observation that addition of 1 M
thapsigargin [an inhibitor of sarcoplasmic and endoplasmic
reticulum Ca2+-ATPases (SERCA)] in the presence of 1 ng/ml
LPS resulted in the activation of IL23A gene transcription (Fig.
3C).
We then examined in more detail the functional
consequences of the maturation signals generated by
simultaneous RyR1 and Toll-like receptor activation. The
capacity of iDCs treated with LPS plus caffeine to stimulate
allospecific T-cell proliferation was assayed by measuring
[3H]thymidine incorporation. As shown in Fig. 3D, iDCs are
relatively poor allostimulatory cells (white bars) and the low
dose of LPS used to activate DCs in this assay (1 ng/ml) was
also not so efficient, causing a 1.6-fold increase in T-cell
proliferation (grey bars). Incubation of iDCs with 100 M ATP
(which induces a large [Ca2+]i transient) plus 1 ng/ml LPS did
not significantly improve [3H]thymidine incorporation by T
cells (horizontally lined bars), as compared with LPS treatment
alone. However, treatment of iDCs with 10 mM caffeine plus
1 ng/ml LPS provided synergistic signals resulting in a twofold
increase in [3H]thymidine incorporation in T cells (hatched
bars). This effect was specific as it could be blocked by
inhibiting RyR1-mediated Ca2+ signaling by pretreating iDCs
Fig. 2. Single-cell intracellular calcium imaging on iDCs.
(A,C) Single-cell intracellular calcium measurements in fura-2-
loaded iDCs obtained after 5 days of culture. The traces show
changes in fura-2 fluorescence ratio (340/380 nm) in a single iDC
after addition of caffeine or ATP. Experiments were performed in
Krebs-Ringer containing 1 mM Ca2+. (B,D) Average peak increases
in fluorescence ratio induced by the addition of the indicated
agonists to fura-2-loaded iDCs. Results represent the mean 
increase in fluorescence (calculated by subtracting the peak
fluorescent ratio from the resting fluorescent ratio) obtained after
addition of 600 M 4-chloro-m-cresol, 10 mM caffeine or 150 mM
KCl (B) or 100 M ATP (D). No difference was found in the peak
Ca2+ in response to RyR activation (P=0.820), but the amount of
Ca2+ released by 100 M ATP was significantly higher (P<0.00001).
Results represent the mean (± s.e.m.)  increase in fluorescence in
DCs isolated from four different donors.
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with 20 M dantrolene, prior to the addition of 10 mM caffeine
and 1 ng/ml LPS (diagonally lined bars). Taken together, these
results suggest that the signals generated in human DCs
through Toll-like receptors (by the addition of LPS) and by
RyR1 activation are different, and that their combined
activation results in synergistic effects.
Although RyR1 can be pharmacologically activated by a
variety of agonists, how its activation occurs in iDCs in vivo
remains puzzling. We were intrigued by the finding that the
addition of KCl causes a rise in the [Ca2+]i in iDCs and
reasoned that this may have physiological relevance. In fact,
cells dying in the vicinity of iDCs in a restricted
microenvironment such as an inflamed tissue could release
their intracellular K+ into the extracellular milieu, thereby
providing the necessary costimulating signal(s) to iDCs
residing in neighboring areas. In order to verify our hypothesis,
we set up a series of experiments; first we tested whether the
effects of caffeine on DC maturation could be monitored by
flow cytometry, by following the surface expression of CD83,
a good phenotypic indicator of DC maturation (Zhou and
Tedder, 1996; Lachmann et al., 2002). Fig. 4A shows that as
early as 4 hours after stimulation 1 g/ml LPS induced
significant surface expression of CD83; this incubation time
was chosen for all subsequent experiments and the results
obtained by adding different stimuli were compared with those
obtained by treating cells with 1 g/ml LPS, which was set at
100% induction of CD83 expression. Fig. 4A shows that
addition of 10 mM caffeine alone, 100 M ATP plus 1 ng/ml
LPS, or pretreatment of cells with 20 M dantrolene followed
by the addition of 10 mM caffeine plus 1 ng/ml LPS did not
result in significant induction of CD83 expression.
Pretreatment of DCs with 20 M dantrolene did not affect the
induction of CD83 surface expression stimulated by 1 g/ml
LPS. However, the addition of 10 mM caffeine plus 1 ng/ml
LPS caused a significant induction of CD83 surface expression
(P<0.001; Student’s t-test).
We followed the same protocol to verify whether the
hypothesis that KCl or the content of necrotic cells could
Fig. 3. RyR activation induces transcription of genes involved
in DC maturation and potentiates allospecific T-cell
stimulation. (A) In vitro-derived iDCs were cultured for 18
hours in the presence of the indicated concentrations of LPS
and with 10 mM caffeine and 20 M dantrolene, as indicated.
Total RNA was extracted and CD83, IFN, IL12B and IL23A
gene expression was evaluated by quantitative real-time PCR.
Gene expression results are expressed as fold-increase as
compared with values obtained in iDCs treated with medium +
1 ng/ml LPS. One representative experiment out of four is
shown. (B) Experiment as in A except that in vitro-derived
iDCs were cultured for 18 hours in the presence of 1 ng/ml
LPS + 100 M ATP (left panel) or in the presence of 10 mM
caffeine and 20 M dantrolene, as indicated (right panel).
Gene expression results are expressed as fold-increase as
compared with values obtained in iDCs treated with medium +
1 ng/ml LPS (left panel; ATP experiments) or as fold-increase
as compared with values obtained in iDCs treated with
medium alone (right panel). One representative experiment out
of four is shown. (C) Experiment as in A except that in vitro-
derived iDCs were cultured for 18 hours in the presence of 1
M thapsigargin, or the indicated concentration of caffeine or
1 M thapsigargin + 1 ng/ml LPS. Total RNA was extracted
and IL23A gene expression was evaluated by quantitative real-
time PCR. One representative experiment out of four is shown.
(D) Immature DCs were harvested on day 5 of differentiation
and stimulated with 1 ng/ml LPS (grey box), with 10 mM
caffeine + 1 ng/ml LPS (hatched box), with 20 M dantrolene
+ 10 mM caffeine + 1 ng/ml LPS (diagonal lines) or with 100
M ATP + 1 ng/ml LPS (horizontal lines), or left untreated
(empty box). DCs were then washed and added to allogenic
PBMC at a ratio of 10:1 for 5 days. [3H] thymidine was then
added and cells were cultured for another day. The bars
indicate the mean value of c.p.m. (± s.e.m.) from triplicate
samples from one donor. The experiment was repeated with
similar results at least four times with different donors.
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mimic the synergistic effects of caffeine on iDC maturation.
Immature DCs were incubated with Krebs-Ringer in which
NaCl was substituted for KCl (in order to maintain the
osmolarity), plus 1 ng/ml LPS for 30 minutes at 37°C; the
medium was then replaced by differentiation medium
containing 1 ng/ml LPS and the cells were incubated for 4
hours. The KCl-washout step was necessary as iDCs were
sensitive to prolonged exposure to KCl. As shown in Fig. 4B,
the addition of KCl and sub-optimal LPS (1 ng/ml) to iDCs
promoted surface expression of CD83, which could be
inhibited by pretreatment with 20 M dantrolene. Fig. 4C
shows that the addition of filtered soluble extracts from
necrotic HEK293 cells in the presence of 1 ng/ml LPS caused
a significant number of cells to express surface CD83; this
stimulation of CD83 surface expression was significantly
decreased by preincubation with 20 M dantrolene
(P<0.0001), or by dialysis of the filtered extracts (P<0.005). In
the former cases, however, some induction of CD83 expression
was still present, indicating that other factors promoting iDC
maturation independently of RyR activation are also released
from dying cells.
In order to dissect the intracellular pathways involved in
Toll-like receptor and RyR activation, we examined (1) the
effects of LPS and caffeine on the translocation of p65 (RelA,
a component of the NF-kB complex) to the nucleus and (2) the
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sensitivity of DC maturation to cyclosporine A, which would
suggest the involvement of the Ca2+/calmodulin phosphatase,
calcineurin. Fig. 5A (top panels) shows that in untreated iDCs
and in cells treated for 5 minutes with 10 mM caffeine and/or
1 ng/ml LPS, p65 was mainly distributed in the cytoplasm;
however, incubation with 1 g/ml LPS for 60 minutes caused
its nuclear translocation in a large number of cells (Fig. 5A,
bottom panel, arrowheads). Caffeine stimulation of iDCs
evokes a low-amplitude calcium signal (Fig. 2), and this low-
amplitude calcium signal alone or in combination with 1 ng/ml
LPS is not sufficient to activate the nuclear translocation of NF-
kB. These results support the hypothesis that some intracellular
signals generated by LPS-mediated activation of Toll-like
receptors in DCs are led by NF-kB-dependent events, whereas
caffeine-activated pathways are NF-kB independent.
We next investigated whether the caffeine low-amplitude
calcium signal is sufficient to activate an alternative signaling
pathway, namely Ca2+/calmodulin-dependent phosphatase
calcineurin. We probed the effect of caffeine on maturation of
iDCs by using the calcineurin pathway inhibitors cyclosporine
A (Barford, 1996) and deltamethrin (Enan and Matsumara,
1992). Fig. 5B shows that the synergistic effects of 1 ng/ml
LPS and 10 mM caffeine (light-grey bars) on maturation of
iDCs could be completely abrogated by pretreatment of iDCs
with 2 M cyclosporine A and 10 M deltamethrin. These
Fig. 4. Incubation of iDCs with KCl or soluble extracts from necrotic cells promotes surface expression of CD83. iDCs were treated for 4 hours
as indicated and the percent positive CD83 cells was determined by flow cytometry. (A) Stimulation with 10 mM caffeine alone or 100 M
ATP + 1 ng/ml LPS did not significantly increase CD83 surface expression; incubation with 10 mM caffeine + 1 ng/ml LPS significantly
increased CD83 surface expression (P<0.001). This effect was blocked by pretreatment with 20 M dantrolene. (B) When KCl was added, cells
were incubated with Krebs-Ringer saline (in which the NaCl had been substituted for KCl) for 30 minutes at 37°C; they were then centrifuged,
and fresh medium containing 1 ng/ml LPS was added and cells were incubated at 37°C for 4 hours. (C) For experiments in which iDCs were
incubated with the supernatant from necrotic HEK293 cells, extracts were prepared as described in the Materials and methods section and
either used directly (+ necrotic cell extract ± 20 M dantrolene) or dialysed overnight against 1PBS (dialysed necrotic cell extract). Results
are expressed as mean (± s.e.m.) percentage induction of CD83 surface expression of at least three experiments performed on iDCs purified
from blood of different donors; values obtained by treating iDCs with 1 g/ml LPS was considered 100%. *P and **P, significant difference in
the treated population compared with iDCs treated with 1 ng/ml. ***P, significant difference from iDCs treated with 1 ng/ml LPS + necrotic
cell extracts.Jo
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results are consistent with the idea that in addition to NF-kB
the Ca2+-calcineurin-sensitive signaling pathway is also
involved in the maturation of human DCs.
Discussion
The present study shows that activation of RyR1 in iDCs
generates, through a calcineurin-sensitive pathway, a
costimulatory signal that enhances the sensitivity of iDCs to
bacterial stimuli, leading to their maturation. These effects are
unveiled when subthreshold concentrations of LPS are used.
DCs express both IP3R and RyR1 intracellular Ca2+ channels
(Hosoi et al., 2001; Stolk et al., 2006; Goth et al., 2006) and
the involvement of Ca2+-dependent signaling events in their
activation has been clearly established. In fact, (1) treatment of
human iDCs with the Ca2+ ionophore A23187 induces
upregulation of major histocompatibility complex (MHC) and
costimulatory molecules and CD83 expression (Czerniecki et
al., 1997) and activates the transcription of IL23A (this study),
and (2) promotes T-cell activation (Faries et al., 2001).
Moreover, (3) treatment of mature human DCs with ionomycin
triggers release of pro-IL-1 (Gardella et al., 2001).
As to the types of intracellular Ca2+-release channels
involved in DC activation and/or maturation, Stolk et al.
recently showed the RyRs are not indispensable because bone
marrow precursors obtained from the liver of RyR1 knockout
(KO) mice injected into sublethally irradiated congenic hosts
could still be induced to differentiate and mature into normal
DCs (Stolk et al., 2006). Notably, however, the Ca2+ signaling
machinery possesses a vast array of toolkit components, which
can be mixed and matched to deliver Ca2+ signals (Berridge et
al., 2003). Thus, one can assume that in the DC precursors
obtained from (lethal) RyR1 KO mice other molecules
involved in intracellular Ca2+ signaling are compensating for
the depletion of RyR1. Clearly, under physiological conditions
RyR1 activation, together with signals generated through
triggering of Toll-like receptors, generates costimulatory
signals involved in the maturation of human DCs.
An interesting observation arising from this study is that
addition of KCl to iDCs is accompanied by a rapid and transient
increase in [Ca2+]i. In skeletal muscle, depolarization of the
plasma membrane is sensed by an L-type Ca2+ channel, which
undergoes a conformational change allowing it to interact
directly with the RyR, thereby activating Ca2+ release from the
sarcoplasmic reticulum (Sutko and Airey, 1996; Franzini-
Armstrong and Protasi, 1997). Although DCs are not electrically
excitable, one can envisage that massive release of KCl from
cells dying in the vicinity of DCs may activate sensitive channels
present on the plasma membrane coupled to the RyR1, thereby
leading to RyR1 activation and thus Ca2+ release. Such a
conclusion is supported by two sets of data: (1) the
demonstration that treatment of iDCs with KCl promotes surface
expression of CD83, which can be antagonized by dantrolene,
and (2) the fact that incubation of iDCs with filtered soluble
extracts, but not dialysed extracts, from necrotic cells promoted
surface expression of CD83 that could partially be prevented by
the addition of dantrolene. Similar results were reported by
Sauter et al. (Sauter et al., 2000), who showed that incubation
of iDCs with extracts from necrotic cells, but not apoptotic cells,
induces DC maturation. Clearly, some of the signals generated
by necrotic cells are capable of activating the iDC RyR,
providing maturation stimuli. Based on these results, we propose
that the intracellular contents released from dying cells in the
vicinity of iDCs provide RyR1-dependent costimulatory
signal(s), leading to full maturation of DCs even in the presence
of suboptimal concentrations of bacterial stimuli. A schematic
representation of our hypothesis concerning the signals
Fig. 5. LPS but not caffeine induces nuclear translocation of NF-kB, whereas caffeine-induced maturation is sensitive to cyclosporine A (CsA).
iDCs were left untreated or stimulated for 5 or 60 minutes at 37°C, as indicated. Cells were allowed to stick to poly-L-lysine-treated coverslips
and permeabilized with acetone:methanol. Cells were incubated with rabbit anti-p65 polyclonal antibodies (Ab), followed by Alexa Fluor-488-
labeled secondary Ab and visualized with a confocal microscope as indicated in the Materials and Methods section. Arrowheads indicate
nuclear fluorescence. Images were acquired with a 100 Plan Neofluar oil immersion objective (NA 1.3) mounted on a Zeiss Axiovert 100
confocal microscope. Horizontal bar, 10 m. Arrowheads point to nuclear translocation of p65. (B) Surface expression of CD83 in
unstimulated iDCs (empty bars) or iDCs stimulated with 1 ng/ml LPS (dark-grey bars) ± 10 mM caffeine (light-grey bars) or pretreated with
2 M CsA for 30 minutes and then with 10 mM caffeine + 1 ng/ml LPS (slashed grey bars), or pretreated with 10 M deltamethrin for 30
minutes and then with 10 mM caffeine + 1 ng/ml LPS (hatched grey bars). Results are expressed as percent (mean ± s.e.m.; n=3) induction of
CD83 surface expression: 100% was the value obtained by stimulating cells with 1 g/ml LPS for 4 hours. **P, significant difference in the
treated population compared with iDCs treated with 1 ng/ml.
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underlying RyR1 activation and their involvement in the event
leading to iDC maturation is illustrated in Fig. 6.
As to the involvement of specific transcription factors in DC
maturation and function, NF-kB has been shown to play a role
in the regulation of transcription of several genes, including
those encoding IL1A and IL1B, IL6, IL8, IL12B, TNF and
IFN and CD86 (Ghosh et al., 1998; Grohmann et al., 1998;
Lee et al., 1999). Under resting conditions NF-kB forms an
inactive complex (NF-kB1+RelA+IkB) detectable in the
cytoplasm, which upon activation translocates to the nucleus
where it binds to specific promoter sequences and functions as
a transcriptional activator. Although it is well-established that
the activation of Toll-like receptors by LPS induces nuclear
translocation of NF-kB (Ghosh et al., 1998; Lee et al., 1999)
(and this study), this does not occur with caffeine, suggesting
the involvement of other (Ca2+-dependent) transcriptional
regulators. In a previous study we showed that RyR1 activation
in human myotubes leads to cyclosporine-A-sensitive IL6
release (Ducreux et al., 2004). In DCs, the effects of
cyclosporine A are controversial: one report suggests that
pretreatment with cyclosporine A increases maturation and
CD80 expression (Ciesek et al., 2005), whereas others report
that cyclosporine A inhibits IL12 production and upregulation
of costimulatory molecules induced by LPS (Lee et al., 1999;
Tajima et al., 2003). Our results support and extend the latter
conclusion. The synergistic effects of caffeine on LPS-induced
maturation are sensitive to cyclosporine A and deltamethrin,
implying the involvement of calcineurin (Barford, 1996; Enan
and Matsumara, 1992) in RyR1-induced maturation of DCs. In
addition, our data demonstrate that the low-amplitude calcium
signal mediated by RyR synergizes with LPS in inducing DC
maturation, whereas the large Ca2+ transient induced by ATP
does not promote the expression of genes associated with DC
maturation. On the basis of these data, one may postulate that
amplitude modulation of the Ca2+ signal is a mechanism
contributing to the maturation of DCs. A similar control by
amplitude modulation of the Ca2+ signal has been proposed to
play an important role in B-lymphocyte signaling (Dolmetsch
et al., 1997). High LPS concentrations may engage a sufficient
number of Toll-like receptors, and thereby the cooperation of
additional signaling pathways is not required to fully activate
DCs. The model emerging from our data indicates that NF-kB
and calcineurin signaling pathways may ultimately converge to
regulate the transcription of a set of genes involved in DC
maturation. A similar complex regulatory mechanism has been
reported for the transcription of the IL4 gene in T cells, which
is under the control of several transcription factors, including
NF-kB, NF-AT and NF-IL6 (Li-Weber et al., 2004).
Finally, on a lighter note, based on these findings one may
envisage that by drinking caffeine-containing beverages
containing up to 85 mg/150 ml caffeine (Barone and Roberts,
1996) (i.e. 3 mM), iDCs residing in the gut may be exposed to
concentrations of caffeine sufficient to activate them,
especially in the presence of low levels of bacterial derivatives
(Iwasaki and Kelsall, 1999), thereby enhancing their antigen-
presenting capacity. Thus, relatively small amounts of antigens
may be sufficient to induce effective T-cell responses and
protection against enteric infections.
Materials and Methods
DC generation and stimulation
iDCs were generated from human peripheral blood mononuclear cells (PBMC) as
previously described (Schnurr et al., 2004). Briefly, monocytes were purified by
positive sorting using anti-CD14-conjugated magnetic microbeads (Miltenyi
Biotech, Bergisch Gladbach, Germany). The recovered cells (95-98% purity) were
cultured for 5 days at 3105/ml in differentiation medium containing: RPMI, 10%
FCS glutamine, non-essential amino acids and antibiotics (all from Invitrogen,
Basel, Switzerland), supplemented with 50 ng/ml GM-CSF (Laboratory Pablo
Cassarà, Buenos Aires, Argentina) and 1000 U/ml IL4 (a gift from A. Lanzavecchia,
Institute for Research in Biomedicine, Bellinzona, Switzerland). Maturation was
induced by an 18-hour culture, unless otherwise stated, in the presence of the Toll-
like receptor-4 agonist LPS (from Salmonella abortus equi; Sigma Chemicals, St
Louis, MO) at the doses indicated in the different experiments. The phenotype of
the cells was evaluated prior to and after maturation by flow cytometry. Briefly, cells
were washed and resuspended in phosphate-buffered saline (PBS). They were then
incubated for 30 minutes at 4°C in the presence of 1:20 dilutions of fluorochrome-
labeled commercial monoclonal antibodies recognizing the following surface
markers: CD1a, CD14, CD40, CD80, CD86, CD83, CD54, HLA-ABC, HLA-DR,
CD3, CD19 and CD56, or isotype-matched controls (BD Pharmingen, Basel,
Switzerland). After two washes, specific fluorescence was evaluated by flow
cytometry, by using a FACSCalibur instrument equipped with Cell Quest software
(Becton Dickinson, San Josè, CA). Plasmacytoid DCs were magnetically isolated
from peripheral blood using BDCA-2 DC isolation kits (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturer’s instructions. The number and
viability of DCs was determined by trypan blue exclusion and purity was assessed
by flow cytometry. For functional experiments, in vitro-derived iDCs were cultured
Fig. 6. Cartoon depicting signaling pathways involved
in DC maturation. In the presence of sub-optimal Toll-
like receptor ligand, the signal(s) generated from cells
dying in the vicinity of iDCs bind to receptors that are
coupled to the RyR1, activating calcium release. This
intracellular pathway leading to DC maturation through
RyR1 activation is dependent upon the activity of
calcineurin as it could be blocked by cyclosporine A
and deltamethrin. PM, plasma membrane.
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in the presence of the indicated concentration of LPS ± 10 mM caffeine ± 20 M
dantrolene or a standard, optimal concentration of LPS (1 g/ml) as control for the
indicated time period. In some experiments, iDCs were stimulated with 100 M
ATP as indicated or with 100 mM KCl plus 1 ng/ml LPS for 30 minutes, followed
by removal of KCl and addition of differentiation medium containing 1 ng/ml LPS
for 4 hours. When the latter protocol was applied, NaCl was substituted for KCl in
order to maintain osmolarity of the medium. For experiments in which iDCs were
incubated with the supernatant of necrotic cells, experiments were performed
essentially as described by Sauter et al. (Sauter et al., 2002); briefly, 6106 HEK293
cells were rinsed twice with PBS, resuspended in 3 ml PBS and subjected to five
cycles of freeze-thawing. Viability was assessed by trypan blue exclusion and was
>95%. Cells were centrifuged, the resulting supernatant was filtered through a 0.2
m Millipore filter and one half was added to iDC cultures (0.8106 cells) in 1 ml
differentiation medium plus a final concentration of 1 ng/ml LPS; the other half was
added to iDCs that had been pretreated with 20 M dantrolene for 30 minutes and
then processed as described above. Cells were incubated for 4 hours at 37°C. For
experiments in which iDCs were incubated with the dialysed supernatant of necrotic
cells, experiments were performed as described above, except that the supernatants
were dialysed overnight against 1PBS, filtered and then added to iDCs.
Ryanodine receptor isoform expression
Total RNA was isolated from leukocyte populations and reverse transcribed into
cDNA as previously described (Girard et al., 2001). The expression of genes
encoding ryanodine receptor isoforms was investigated by PCR analysis using
previously reported specific primers and conditions (Hosoi et al., 2001).
Immunofluorescence analysis and single-cell intracellular Ca2+
measurements
Immunofluorescence analysis was performed on paraformaldehyde-fixed DCs using
allophycocyanine-conjugated anti-CD1a (BD Pharmingen), or on acetone:methanol
(1:1)-fixed iDCs, using a goat anti-RyR raised against the NH2-terminus and
recognizing the three RyR isoforms (Santa Cruz Biotech), followed by Alexa Fluor-
555-conjugated donkey anti-goat antibodies (Molecular Probes) or rabbit anti-NF-
kB (sc-109; Santa Cruz Biotech), followed by Alexa Fluor-488-conjugated chicken
anti-rabbit antibodies (Molecular Probes), as previously described (Ducreux et al.,
2004). Fluorescence was visualized using a 100 Plan Neofluar oil immersion
objective (NA 1.3) mounted on a Zeiss Axiovert 100 confocal microscope.
Single-cell intracellular calcium measurements were performed on fura-2-loaded
iDCs attached to poly-L-lysine-treated glass coverslips mounted onto a 37°C
thermostated chamber that was continuously perfused with Krebs-Ringer medium
containing 1 mM CaCl2. Individual cells were stimulated with the indicated agonist
in Krebs-Ringer (plus 1 mM CaCl2) by way of a 12-way 100 mm diameter quartz
micromanifold computer-controlled microperfuser (ALA Scientific, Westbury, NY),
as previously described (Ducreux et al., 2004). Online (340 nm, 380 nm and ratio)
measurements were recorded using a fluorescent Axiovert S100 TV inverted
microscope (Carl Zeiss, Jena, Germany) equipped with a 40 oil immersion Plan
Neofluar objective (0.17 NA), filters (BP 340/380, FT 425, BP 500/530) and attached
to a Hamamatsu multiformat CCD camera. The cells were analyzed using an Openlab
imaging system and the average pixel value for each cell was measured at excitation
wavelengths of 340 and 380 nm, as previously described (Ducreux et al., 2004).
Quantitative gene expression analysis
Eighteen hours after stimulation, total RNA was extracted from DCs (Qiagen, Basel,
Switzerland) and treated with Deoxyribonuclease I (DNase I) (Invitrogen, Carlsbad,
CA) to eliminate contaminant genomic DNA. After reverse transcription using the
Moloney MurineLeukemia Virus Reverse Transcriptase (M-MLV RT) (Invitrogen),
cDNA was amplified by quantitative real-time PCR in the ABI PrismTM 7700 using
the TaqMan® technology. Commercially available exon-intron junction-designed
primers for GAPDH, CD83, IFN, IL12B and IL23A (Applied Biosystems, Forster
City, CA) were used. Gene expression was normalized using self-GAPDH as
reference.
Allostimulatory properties of DCs
Allostimulatory capacity of DCs treated with different concentrations of LPS alone
or with 100 M ATP, 10 mM caffeine plus or minus 20 M dantrolene, was assayed
by standard mixed lymphocyte reaction (MLR) tests by culturing cells in the
presence of allogenic PBMC in RPMI medium supplemented with 5% pooled
human serum at a 10:1 ratio (Mohty et al., 2002). Lymphocyte proliferation was
evaluated by [3H]-thymidine incorporation.
Activation of intracellular signaling pathways
NF-kB translocation was monitored by indirect immunofluorescence on DCs treated
with LPS and/or caffeine (10 mM) as indicated, for 5 or 60 minutes at 37°C. Cells
were fixed with acetone:methanol and processed as described above for RyR
immunofluorescence, using rabbit anti-NF-kB [anti-p65 (RelA) polyclonal
antibodies; Santa Cruz Biotech], followed by Alexa Fluor-488-conjugated chicken
anti-rabbit antibodies (Molecular Probes).
Involvement of the calcium/calmodulin-dependent calcineurin signaling pathway
was determined by studying the sensitivity of CD83 surface expression to
cyclosporine A or deltamethrin. Briefly, iDCs were pretreated with carrier,
cyclosporine A (2 M) (Sigma Chemicals) or deltamethrin (10 M) (Fluka
Chemicals, Buchs, Switzerland) for 30 minutes, followed by incubation for 4 hours
with 1 g/ml LPS or sub-optimal concentrations of LPS in the presence or absence
of 10 mM caffeine. Cells were harvested and surface expression of CD83 was
investigated by flow cytometry using FITC-labeled anti-CD83 monoclonal
antibodies (BD Pharmingen).
Statistical analysis and software programs
Statistical analysis was performed using the Student’s t-test for unpaired samples;
means were considered statistically significant when the P value was <0.05. The
Origin computer program (Microcal Software, Northampton, MA) was used to
generate graphs and for statistical analysis; figures were assembled using Adobe
Photoshop.
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Ryanodine Receptor Activation by Cav1.2 Is Involved in
Dendritic Cell Major Histocompatibility Complex Class II
Surface Expression*
Received for publication, June 11, 2008, and in revised form, October 10, 2008 Published, JBC Papers in Press,October 16, 2008, DOI 10.1074/jbc.M804472200
Mirko Vukcevic‡, Giulio C. Spagnoli§, Giandomenica Iezzi§, Francesco Zorzato¶, and Susan Treves‡1
From the ‡Departments of Anaesthesia and Biomedicine and §Institute of Surgical Research, Basel University Hospital,
4031 Basel, Switzerland and the ¶Department of Experimental and Diagnostic Medicine, General Pathology section,
University of Ferrara, 44100 Ferrara, Italy
Dendritic cells express the skeletalmuscle ryanodine receptor
(RyR1), yet little is known concerning its physiological role and
activation mechanism. Here we show that dendritic cells also
express the Cav1.2 subunit of the L-type Ca2 channel and that
release of intracellular Ca2 via RyR1 depends on the presence
of extracellular Ca2 and is sensitive to ryanodine and nifedip-
ine. Interestingly, RyR1activation causes a very rapid increase in
expression of major histocompatibility complex II molecules
on the surface of dendritic cells, an effect that is also observed
upon incubation of mouse BM12 dendritic cells with trans-
genic T cells whose T cell receptor is specific for the I-Abm12
protein. Based on the present results, we suggest that activa-
tion of the RyR1 signaling cascade may be important in the
early stages of infection, providing the immune system with a
rapid mechanism to initiate an early response, facilitating the
presentation of antigens to T cells by dendritic cells before
their full maturation.
Ca2 signals regulate a variety of functions in eukaryotic cells
frommuscle contraction andneuronal excitability to gene tran-
scription, cell proliferation, and cell death. To efficiently utilize
Ca2 as a second messenger, cells are equipped with an essen-
tial toolbox kit composed of a variety of proteins that allow
Ca2 ions to flow into the cytoplasm and be removed from the
cytoplasm, proteins that store/buffer Ca2 in intracellular
organelles, and proteins acting as sensors for intracellular Ca2
levels as well as Ca2-regulated enzymes (1, 2). In both excita-
ble and non-excitable cells, generation of an intracellular Ca2
transient is due to the release of Ca2 from intracellular stores
via inositol 1,4,5-trisphosphate or ryanodine receptors (RyRs)2
present on the endoplasmic (ER)/sarcoplasmic reticulum
membranes and opening of Ca2 channels present on the
plasmamembrane. Both the amplitude and the frequency of the
Ca2 signal can be sensed by specific proteins allowing a cell to
respond appropriately to signals, which apparently only give
rise to an increase in the intracellular Ca2 concentration
([Ca2]i). In general, non-excitable cells are endowed with ino-
sitol 1,4,5-trisphosphate receptors which open in response to
the generation of the receptor coupled second messenger ino-
sitol 1,4,5-trisphosphate, allowing Ca2 to flow out of the ER.
On the other hand, excitable cells, which need to respond to
signals within milliseconds, are equipped with RyR Ca2 chan-
nels (1). Regulation of the latter class of proteins is notmediated
by the generation of a second messenger but rather through
coupling with another protein component present on the
plasma membrane, the L-type Ca2 channel (3). In fact, in car-
diac and skeletal muscles, signaling to the RyR is coupled to the
dihydropyridine receptor (DHPR) L-typeCa2 channels, which
sense changes in membrane potential thereby activating Ca2
release from the sarcoplasmic reticulum. L-type Ca2 channels
are composed of an 1 subunit (Cav), which spans the mem-
brane and contains the pore region, and the four additional
subunits1,2, , and . There are at least four genes encoding
the 1 subunits (Cav1.1-Cav1.4), and all mediate L-type Ca2
currents, although their products are preferentially expressed
in different tissues/subcellular locations (3, 4). Cav1.1 is local-
ized in the transverse tubules and is involved in skeletal muscle
excitation-contraction coupling; Cav1.2 is expressed in cardiac
and smoothmuscle cells, endocrine cells, and pancreatic cells
as well as in neuronal cell bodies and is involved in cardiac
excitation-contraction coupling, hormone release, transcrip-
tion regulation, and synaptic integration. Cav1.3 and Cav1.4
have a more widespread distribution, including neuronal cell
bodies, dendrites, pancreatic cells, cochlear hair cells, adrenal
gland, and mast cells where they are involved in hormone/neu-
rotransmitter release, regulation of transcription, and synaptic
regulation (4).
Ryanodine receptors belong to a family of intracellular Ca2
release channels composed of at least three different isoforms
that have been characterized extensively biochemically, func-
tionally, and at the molecular level (5–7). Type 1 RyRs are
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encoded by a gene on human chromosome 19 and are mainly
expressed in skeletal muscle and to a lower extent in Purkinje
cells. Mutations in this gene are associated with the rare neuro-
muscular disorders malignant hyperthermia, central core dis-
ease, and some forms of multiminicore disease (8, 9). Type 2
RyR is mainly expressed in cardiac muscles and cerebellum.
Mutations in its gene are associated with genetic variants of
congestive heart failure, namely catecholaminergic polymor-
phic ventricular tachycardia and arrhythmogenic right ventric-
ular dysplasia (10, 11). Type 3 RyRs are expressed in a variety of
excitable tissues aswell as in immaturemuscle cells (12). Recent
reports have demonstrated that type 1 RyRs are also expressed
in some cells of the immune system (13), particularly B-lym-
phocytes anddendritic cells (DCs)where their pharmacological
activation gives rise to a rapid and transient increase in the
intracellular Ca2 concentration (14–19).
Although both B-lymphocytes and DCs can act as antigen
presenting cells and initiate T cell-driven immune responses
(20), DCs play a central role in the immune system; they are
strategically located in peripheral tissues where they continu-
ously sample their environment for the presence of antigens.
Upon encounter with microbial products or tissue debris,
immature DCs (iDCs) stop endocytosing, undergo maturation,
and become the most potent antigen presenting cells known.
Mature DCs up-regulate co-stimulatory molecules and anti-
gen-presenting molecules, transcribe mRNA for specific cyto-
kines, and migrate to secondary lymphoid organs where they
interact with naïve T cells to initiate specific immune responses
(21). Complete maturation of DCs is thought to require at least
10–20 h (22, 23). The involvement of Ca2 signaling events in
DC maturation had been postulated for a number of years, but
only recently was it demonstrated that RyR1-mediated Ca2
signals can act synergistically with signals generated via Toll-
like receptors driving DC maturation (17, 19). Experimentally,
iDCs can be induced to undergo maturation by treatment with
high (M) concentrations of lipopolysaccharide. Physiologi-
cally, however, an inflamed region most likely contains a mix-
ture of bacterial components, tissue and cellular debris, and
other cellular components, including ions released from dying
cells.
Several questions emerge concerning the role(s) of RyRs in
DCs. (i) Why do these cells utilize the rapid acting RyRs to
achieve such a slow process such as maturation; are RyRs
involved in other aspects of DC function? (ii) What is the phys-
iological route of RyR1 activation inDCs? In skeletalmuscle the
Cav1.1 subunit of the DHPR L-type Ca2 channel present on
the transverse tubular membrane acts as a voltage sensor and
interacts directly with the RyR1 to initiate Ca2 release. Are
DCs equipped with a similar signaling pathway?
In the present report we show that DCs are endowed with a
DHPRwhich is activated bymembrane depolarization and trig-
gers Ca2 release via RyR1. More importantly we show that
activation of this signaling pathway is both necessary and suffi-
cient to cause the rapid release of an intracellular pool of MHC
class II molecules onto the plasma membrane. We hypothesize
that a such a rapid signalingmachinerymay be important under
specific conditions, namely in the very early phases of an
immune response when T cells and iDCs may become inti-
mately connected; engagement of T cell receptors with the
MHC class II molecules on the surface of iDCs rapidly activates
T cells to release factors stimulating an increase in the level of
expression of MHC class II molecules on the surface of iDCs,
possibly supporting very early activation steps of T cells.
EXPERIMENTAL PROCEDURES
Isolation and Generation of Dendritic Cells—Human iDCs
were generated from peripheral bloodmononuclear leukocytes
as previously described (17). Brieflymonocyteswere purified by
positive sorting using anti-CD14 conjugated magnetic
microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany).
Sorted monocytes were cultured for the following 5 days in
differentiation medium containing RPMI, 10% fetal calf serum,
glutamine, nonessential amino acids, and antibiotics (Invitro-
gen) supplemented with 50 ng/ml granulocyte-macrophage
colony-stimulating factor (Laboratory Pablo Cassara`, Buenos
Aires, Argentina) and 1000units/ml interleukin 4 (a gift fromA.
Lanzavecchia, Bellinzona, Switzerland).
Murine dendritic cells were isolated by positive sorting from
spleens treatedwith collagenaseD (1mg/ml;Worthington Bio-
tech; Lakewood, NJ) using anti-CD11c-coated magnetic
MicroBeads according to the manufacturer’s instructions
(Miltenyi Biotech). The phenotype of cells was evaluated before
experiments by flow cytometry using a FACSCalibur instru-
ment equipped with Cell Quest software (BD Biosciences) as
previously described (17).
Preparation of Necrotic Cell Extracts—Extracts were pre-
pared essentially as described (17); briefly, cultured HEK293
cells (1–1.5  107) were harvested, rinsed twice with PBS,
resuspended in PBS, and subjected to 5 cycles of freeze-thaw-
ing. Viability was assessed by trypan blue exclusion and was
5%. Large cellular debris were removed by centrifugation, and
their supernatant was filtered twice through a 0.22-m Milli-
pore filter and stored at70 °C.Where indicated, extracts were
dialyzed overnight at room temperature against PBS using a
3000 Da cut-off Spectrapore dialysis membrane (Spectrum
Laboratories). Extracts were then centrifuged and filtered twice
through 0.22-mMillipore filters.
Stimulation of iDC and CD83 Expression—In vitro derived
iDCs were cultured for 4 h at 37 °C in the presence of 1 g/ml
LPS (from Salmonella abortus equi, Sigma) or in the presence
of 1 ng/ml LPS supplemented with supernatants from necrotic
cells. Briefly, necrotic cell extracts obtained from 1 107 cells
(1.2 ml) were added to 0.8  106 iDCs cultured in 1 ml of dif-
ferentiationmediumplus 1 ng/ml LPS; when nifedipine or dan-
trolene were used iDCs were pretreated at 37 °C for 45 min in
the dark with 10 M nifedipine (Calbiochem) or 20 M dan-
trolene (Sigma) before the addition of the necrotic extract. Cells
were harvested, and surface expression of CD83 was investi-
gated by flow cytometry using FITC-labeled anti-CD83 mono-
clonal antibodies (BD Pharmingen) on paraformaldehyde (1%
in PBS) fixed cells.
Single-cell Intracellular Ca2 Measurements—Measure-
ments were performed on fura-2 (Molecular Probes, Eugene,
OR)-loaded iDCs. In some experiments fura-2 loading and
incubation with 500 M ryanodine (Calbiochem) were per-
formed simultaneously. After loading, cells were rinsed once,
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resuspended in Krebs-Ringermedium and allowed to adhere to
glass coverslips, which were then mounted onto a 37 °C ther-
mostatted chamber thatwas continuously perfusedwithKrebs-
Ringer medium containing 1 mM CaCl2. Individual cells were
stimulated with the indicated agonist by way of a 12-way
100-mm diameter quartz micromanifold computer-controlled
microperfuser (ALA Scientific, Westbury, NY) as previously
described (15). Online (340 nm, 380 nm, and ratio) measure-
ments were recorded using a fluorescent Axiovert S100 TV
invertedmicroscope (Carl Zeiss, Jena, Germany) equippedwith
a 40 oil immersion Plan Neofluar objective (0.17 NA) and
filters (BP 340/380, FT 425, BP 500/530) and attached to a
Hamamatsu multiformat CCD camera. Cells were analyzed
using an Openlab imaging system, and the average pixel value
for each cell wasmeasured at excitationwavelengths of 340 and
380 nm, as previously described (15).
Membrane PotentialMeasurements—Changes inmembrane
potential were assessed after the changes in fluorescence of the
lipophilic dye bis-(1,3-diethylthiobarbiturate)-trimethineox-
onal (bis-oxonol) as described by the manufacturer (Molecular
Probes). iDCs (0.65 106 cells/ml) were rinsed, resuspended in
PBS, and added to a cuvette containing 200 nM bis-oxonol in
PBS. After allowing the dye to equilibrate, changes in fluores-
cence were monitored with a PerkinElmer Life Sciences LS50
spectrofluorometer equipped with magnetic stirrer and ther-
mostatted at 37 °C.
Immunofluorescence Analysis—Immunofluorescence analy-
sis was performed as indicated onmethanol-fixed or methanol:
acetone (1:1)-fixed iDCs using rabbit anti-Cav1.2 antibody
(anti-CCAT, a gift from Natalia Gomez-Ospina and Prof.
Ricardo Dolmetsch, Department of Neurobiology, Stanford
University School of Medicine, Stanford CA), goat anti-RyR
(Santa Cruz Biotechnology Inc.), mouse anti-human HLA DR
(Caltag Laboratories, BurlingameCA) followed by Alexa Fluor-
488-conjugated chicken anti-rabbit IgG, Alexa Fluor-555-con-
jugated donkey anti-goat IgG (Molecular Probes), or PE-conju-
gated goat anti-mouse IgG (Southern Biotech). Fluorescence
was visualized using a 100 Plan NEOFLUAR oil immersion
objective (NA 1.3) mounted on a Zeiss Axiovert 100 as previ-
ously described (17).
Immunoblotting and Reverse Transcription PCR Analysis—
For Western blots iDCs (1  107 cells) were washed 3 times
with PBS, and the pellet was then resuspended in 500 l of
detergent extraction buffer containing 1% Nonidet, 0.5%
sodium deoxycholate, 150 mMNaCl, 5 mM EDTA, 50 mM Tris-
HCl, pH 8.0, plus anti-proteases (EDTA-free, Roche Applied
Science), passed through a 25-gauge needle, and incubated for 5
min at 95 °C. The solubilized proteins from 1  106 cells were
loaded in each lane and separated on a 6% SDS-PAG. Proteins
were transferred onto nitrocellulose, and the blots were probed
with a rabbit anti-Cav1.2 antibody (1:2000) followed by perox-
idase-conjugated protein G (1:50000. Fluka Biochemicals,
Buchs, Switzerland). The immunopositive bands were visual-
ized by autoradiography using the Super signal West Dura
chemiluminescence kit from Thermo Scientific.
Reverse transcription PCR was performed as previously
described (15). Total RNAwas isolated from8 106 iDCs using
the ULTRASPEC RNA isolation system (Biotex Labs) and
reverse-transcribed using a cDNA synthesis kit following the
instructions provided by themanufacturer (Roche Applied Sci-
ence). Approximately 100 ng of cDNA were used per PCR
amplification using anApplied Biosystems 2720 thermal cycler.
The following primers spanning exons 15–16 were used to
amplify the Cav1.2 transcript: forward, 5-AAA TTT CCCT
GGG ACTG TTG; reverse, 5-GGT TAT GCCC TCCC CTG.
Such primers yield a DNA fragment of300 bp when amplify-
ing cDNA; amplification from genomic DNA would be highly
unlikely under normal PCR conditions as the expected frag-
ment is too large (2800 bp). Amplification conditions were 5
min at 95 °C followed by 35 cycles of 30 s annealing at 92 °C, 40 s
extension at 50 °C, and 40 s denaturation at 72 °C followed by a
final extension for 5 min at 72 °C using the 2.5 Master Mix
Taq polymerase from Eppendorf. The products of the PCR
reaction were separated on a 6% polyacrylamide gel, and the
bands were visualized by ethidium bromide staining.
Functional Properties of iDCs—Endocytosis was studied by
incubating iDCs in RPMI medium containing FITC-labeled
dextran (final concentration 0.5 mg/ml; Fluka Chemicals,
Buchs, Switzerland) for 30min at 37 °C. Cells were washed in
ice-cold PBS 2 times and fixed with 1% paraformaldehyde,
and the number of FITC-positive cells was assessed by flow
cytometry.
Surface expression ofMHC class I and class II molecules was
monitored in iDCs stimulated with 10 mM caffeine for 1–60
min at 37 °C or on iDCs stimulated with 100 mM KCl, necrotic
cell extracts, 100 M ATP, or 1 g/ml LPS for 1 min. To mon-
itor surface expression of MHC class I and II molecules, stim-
ulated cells were washed with ice-cold PBS, labeled, and ana-
lyzed by flow cytometry using FITC-labeled anti-human HLA
DRandHLAA,B,Cor, in the case ofmouseCD11c cells, with
FITC-labeled anti mouse I-Ab monoclonal antibody (BD
Pharmingen).
In Vivo Investigation of Mouse DC-T cell Interactions;
Increase in [Ca2]i and RapidMHCClass II Induction—CD11c
positive DCs were isolated from the spleens of either B6.C-H-
2bm12Ly 5.1 mice (abbreviated BM12DC) or B6.Ly 5.1 mice (a
generous gift of Prof. Ed Palmer, Department of Biomedicine,
Basel University Hospital, Basel, Switzerland). T-lymphocytes
were isolated from the lymphnodes ofABMRg/mice. These
T cells recognize the I-Abm12 protein expressed on the surface
of B6.C-H-2bm12.Ly5.1DCs but do not recognize the I-Ab pro-
tein expressed on the surface of B6.Ly5.1 DCs (24). T-lympho-
cytes were divided in two groups; one group was left untreated,
whereas the other was incubated with 100 nM charybdotoxin
(Alexa Biochemicals) for 45 min to block K channels (25),
after which the cells were washed to remove excess toxin.
ForCa2 imaging BM12DCwere loadedwith the fluorescent
Ca2 indicator fluo-4 AM (Invitrogen; 5 M final concentra-
tion) for 60 min at 37 °C. In some experiments BM12DCs were
simultaneously incubated with 500 M ryanodine (Calbio-
chem) and fluo-4AM.Cells were thenwashed and resuspended
in Krebs-Ringer containing 1mMCaCl2 and 0.2% bovine serum
albumin. BM12DC were allowed to adhere to glass coverslips
which were then mounted on a 37 °C thermostatted chamber.
Experiments were started by adding T-lymphocytes to the cov-
erslip onto which the BM12DCs had been applied. Changes in
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fluo-4 fluorescence were monitored with a Nikon Eclipse
TE2000-E fluorescent microscope equipped with a CFI APO
TIRF 60 objective. Changes in fluorescence were detected by
exciting at 488 nm and recording the emission at 510-nm via an
electron multiplier C9100–13 Hamamatsu CCD camera.
Image analysis was performedwith theMetaMorph (Molecular
Devices) analysis software package.
For MHC II induction untreated T-lymphocytes or T-lym-
phocytes preincubated with 100 nM charybdotoxin (Alexa Bio-
chemicals) for 45 min and washed to remove excess toxin were
used. Both batches of T cells were placed in 1.5-ml Eppendorf
tubes together with the CD11c positive B6 or B6.C-H-2bm12
DCs. Cells were spun down for 30 s using a Tomy PMC-060
capsulefuge and incubated at 37 °C for an additional 5 min.
They were then diluted with ice-cold PBS, washed, and labeled
with FITC-anti-mouse I-Ab, biotin-labeled anti-CD11c plus
APC (allophycocyanin)-labeled streptavidin, and PE-labeled
anti-CD45.1 (all from BD Pharmingen). Expression of MHC
class II molecules was determined on triple positive cells by
flow cytometry.
Statistical Analysis and Software Programs—Statistical anal-
ysis was performed using the Student’s t test for unpaired sam-
ples; means were considered statistically significant when the p
value was 0.05. The Origin computer program (Microcal
Software, Inc., Northampton,MA) was used to generate graphs
and for statistical analysis. Figures were assembled using Pho-
toshop Adobe.
RESULTS
Upstream Events Leading to RyR1 Activation—In an earlier
report (17) we showed that (i) iDCs only express the type 1 RyR
isoform, (ii) the addition of caffeine, 4-chloro-m-cresol, or KCl
to iDC causes a RyR1-dependent increase in the intracellular
Ca2 concentration ([Ca2]i), and (iii) the signaling cascade
activated by the Ca2 increase acts synergistically with signals
generated via Toll-like receptors, stimulating DC maturation
(17). Because RyRs are present in intracellular membranes and
are not directly accessible to stimulation, our first aim was to
identify events upstream from RyR1 activation by first search-
ing for, and then using amore physiological stimulus leading to
DC maturation.
Fig. 1 shows that treatment of iDCs with a suboptimal con-
centration of lipopolysaccharide (LPS 1 ng/ml) for 4 h in the
presence of necrotic cell extracts, a stimulus that has been
shown to cause maturation (26), leads to a significant increase
in the surface expression of CD83, a reliable phenotypicmarker
for DC maturation (17, 27, 28). The signals generated by the
addition of the necrotic cell extracts and leading to maturation
were significantly decreased by pretreatment of cells with dan-
trolene (p 0.034), an inhibitor of the RyR1 (29) and nifedipine
(p  0.019), a well known L-type Ca2 channel inhibitor (4).
The functional involvement of a nifedipine- and ryanodine-
sensitive Ca2 signal was confirmed by direct measurements of
the intracellular [Ca2] (Fig. 2, A and B). Individual fura-2
loaded iDCs were stimulated with filtered extracts from
necrotic cells. This treatment caused a transient and rapid
increase in [Ca2]i, which was significantly decreased (p 
0.0001) by preincubation of iDCs with 500 M ryanodine (Fig.
2A, inset) (at high concentrations ryanodine blocks the RyR (30,
31); dantrolene, which is used to inhibit RyR-signaling events, is
fluorescent and interferes with imaging when using fluorescent
Ca2indicators) or 10 M nifedipine (p  0.0001; Fig. 2A); in
fact, the mean  fluorescence induced by necrotic extracts was
0.210 0.011 in untreated cells and 0.134 0.094 and 0.029
0.008 in cells pretreated with 500 M ryanodine or 10 M nife-
dipine, respectively. A similar result was observed after the
addition of 100 mM KCl to iDCs (Fig. 2B). In the latter case, if
the experiments were performed in the absence of extracellular
Ca2 and in the presence of 100 M La3 to block Ca2 influx
(32) or on iDCs which had been pretreated with 500 M ryan-
odine or 10 M nifedipine, the mean increases in fluorescence
induced by the addition of 100 mM KCl were significantly
reduced (Fig. 2B; p  0.0001), indicating that the intracellular
Ca2 transient is dependent on the activation of the RyR1, on
influx of Ca2 from the extracellular medium, and is sensitive
to micromolar concentrations of nifedipine.
These results suggest that KCl and necrotic cell extracts may
act in a similar fashion; KCl causes membrane depolarization,
and this can be followed experimentally with the fluorescent
membrane potential dye bis-oxonol whereby depolarization
increases the fluorescence of bis-oxonol (Fig. 2C, left and cen-
tral panels), whereas hyperpolarization causes a decrease in
fluorescence. The addition of filtered necrotic cell extracts to
iDCs causes plasma membrane depolarization (Fig. 2C, right
panel), and the extent of depolarization is proportional to the
number of cells from which the extracts were prepared (not
shown); overnight dialysis of the necrotic extract against PBS
with a 3000-Da cut-off membrane abolished its depolarizing
effect (Fig. 2C, right panel).
FIGURE 1. Surface expression of CD83 induced by necrotic cell extracts is
sensitive to dantrolene and nifedipine. iDCs were treated for 4 h as indi-
cated, and the number of positive CD83 cells was determined by flow cytom-
etry on paraformaldehyde (1% in PBS) fixed cells. Stimulation with 1 ng/ml
LPS alone induced a small increaseCD83 surface expression; the concomitant
presence of supernatants from necrotic HEK293 cells, prepared as described
under “Experimental Procedures” increased CD83 significantly as compared
with iDCs treated with 1 ng/ml LPS (*, p  0.02). This effect was blocked by
pretreatment of iDCswith the RyR1 inhibitor dantrolene (20M; p 0.034) or
with the L-type Ca2 channel inhibitor nifedipine (10 M; p 0.019). Results
are expressed as themean (S.E.) % induction of CD83 surface expression of
at least three experiments carried out on iDCs purified frombloodof different
donors; values obtained by treating iDCs with 1 g/ml LPS were considered
100%.
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In cardiac and skeletal muscles, signaling to the RyR1 is cou-
pled to DHPR L-type Ca2 channels, which sense changes in
membrane potential thereby activating Ca2 release from the
sarcoplasmic reticulum. Because human iDCs express the 1
subunit of the DHPR (33), we wondered whether the depolar-
ization-coupled Ca2 release observed in iDC could be due to
the expression of a Cav1 isoform by these cells. Immunofluo-
rescence analysis using confocalmicroscopy onmethanol-fixed
iDCs labeled with anti-Cav1.2 Abs followed by Alexa Fluor-
488-conjugated anti-rabbit IgG (Fig. 3A, panel 1) and anti-MH-
CII Abs (Fig. 3A, panel 2) followed by PE-conjugated anti-
mouse IgG confirmed partial co-localization of the two
proteins on the plasma membrane of iDCs (Fig. 3A, panel 5).
We next verified if there was co-localization between Cav1.2
and the RyR by performing immunofluorescence analysis on
permeabilized acetone-methanol-fixed iDCs. Under these con-
ditionsCav1.2 appeared to be discretely distributedwithin iDCs
(Fig. 3B, panel 1), whereas immunostaining for the RyR1
showed a more reticular pattern of distribution (Fig. 3B, panel
2); merging the two images shows that part of the positive flu-
orescent signals obtained with anti-Cav1.2 and anti-RyR over-
lap (Fig. 3B, panel 5), indicating that the two proteins co-local-
ize within certain domains of iDCs. To confirm that the
antibodies recognize a protein corresponding to Cav1.2, we
performed Western blot analysis. Fig. 3C shows that the anti-
Cav1.2 Abs we used, which were specifically raised against the
COOH terminus of Cav1.2 (34), recognize a band in total iDC
extractsmigrating with an apparentmolecularmass of 200 kDa
as well as another immunopositive band with a slightly slower
mobility; very similar results were obtained by Gomez-Ospina
who used these Ab to identify Cav1.2 in neurons (34). Finally,
reverse transcription-PCR using primers specifically designed
FIGURE 2.Necrotic cell extracts andKCl induce anifedipine-sensitive increase in [Ca2] in iDCs aswell asmembranedepolarization.A and B, single cell
intracellular calcium measurements in fura-2-loaded iDCs. The traces in the insets show changes in the fura-2 fluorescence ratio (340/380 nm) in single iDC
perfused with necrotic cell extracts (A) or 100 mM KCl (B) Continuous line, no pretreatment; dashed line, cells pretreated with 500 M ryanodine for 60 min.
Experiments were performed in Krebs-Ringer containing 1 mM Ca2 except when La3(100 M) was added, in which case only contaminating Ca2 was
present. When nifedipine or ryanodine were used, cells were preincubated with 10 M nifedipine or 500 M ryanodine during the fura-2 loading. The
histograms represent the mean (S.E. of the indicated n values)  increase in fluorescence, calculated by subtracting the peak fluorescence ratioresting
fluorescence ratio): *, p 0.0001. C, membrane potential changes were monitored by following the change in fluorescence of bis-oxonol as detailed under
“Experimental Procedures.” After allowing thedye to equilibrate, either KCl or filterednecrotic extracts obtained from2.9106 cellswere added to the cuvette
while continuouslymonitoring the emission at 516 nm. An upward deflection indicatesmembrane depolarization. Experimentswere carried out at least three
timesgiving similar results. Themean (S.E.) of 4–6 valueswereused togenerate the fluorescence-KCl dose-dependent curve shown inpanel C (center).a.u.,
arbitrary units.
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to amplify the human Cav1.2 transcript generated a band cor-
responding to the expected size (Fig. 3D) when amplifying
cDNA. PCR amplification using primers specific for human
Cav1.1 and Cav1.3 failed to amplify any band from cDNA of
DCs (results not shown).
Rapid Events Occurring after RyR1Activation—Wewere also
interested in investigating if activation of the RyR1 leads to any
direct changes in DCs. Immature DCs are extremely efficient at
endocytosing (20, 21), so our first experiments were aimed at
determining whether pretreatment of cells with a RyR1 agonist
affects their capacity to endocytose FITC-labeled dextran. No
difference in mean fluorescent intensity was observed between
untreated iDCs or cells treated with 10 mM caffeine or 100 mM
KCl. In 5 different experiments the mean  S.E. % of FITC-
positive cells was 98.5 18.7% for cells pretreated with 100mM
KCl and 100% for iDCs (p	 0.899).
We next investigated whether RyR1 activation is linked to
surface expression ofMHCmolecules. DCs express one pool of
MHC class I molecules that are syn-
thesized and loaded with antigenic
peptides in the ER and two main
populations of MHC class II mole-
cules; one pool is synthesized de
novo and is loaded with processed
antigenic peptides in the ER,
whereas the other is preformed and
located within re-cycling endo-
somes (20). Immature dendritic
cells were stimulated for 1–60 min
with the RyR1 agonist caffeine,
stained with anti-MHC I or anti-
MHC II antibodies, and processed
by flow cytometry. Fig. 4A shows
that as early as 1 min after stimula-
tion, there was a significant increase
in surface fluorescence associated
withMHC class II expression which
then decayed back to resting levels
after 60 min of incubation at
37 °C. The increase inmean fluores-
cence intensity was reproducible
and was specifically generated via
DHPR-RyR1 signaling because (i) it
also occurred after the addition of
necrotic cell extracts and 100 mM
KCl and (ii) the latter effects could
be blocked by pretreatment of iDCs
with dantrolene and nifedipine (Fig.
4B), (iii) it did not occur in cells
treated with high levels (1 g/ml) of
LPS or with ATP, the latter agonist
also generating a Ca2 signal, but
via inositol 1,4,5-trisphosphate
receptor activation (35), and (iv)
KCl and necrotic extracts did not
affect surface expression of MHC
class I molecules (Fig. 4C). Such an
effect may represent a specific and
physiological pathway utilized by iDCs to rapidly expressMHC
class II molecules on their surface. The above-mentioned
experimentswere performedon “in vitro” generatedDCs;when
the same experiments were carried out on naturally occurring
DCs isolated from mouse spleens, the addition of 100 mM KCl
and necrotic cell extracts also caused a significant increase in
surface expression of MHC class II molecules (Fig. 5A).
These findings are intriguing because of their rapid time
course and because of their specificity but yield no informa-
tion regarding their physiological role. We wondered
whether the activation of the RyR1 signaling system could be
important under specific conditions, namely when iDCs are
present in an inflamed environment containing antigens as
well as T cells. Notably, the classical pathways for T cell
activation is via the inositol trisphosphate signaling pathway
which leads to an increase in the [Ca2]i by releasing Ca2
from intracellular stores and by opening Ca2 channels on
the plasma membrane (36). To compensate for the change in
FIGURE 3. Cav1. 2 is expressed in iDCs and shows partial co-localization with the RyR. A, immunofluores-
cence analysis on methanol fixed human iDCs. Shown are iDCs stained with rabbit anti-Cav1.2 polyclonal
antibodies followed by Alexa Fluor-488-conjugated anti-rabbit IgGs (1) or Alexa Fluor-488 conjugated anti-
rabbit IgGs alone (3) andmouse anti-MHC II (HLA DR) Abs followed by PE-conjugated goat anti-mouse Abs (2)
or PE conjugate goat anti-mouse Abs alone (4). Panel 5 shows the merged images, and yellow-orange pixels
indicate overlapping fluorescent signal; bars indicate 10 m. B, immunofluorescence analysis on acetone:
methanol fixed-iDCs (1). iDCs stained with rabbit anti-Cav1.2 polyclonal antibodies followed by Alexa Fluor-
488-conjugated anti-rabbit Abs or Alexa Fluor-488-conjugated anti-rabbit Abs alone (3) or goat anti-RyR poly-
clonal Ab followedbyAlexa Fluor-555 conjugated anti-goat Abs (2) or Alexa Fluor-555 conjugate Abs alone (4).
Panel 5 shows the merged images, and yellow-orange pixels indicate overlapping fluorescent signals; bars
indicate 10 m. All images were acquired with a 100 Plan NEOFLUAR oil immersion objective (NA 1.3)
mounted on a Zeiss Axiovert 100 confocal microscope. C, Western blot of total proteins of iDC (1  106
cell/lane) separated on a 6% SDS polyacrylamide gel. The blot was incubated with rabbit anti-Cav1.2 followed
by protein-G peroxidase. The immunoreactionwas visualized by chemiluminescence.D, reverse transcription-
PCR confirms the presence of the transcript for human Cav1.2 in iDC (see “Experimental Procedures” for details
of the experimental conditions and primers used).
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membrane potential caused by the Ca2 influx, K channels
(Kv1.3 and KCa) open, allowing efflux of K ions out of the T
cells, thus repolarizing the T cell membrane potential (37).
To determine whether these events (i.e. the K efflux fromT
cells and DHPR-RyR1 activation in DCs) are functionally cou-
pled in vivo, we studied if the direct interaction of antigen-
specific T cells with DCs causes an increase in MHC II surface
expression as well as an increase in the [Ca2]i of the DCs. To
carry out the in vivo experiments, we exploited the fact that T
lymphocytes fromABMRg/mice express a transgenic T cell
receptor which recognizes the class II MHC protein I-Abm12
expressed on the surface of DCs from BM12Ly5.1 mice but not
class II MHC protein I-Ab expressed on the surface of control
B6.Ly5.1 mice (24). CD11c-positive splenic DCs isolated from
B6.Ly5.1 or BM12Ly5.1 mice were co-centrifuged with T cells
from ABM Rg/ mice and incu-
bated an additional 5 min at 37 °C.
Cells were then diluted with ice-
cold PBS, stained with fluorescent
Abs, and analyzed by flow cytom-
etry. A further control consisting of
T cells pretreated with charybdo-
toxin to block K channels on T
cells was also included. This toxin
specifically blocks Kv1.3/KCa chan-
nels at nM concentrations and
inhibits K efflux (25). When DCs
from B6.Ly5.1 were incubated with
T cells, there was an approximate
2.5-fold increase in the level of
MHC class II molecules expressed
on splenic DCs, indicating that co-
centrifugation may non-specifically
activate toa lowextentbothcell types.
Interestingly, when BM12Ly5.1 DCs
were co-centrifuged with untreated
ABMRg/Tcells, therewasa5-fold
increase in the level of MHC class II
surface expression on splenic DCs
(Fig. 5B). This 5-fold increase in class
IIMHCexpression is specific as itwas
inhibited in the charybdotoxin-
treated T cell group, supporting the
idea that the full increase in MHC II
expression is due to specific T cell K
channel opening occurring as a con-
sequenceof theTcell/DCinteraction.
We used a similar approach to
confirm that the interaction of
BM12Ly5.1 DCs with ABM Rg/
T cells causes a ryanodine-sensitive
increase in the [Ca2]i of DCs. Fig.
5C shows a typical result obtained
after the addition of ABM Rg/ T
cells to Fluo-4-loaded BM12DCs.
As can be seen, the [Ca2]i of those
DCs which were found to have T
cells attached to them at the end of
the experiment (inset, Fig. 5C) was found to increase in an oscil-
latory manner. This event was not synchronized in the
responding cells as the moment of interaction between the two
populations of cells was not coordinated. In line with our
hypothesis, the increase in [Ca2]i induced by the
BM12Ly5.1DC Rg/ T cell interaction was most likely due to
opening of K channels on the T cells, as the Ca2 transients in
the DCs were profoundly diminished after pretreatment of T
cells with carybdotoxin (Fig. 5D). Finally, pretreatment of DCs
with 500 M ryanodine completely blocked the changes in
[Ca2]i (Fig. 5E).
DISCUSSION
In the present paper we investigated the signaling system
involving the RyR in iDCs and show that the upstream events
FIGURE 4. Pharmacological activation of RyR induces a rapid increase in membrane-associated MHC
class II molecules in iDC. A, iDCs were treated with 10 mM caffeine for the indicated time, labeled with
FITC-labeled anti-human HLA DR, fixed with paraformaldehyde, and analyzed by fluorescence-activated cell
sorter as detailed under “Experimental Procedures.” Results represent themean fluorescent intensity (S.E.) of
four experiments carried out on different donors. *, p  0.015. The inset shows a fluorescence-activated cell
sorter histogramshowingFITC fluorescence in immatureDCs (black line) and in iDCsafter theadditionof 10mM
caffeine for 1 min (gray line). B, iDCs were treated for 1 min with the indicated substance and processed as
described inA. Results represent themean S.E. of 4–6 experiments. Significant differenceswere observed in
the mean fluorescence intensity between iDCs and cells treated with necrotic cell extracts and between iDCs
and cells treated with 100 mM KCl; significant differences in mean fluorescence intensity were observed
between iDCs treated with necrotic cell extracts and KCl as compared with themean fluorescence intensity of
cells receiving similar treatments but preincubated with 10 M nifedipine or 20 M dantrolene; *, p  0.03;
**, p 0.05. C, iDCs were treated for 1min as indicated, labeled with FITC-labeled anti-human HLA A, B, C, and
processed for fluorescence-activated cell sorter analysis as described for A. Results represent the mean fluo-
rescence intensity (S.E.) of five experiments carried out on different DC donors. Mean fluorescence intensity
values were not significantly different in treated cells and iDC.
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leading to Ca2 release via the RyR1 are similar to those occur-
ring in striated muscles and involve the functional interaction
with the DHPR L-type Ca2 channel. We also show that RyR1
activation has direct and rapid physiological consequences
leading to an increase in the level of MHC class II molecules on
the surface of iDCs within seconds.
Such a systemmay be important in
the very early stages of an infection
whereby prompt activation of the
adaptive immune system could
occur allowing rapid priming of T
cells without having to wait for
iDCs to undergo full functional
maturation.
Although the expression of the
RyR1 isoform in human and mouse
dendritic cells has been clearly
established (14, 16–17, 19), little
information if any is available con-
cerning its physiological mode of
activation. In fact, RyRs are intracel-
lular Ca2 channels localized on
sarcoplasmic reticulum/ER mem-
branes, and at least in excitable cells,
their activation is coupled to DHPR
L-type Ca2 channels present on
the plasma membrane (3, 4). The
latter channels have been character-
ized at the molecular, physiological,
pharmacological, and biophysical
level; they require strong depolariz-
ing signals to open, can be blocked
specifically by dihydropyridines and
other organic Ca2 channel block-
ers, act as voltage sensors mediating
Ca2 influx in response to mem-
brane depolarization, and regulate a
number of processes including
muscle contraction, insulin secre-
tion, neurotransmission, and gene
transcription (4). DHPRs are mac-
romolecular structures made up of
four or five distinct subunits that are
encoded by multiple genes. The 1
subunit constitutes the voltage sen-
sor and the pore and usually associ-
ates with the 1 and 2 subunits.
Although DHPRs are predomi-
nantly expressed in excitable tissues
such as neurons and muscle cells,
pancreatic cells, and endocrine cells
as well as T-lymphocytes have been
shown to express theCav1.2 isoform
of L-type Ca2 channels (38–40).
In an early report Poggi et al. (33)
showed that human DC express the
1 subunit of the DHPR as well an 
subunit because they were stained
with the fluorescent dihydropyridine analogue DM-BODIPY-
DHP. They also demonstrated the involvement of DHPR-sen-
sitive Ca2 channels in some DC functions such as apoptotic
body engulfment and interleukin-12 production. We have
extended these results and report that DCs have evolved a chi-
FIGURE5.SurfaceexpressionofMHCclass IImolecules ispromotedbyspecific T cell-DC interactionorby
KCl and necrotic cell extracts and is accompanied by an increase in the [Ca2]i in the DCs. A, % induction
in MHC II surface expression in CD11c-purified DCs isolated frommouse spleen cells after the addition of 100
mMKCl or necrotic cell extracts (mean%S.E.,n	 3–4 experiments); **, p 0.007. B, CD11c-positive dendritic
cellswere isolated from the spleens of either B6.C-H-2bm12Ly5.1mice (BM12DC) or B6.Ly5.1mice (control DC)
and co-centrifugedwith T cells isolated from lymph nodes of ABMRg/mice. T cells were either untreated or
preincubated with 100 nM charybdotoxin (Chyb tox) for 45 min to block Kv1.3 and IKCa1 channels. After co-
centrifugation, DC andT cellswere incubated an additional 5min at 37 °C. Cellswere thendilutedwith ice-cold
PBS, washed, and stained with FITC-labeled anti-mouse I-Ab monoclonal antibody, biotin-labeled anti-mouse
CD11c (Integrin x chain) monoclonal antibody, and PE-labeled anti-mouse CD45.1 monoclonal antibody.
After selection of triple positive cells by fluorescence-activated cell sorter, MHC II expression was analyzed.
Results are expressed as % increase in the mean fluorescent intensity compared with iDC (S.E. of three
experiments; **,p0.007).C–E showchanges in the [Ca2]i in fluo-4 loadedBM12DCafter the additionofABM
Rg/ T cells. Experiments were performed as described under “Experimental Procedures.” C, BM12DC T
cells.D is as in C except that T cells were preincubatedwith 100 nM charybdotoxin before addition to DCs. E, as
in C, except DCs were incubated with 500 M ryanodine during fluo-4 loading. Results are expressed as F/F0
where F is the fluorescent value at any given time, and F0 is the initial fluorescence level obtained at time 0.
Panels represent typical results obtained in six different experiments. Insets in panel C show brightfield pho-
tomicrographof BM12DCat t	0 andbrightfield epifluorescenceof fluo-4-loadedBM12DCat the endof the
experiment (250 s).Numbers indicateDCs thatwere analyzed andhadT cells (arrows) adjacent to them. Thebar
indicates 10 m.
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meric configuration, expressing the cardiac isoform of the 1
subunit (i.e. the Cav1.2 isoform), which functionally interacts
with the skeletal isoformof the RyR. The first question arising is
how can a functional coupling between the “cardiac” Cav1.2
isoform and the “skeletal” RyR1 isoform operate? In muscle
cells depolarization of the plasma membrane is sensed by the
Cav1, which acts as a voltage sensor activating the RyR to
release Ca2 from intracellular stores. In skeletal muscle the
Cav1.1 subunit and RyR1 interact directly (41–43), whereas in
heart cells, which express type 2 RyR, the Cav1.2 subunit acts
both as a voltage sensor and as a Ca2 channel, and the depo-
larizing signal allows Ca2 to flow into the cells from the extra-
cellular environment (44). It is the influx of Ca2 which acti-
vates RyR2 through a mechanism of Ca2-induced Ca2
release. We suggest that in DCs, coupling between the DHPR
and the RyR1 occurs as outlined in Fig. 9 of Schuhmeier et al.
(45); membrane depolarization caused by an increase in K is
sensed by Cav1.2 present on the plasma membrane of DCs.
Once activated, these channels allow Ca2 influx. In turn, this
local increase in [Ca2]i in the DCs activates RyR1 through a
Ca2 induced Ca2 releasemechanism. Such a configuration is
supported by the fact that RyR activation in DCs is strongly
dependent on extracellular Ca2 and can be blocked by nifedip-
ine. That this chimeric arrangement could function is sup-
ported by (i) the observation that electrical stimulation of dys-
genic myotubes (which express RyR1 but lack endogenous
DHPR), reconstituted with the cardiac Cav1.2, evokes myotube
contraction albeit only in the presence of Ca2-containing
medium (41) and (ii) by a report of Schuhmeier et al. (45) who
showed that different Cav channel isoforms (1.1, 1.2, and 2.1)
can functionally interact with RyR1.
The most intriguing questions arising from the observation
that DCs express DHPRs are how and when would these volt-
age-sensor-activated Ca2 channels be activated physiologi-
cally? Indeed DCs are not typically classified as electrically
excitable cells, yet we show that the addition of either necrotic
cell extracts or KCl both cause (i) plasma membrane depolar-
ization, (ii) nifedipine-sensitive increase in [Ca2]i, and (iii)
rapid and nifedipine-sensitive increase in surface expression of
MHC class II molecules. Necrotic and dying cells are present in
any tissue after extensive injury due to physical or mechanical
traumas, inflammation, or infections, and they can release a
number of factors and proteins including uric acid crystals, nucle-
ar-mobility group box 1 protein, and heat shock proteins (HSP96,
-90, -70andcalreticulin)whichcanall induceDCmaturation (46–
48). In addition, because the intracellular K concentration is
140 mM, dying cells will necessarily release K ions into the
extracellular medium; our results support the hypothesis that
necrotic cells may lead to activation of the DHPR-RyR signaling
pathway by releasing a number of factors, including K. This is
supported by the finding that necrotic extracts passed through a
0.22-m filter caused a nifedipine-and ryanodine-sensitive
increase in the [Ca2]i as well as membrane depolarization, but
extracts dialyzed against PBS using a 3000-kDa cut-offmembrane
did not alter the membrane potential. Because ions would be
removed by dialysis, these data suggest that K released from the
dead cells may be physiologically involved in the in vivo activation
of the DHPR-RyR1 signaling pathway.
Another important question is whether the DHPR-RyR1 sig-
naling pathway is only involved in the generation of co-stimu-
latory signals leading to DC maturation or whether it can rap-
idly and directly activate specific functions. Our results exclude
that endocytosis, a process intimately connected with iDC
function, and expression of MHC class I molecules on the
plasma membrane are influenced by activation of the RyR sig-
naling pathway. On the other hand, our results show that sur-
face expression of MHC class II molecules is rapidly (within
seconds) and significantly increased by the activation of the
RyR1 signaling pathway. DCs synthesize large quantities of
MHC class II molecules which classically bind peptides derived
from endocytosed proteins and present them on their surface
for interaction with T cells to initiate a specific immune
response. They also express empty MHC II molecules on their
surface as well as sequestered MHC class II molecules within
intracellular compartments (22, 49). These sequestered mole-
cules apparently reside unproductively within the cell. The
results of the present study indicate that activation of the
DHPR-RyR1 pathway causes expression of preformed MHC
class II molecules on the surface of DCs. Empty surfaceMHC II
molecules can be loadedwith antigenic peptides from the extra-
cellular medium, allowing even immature DCs to present pep-
tides to T cells without intracellular processing (50, 51). We
hypothesize that RyR1 activation in DCs leads to the rapid sur-
face expression of sequestered MHC II molecules. This would
be particularly important for iDC and T cells to interact effi-
ciently directly in an inflamed tissue where dead or dying cells
are present, leading to the rapid amplification of a specific
immune response. Such a rapid activationmust be strictly con-
trolled and most likely requires T cells and iDCs to generate
orthograde and retrograde signals, which would strengthen the
intracellular signals generated and lead to T cell-dependent
immune responses. That T cells are capable of releasing soluble
factors which trigger DCs is substantiated by our findings that
FIGURE 6. Schematic depicting the model of RyR1-dependent signaling
pathways in DC. KCl released from dead cells in the vicinity of DCs causes
membranedepolarization,which is sensedby theDHPRvoltage sensor. Alter-
natively, interaction of T cells with iDC, strong enough to activate an increase
in the [Ca2]i via release from intracellular stores andactivationof Ca
2 influx,
is accompanied by efflux of K to repolarize the T cell membrane potential.
This K is releasedonto the iDCs and canbe sensedby theDHPR. This leads to
activation of the RyR1 signaling pathway causing the rapid expression of
MHC class IImolecules onto the surface of iDCs. The lattermolecules could be
loaded with antigenic peptides and interact in situ with T cells to initiate an
early and rapid specific immune response. TCR, T cell receptor; CRAC, Ca2
release activated Ca2 channel.
RyR1 Signaling in Dendritic Cells
DECEMBER 12, 2008•VOLUME 283•NUMBER 50 JOURNAL OF BIOLOGICAL CHEMISTRY 34921
 at N
ovartis G
lobal, on June 13, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
the direct interaction of murine T cells with a transgenic T cell
receptor specific for the I-Abm12 protein and BM12Ly5.1DC
(which express the I-Abm12) causes (i) a 5-fold increase in sur-
face expression ofMHCclass IImolecules and (ii) an increase in
theCa2 in theDCswhich is sensitive to high concentrations of
ryanodine, which inactivate the RyR Ca2 channel (30, 31), and
charybdotoxin, which blocks K channels on T cells. We sug-
gest that the increase inMHC II surface expression is promoted
by efflux of K via channels present on the surface of T cells
which open after the increase in [Ca2]i triggered by engage-
ment of the T cell receptor. This idea is supported by the obser-
vation that up-regulation of MHC II could be blocked by pre-
treatment of T cells with the K channel toxin charybdotoxin.
A schematic outlining this hypothesis is depicted in Fig. 6.
In conclusion we present evidence that the DHPR-RyR1 sig-
naling machinery plays an important role in up-regulation of
MHC class II molecules on the surface of DCs, and this signal-
ing pathway could be an important target for drugs aimed at
improving the immune system by increasing the efficiency of
antigen presentation or at impairing the immune system by
decreasing presentation of autoantigens responsible for the
induction of autoimmune disorders.
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Spontaneous Ca2 oscillations have been observed in a num-
ber of excitable and non-excitable cells, but in most cases their
biological role remains elusive. In the present study we demon-
strate that spontaneous Ca2 oscillations occur in immature
human monocyte-derived dendritic cells but not in dendritic
cells stimulated to undergomaturation with lipopolysaccharide
or other toll like-receptor agonists. We investigated the mecha-
nism and role of spontaneous Ca2 oscillations in immature
dendritic cells and found that they are mediated by the inositol
1,4,5-trisphosphate receptor as they were blocked by pretreat-
ment of cells with the inositol 1,4,5-trisphosphate receptor
antagonist Xestospongin C and 2-aminoethoxydiphenylborate.
A component of the Ca2 signal is also due to influx from the
extracellular environment and may be involved in maintaining
the level of the intracellular Ca2 stores. As to their biological
role, our results indicate that they are intimately linked to the
“immature” phenotype and are associated with the transloca-
tion of the transcription factor NFAT into the nucleus. In fact,
once the Ca2 oscillations are blocked with 2-aminoethoxydi-
phenylborate or by treating the cells with lipopolysaccharide,
NFAT remains cytoplasmic. The results presented in this report
provide novel insights into the physiology of monocyte-derived
dendritic cells and into themechanisms involved inmaintaining
the cells in the immature stage.
Dendritic cells (DCs)2 are the most potent antigen present-
ing cells and are thought to be the initiators and modulators of
the immune response (1). In general, DCs exist in two forms,
immature DCs (iDC) and mature DCs. Immature DCs are
extremely efficient at endocytosis; they reside in the peripheral
tissues and continuously sample their environment for the
presence of foreign antigens. After capturing antigens, they
become activated and migrate to the lymphoid tissues and in
the process lose the ability to take up new antigens, increase
their surface expression of major histocompatibility complex II
molecules and co-stimulatory molecules involved in antigen
presentation to T cells, and reach their full maturation stage
(1–3). Although generally correct, this picture is nowproving to
be too simple. For example, it was recently found that iDCs are
also involved in induction and maintenance of T cell tolerance
in peripheral tissues (4).
Immature DCs, produced by culturing monocytes for 5 days
in medium containing granulocyte-macrophage stimulating
factor and interleukin-4 (IL-4), are phenotypically, morpholog-
ically, and functionally identical with iDCs occurring in vivo (5).
Their maturation is controlled by Toll-like receptors (TLRs),
one of the best characterized classes of pattern recognition
receptors of mammalian species. Most mammalian species
express about 10–15 different TLRs that are encoded by a yet to
be defined number of genes. Interestingly, distinct subsets of
DCs express different TLRs, and their engagement results in
DC maturation (6). In fact, monocyte-derived DCs can be
induced to mature very efficiently by incubating them with
nanogram to microgram (per ml) concentrations of lipopo-
lysaccharide (LPS) through engagement of TLR4 receptors (7).
In addition, other ligands such as the synthetic TLR7 ligand
imidazoquinoline, a reagent already used as adjuvant in the
treatment of viral infections and skin tumors (8–10), can also
induce maturation of iDCs in vitro. The signaling pathways
leading to DC maturation are complex and involve nuclear
translocation of the transcription factor NF-B as well as
increases in the cytoplasmic Ca2 concentration ([Ca2]) (11–
15). Ca2 is one of the most ubiquitous second messengers
underlying cellular responses such as secretion,motility, prolif-
eration, and death. Interestingly, Ca2-sensitive transcription
factors including NFAT and NF-B regulate the expression of
Ca2-sensitive genes including IL-2, IL-3, IL-4, tumor necrosis
factor-, and interferon- (16, 17). Some cell types exhibit
oscillatory changes of their cytosolic Ca2, and these have been
correlated to a variety of cellular functions. For example, in
T-cells, dependingon their frequency, oscillations triggerCa2-
dependent activation of the transcription factors NFAT,
NF-B, and c-JunN-terminal kinase (JNK) (18). In human bone
marrow-derived mesenchymal stem cells, Ca2 oscillations
have been implicated in differentiation (19), in embryonic stem
cell-derived primitive endodermal cells, oscillations have been
implicated in the exo/endocytotic vesicle shuttle (20), and in
human astrocytoma cells Ca2 oscillations have been impli-
cated in cell migration (21). Ca2 signaling is also known to be
involved in the regulation of immune cell function, and its
* This work was supported by Swiss National Science Foundation Grants
SNF 3200B0-114597 and 3200B0-104060.
1 To whom correspondence should be addressed: Depts. of Anesthesia and
Biomedical Research, Basel University Hospital, Hebelstrasse 20, 4031
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2 The abbreviations used are: DC, dendritic cell; [Ca2]i, intracellular calcium
concentration; iDC, immature DC; LPS, lipopolysaccharide; NFAT, nuclear
factor of activated T-cells; NF-B, nuclear factor -light-chain enhancer of
activated B cells; DAPI, 4 6-diamidino-2-phenylindole, dihydrochloride;
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importance is emphasized by the fact that most immune cells
including DCs express several classes of Ca2 channels on their
plasma membrane (22) as well as intracellular Ca2 channels
belonging to the InsP3R and ryanodine receptor family (23–28).
In this context it is worth mentioning that the involvement of
Ca2 signaling events inDCmaturation has been postulated for
a number of years (14, 15), and we recently demonstrated that
ryanodine receptor 1-mediated Ca2 signals can act synergisti-
cally with signals generated via Toll-like receptors driving DC
maturation (26, 27).
In the present report we show that spontaneous Ca2 oscil-
lations occur in iDCs. These oscillations occur only in iDCs and
are lost during the maturation process, and their abrogation
leads to the cytoplasmic localization of endogenousNFAT. The
results of this study offer additional insights into some of the
signaling processes controlling maturation of DCs.
MATERIALS ANDMETHODS
Generation of Dendritic Cells—iDCs were generated from
human peripheral blood mononuclear cells as previously
described (29). Briefly, monocytes were purified by positive
sorting using anti-CD14-conjugated magnetic microbeads
(Miltenyi Biotech, Bergisch Gladbach, Germany). The recov-
ered cells (95–98% purity) were cultured for 5 days at 3–4 
105/ml in differentiation medium containing RPMI with 10%
fetal calf serum, glutamine, nonessential amino acids, and anti-
biotics (all from Invitrogen) supplemented with 50 ng/ml gran-
ulocyte-macrophage stimulating factor (Laboratory Pablo Cas-
sara`, Buenos Aires, Argentina) and 1000 units/ml IL-4 (a gift
from A. Lanzavecchia, Institute for Research in Biomedicine,
Bellinzona, Switzerland). Maturation was induced by the addi-
tion of LPS 1 g/ml (from Salmonella abortus equi, Sigma) to
the culture medium. In some experiments DC maturation was
induced by the addition of the synthetic TLR7 agonist, imida-
zoquinoline (3M-001) (final concentration 3 M), that was
kindly provided by 3M Pharmaceuticals (St. Paul, MN).
Single Cell Intracellular Ca2 Measurements—Ca2 mea-
surements were performed on DCs loaded with fast Ca2 indi-
cator fluo-4 (Invitrogen; 5 M final concentration). In some
experiments cells were incubated with 100M 2-aminoethoxy-
diphenylborate (2-APB) (Calbiochem), 1 M Xestospongin C
(Calbiochem), or 2 M thapsigargin with 0.5 mM EGTA during
the loading procedure. After loading, cells were rinsed once,
resuspended in Krebs-Ringer medium, and allowed to adhere
to poly-L-lysine (1:60 dilution) (Sigma)-treated glass coverslips
that were than mounted onto a 37 °C thermostatted chamber.
On-line epifluorescence images were acquired every 100ms for
50 s using a Nikon Eclipse TE2000-E fluorescent microscope
equipped with an oil immersion CFI Plan Apochromat 60
TIRF objective (1.45 numerical aperture). Changes in fluores-
cence were detected by exciting at 488 nm and recording the
emission at 510 nm via an electron multiplier C9100–13
Hamamatsu CCD camera which allows fast data acquisition
(maximal temporal resolution 1 frame (110 110 pixels/8 ms).
Where indicated, either 1g/ml LPS or 2MU73122 (BioMol)
was added during the measurements. To investigate the
dynamics of Ca2influx, we measured fluorescent changes in
the TIRF mode; first we identified the focal plane at the cover-
glass/cell membrane contact with a surface reflective interfer-
ence contrast filter, and this focal plane was maintained
throughout the recordings bymeans of the perfect focus system
that exploits an infrared laser beam and a quadrant diode for
online control of the microscope focusing motor. Image analy-
sis was performed with the MetaMorph (Molecular Devices)
software package.
Endocytosis and Quantitative Gene Expression Analysis—
Endocytosis was followed by incubating DCs in RPMI medium
containing 0.5 mg/ml fluorescein isothiocyanate (FITC)-la-
beled dextran (Fluka Biochemicals, Buchs, Switzerland) for 30
min at 37 °C. Cells were washed twice in ice-cold phosphate-
buffered saline fixed with 1% paraformaldehyde, and the num-
ber of FITC-positive cells was assessed by flow cytometry. In
some experiments, before incubation with FITC-dextran, cells
were treated for 45 min with 100 M 2-APB or with LPS (1
g/ml) or with the TLR-7 agonist 3M-001 (3M) for 18 h. Gene
expression was quantified by real time PCR as previously
described (26). Briefly, 1–2 106 iDCs were incubated for 18 h
with 1MXestosponginC, 100M2-APB, 3M imidazoquino-
line (3M-001), or 1 g/ml LPS. Total RNA was extracted and
treated with deoxyribonuclease I (Invitrogen) to eliminate con-
taminant genomic DNA. After reverse transcription using 500
ng of RNA and the Moloney murine leukemia virus reverse
transcriptase (Invitrogen), cDNAwas amplified by quantitative
real-time PCR in the ABI PrismTM7700 using the TaqMan
technology. Commercially available exon-intron junction-de-
signed primers for glyceraldehyde-3-phosphate dehydrogen-
ase, CD83, CD80 CD86, interferon-, and IL23A (Applied Bio-
systems, Forster City, CA) were used. Gene expression was
normalized using self-glyceraldehyde-3-phosphate dehydro-
genase as reference (26). The data from DCs isolated from five
donors were pooled and are expressed as -fold increase in gene
expression compared with untreated iDCs.
Immunofluorescence—Indirect immunofluorescence was
performed onmethanol:acetone (1:1)-fixed DCs using rabbit
anti-NFATc1 (sc-13033) or rabbit anti- NF-B p65 antibody
(sc-109, Santa Cruz Biotechnology) followed by Alexa fluor
488-conjugated chicken anti-rabbit antibody (Invitrogen).
Nuclei were visualized by 4 6-diamidino-2-phenylindole, dihy-
drochloride (DAPI; 100 M) (Invitrogen) staining. Fluores-
cence was detected using a fluorescent Axiovert S100 TV
inverted microscope (Carl Zeiss GmbH, Jena, Germany)
equippedwith an40 FLUARobjective andZeiss filter sets (BP
475/40, FT 500, and BP 530/50; BP 546, FT 560, and 575–640)
for detection of DAPI and FITC fluorescence, respectively.
Immunoblotting Analysis—The cytosolic fraction of 6 106
DCswas extracted as described byHealy et al. (30). Briefly, cells
were washed once and resuspended in 50 l of ice-cold buffer
containing 20mMHEPES, pH 7.5, 5mMNaCl, and 2mM EDTA
to which 50 l of 20 mM HEPES, pH 7.5, 4 mM NaCl, 2 mM
EDTA, and 0.8% Nonidet P-40 were added. Cells were incu-
bated on ice for 2min, and the nuclear andmembrane fractions
were removed by centrifugation (600  g, 10 min, 4 °C). Lae-
mmli loading buffer (10% glycerol, 1% -mercaptoethanol, 2%
SDS, 65 mM Tris-HCl, pH 6.8) was added to the supernatant
(cytosolic fraction) which was boiled for 5 min and then loaded
onto a 7.5% SDS-polyacrylamide gel. Proteins were transferred
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onto nitrocellulose, and the blots
were probed with a rabbit anti-
NFATc1 antibody (1:500; sc-13033,
Santa Cruz Biotechnology) followed
by peroxidase-conjugated proteinG
(1:250,000) and with mouse anti-
tubulin (Santa Cruz sc-5274) fol-
lowedbyperoxidase-conjugatedanti-
mouse IgG (1:200,000). The immu-
nopositive bands were visualized by
autoradiography using the Super
Signal West Dura chemilumines-
cence kit from Thermo Scientific
(for NFAT) and BM chemilumines-
cence kit from Roche Applied Sci-
ence (for -tubulin).
Statistical Analysis and Software
Programs—Statistical analysis was
performed using Student’s t test for
paired samples; means were consid-
ered statistically significant when
the p value was 0.05. When more
than two samples were compared,
analysis was performed by the
ANOVA test followed by the Bon-
ferroni post hoc test. The PROC
MIXED statistical analysis program
(SAS 9.2) on log-transformed data
were used for real-time PCR gene
expression analysis from indepen-
dent biological replicates. The Origin
computer program (Microcal Soft-
ware, Inc., Northampton, MA) was
used to generate graphs and for sta-
tistical analysis. Statistical analysis
of categorical data was performed
using the 2 test for contingency
tables with a 0.05 level of signifi-
cance using R software (R develop-
ment Core team 2008; R Founda-
tion for Statistical Computing,
Vienna, Austria; ISBN 3-900051-
07-0) was used to perform 2 tests.
RESULTS
Immature DCs were loaded with
the fast calcium indicator fluo-4 and were observed by conven-
tional epifluorescence microscopy in the absence of added
stimuli. Such cells display large rhythmic fluctuations of their
cytoplasmic Ca2 (Fig. 1A) with 40% of the cells exhibiting
oscillations with a frequency of one peak every 12.5 s (Table 1).
Interestingly, the addition of LPS (Fig. 1B) or of the TLR-7 ago-
nist (not shown) to iDCs did not affect the high frequency oscil-
lations nor did it cause any immediate changes in the [Ca2]i.
On the other hand, when mature DCs (treated with 1 g/ml
LPS for 18 h) were observed under identical conditions, the
high frequency oscillations were no longer present (Fig. 1C). In
the latter case of the 162 individual cells that were monitored,
FIGURE 1. Immature human dendritic cells show spontaneous Ca2 oscillations. Fluo-4-loaded dendritic
cells were allowed to deposit on poly-L-lysine-treated coverslips, and the changes in fluo-4 fluorescence were
monitored every 100 ms as described under “Materials and Methods.” Shown is a representative trace of the
oscillations observed in immatureDCs (A), in iDCs towhich 1g/ml LPSwas added (arrow) (B), in dendritic cells
treated with LPS (1 g/ml) overnight (mature DCs) (C), in iDCs pretreated with 2-APB for 45 min (D), in iDCs
pretreated with 2 M thapsigargin and 0.5 mM EGTA (E), and in iDCs treated with the PLC-inhibitor U73122 (2
M) (F). Traces are representative of experiments carried out on cells from five different donors. Results are
expressed as F/Fo, where F is the fluorescent value at any given time, and Fo is the initial fluorescence level
obtained at time 0.
TABLE 1
Characterization of spontaneous Ca2 oscillations in DCs
Frequency is represented as a percentage of cells with 1, 2–4, and 4–8 peaks during
50 s. Statistical analysis was performed using the 2 test. p 0.0001. All groups were
significantly different compared to iDC p 0.002.
Total no.
cells
1 peak/
50 s
2–4 peaks/
50 s
4–8 peaks/
50 s
% % %
iDC 83 8.30 51.70 40.00
iDC 100 M La3 60 36.70 45 18.33
iDC 0.5 mM EGTA 66 28.80 53.80 17.40
iDC 100 M 2-APB 116 100 0 0
iDC 1 M Xesto C 56 48.21 41 10.71
LPS-matured DC 162 100 0 0
TLR7-matured DC 266 70.00 20.00 10.00
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100% responded with a single, small increase of the [Ca2]i
within the 50-s measurement (Table 1). To determine the
source ofCa2 in the oscillations, iDCswere treatedwith (i) 100
M 2-APB, a blocker of store-operated Ca2 entry, and of
InsP3-mediated Ca2 release, (ii) 2 M thapsigargin, a SERCA
(sarco(endo)plasmic reticulum calcium ATPase) inhibitor that
leads to depletion of intracellular Ca2 stores, and (iii) 2 M
U73122, an inhibitor of phospholipase C. The addition of these
compounds completely abolished the spontaneous Ca2 oscil-
lations (Fig. 1,D–F). DCs were also incubated with other phar-
macological agents as shown in Table 1; the addition of 100 M
La3 or 0.5 mM EGTA significantly reduced the frequency of
oscillations from 40% cells showing 4–8 peaks/50 s to about
18% cells showing 4–8 peaks/50 s, indicating that Ca2 influx
plays some role in the oscillatory events. The addition of 1 M
Xestospongin C (an inhibitor of InsP3-mediated Ca2 release)
significantly diminished the frequency of the oscillations (Table
1) as well as the peak fluo-4 fluorescence in iDCs (Fig. 2). These
results strongly suggest that the oscillations are mainly due to
InsP3-mediated release of Ca2 from intracellular stores, with a
component (probably involved in store refilling) due to influx
from the extracellular environment. The phenotype of mature
DCs, on the other hand, was quite different irrespective of
whether the cells had been induced to mature via TLR-4 acti-
vation (by overnight incubation with 1 g/ml LPS) or via acti-
vation of TLR-7 (by overnight incubation with 3 M imidazo-
quinoline (3M-001)). In fact, LPS-matured DCs did not show
the high frequency oscillations but rather small and slow (1
peak/50 s) spontaneous fluctuations of their [Ca2]i. Interest-
ingly, incubation with imidazoquinoline, which does not trans-
mit a maturation signal as strong as that conveyed by LPS (see
CD83 expression in Fig. 5A), resulted in DCs with an interme-
diate phenotype; that is, with only a small proportion of cells
showing 2–8 oscillations/min whose magnitude is comparable
with that exhibited by iDCs (Table 1 and Fig. 2). The slow peak
Ca2 increase observed in mature DCs was reduced by more
than 50% by the addition of 100 M 2-APB (Fig. 2), whereas the
peak transient observed in the presence of Krebs-Ringer
medium containing no additional Ca2 and 0.5 mM EGTA was
not different from that observed in the presence of extracellular
Ca2 (1.79  0.31 and 2.10  0.35 F increase in Ca2 and
EGTA containingmedium respectively). These results indicate
that inmatureDCs as well, the slowCa2 transient ismainly do
to release from intracellular stores.
To directly determine whether Ca2 influx accompanies the
oscillations, we examined the DCs by TIRF microscopy, which
allows one to monitor changes in fluorescence occurring at the
plasmamembrane or withinmicrodomains close to the plasma
membrane. As shown in Fig. 3 oscillations are accompanied by
[Ca2]i influx in iDCs. Cells were allowed to attach onto the
glass coverslips, and the areas of attachment were identified
with the surface reflection interference contrast filter (Fig. 3,
panel B). This focal plane was fixed using the perfect focus
system, and changes in the [Ca2]i, which in this case represent
Ca2 events occurring at or very close to the plasmamembrane,
were monitored (Fig. 3, panel C). The pseudocolor images in
panel C represent the changes of fluo-4 fluorescence F (F/Fo)
at four time points, whereas panel D represents the kymo-
graphs of three selected cells (arrows in panel C) showing that
these changes in [Ca2]ioccur at different time points in differ-
ent cells during the 50 s of recording. The specificity of the
signal is demonstrated by the fact that the increase in fluo-4
fluorescence only occurs when cells are bathed in Krebs-Ringer
solution containing 2 mM Ca2 but is absent when cells are
bathed in Krebs-Ringer solution containing 100 M La3 (a
nonspecific blocker of plasma membrane Ca2 channels) or in
LPS-matured DCs (Fig. 3, panel E).
These results support the finding that oscillations of the
[Ca2]i are a specific feature of iDC that is lost upon differenti-
ation but convey little information as to their biological role.
We hypothesized that oscillations may be implicated in main-
taining the immature phenotype by acting on transcription fac-
tors, in particular on the Ca2-sensitive transcription factor
NFAT. To dissect the intracellular pathways directly down-
stream of the spontaneous Ca2 oscillations, we followed the
intracellular localization of endogenous NFAT in oscillating
iDCs or in DCs in which oscillations had been inhibited by
2-APB and in mature DCs. The cytosolic fraction of DCs was
obtained from untreated iDCs, iDCs treated for 15 and 45 min
with 2-APB, LPS-matured DCs, and iDCs treated with cyclos-
porine, a drug that reduces the nuclear translocation of NFAT
by inhibiting theCa2-dependent phosphatase calcineurin. Fig.
4A shows a representativeWestern blot and Fig. 4B shows a bar
graph of the intensities of the immunopositive bands of the
cytosolic content of NFATc1. LPS-matured DCs, which lack
the high frequency Ca2 oscillations, show the highest level of
cytoplasmic expression of NFAT. Similarly, its cytoplasmic
level is high in cyclosporine-treated iDCs but is significantly
reduced in the cytoplasm of untreated iDCs. Treatment of the
latter cells with 2-APB induced the cytoplasmic localization of
NFATc1. Fig. 4C shows the subcellular localization of NFATc1
by immunofluorescence; indeed, in iDCs a number of cells
exhibit nuclear distribution of NFAT (arrows), whereas iDCs
FIGURE 2.Magnitude of spontaneous Ca2 oscillations in DCs. The his-
tograms show the peak Ca2 transient (F/Fo) in untreated iDCs or cells
treated as indicated with 2-APB (100 M), Xestospongin C (Xesto; 1 M),
and LPS (1 g/ml 18 h). Experiments were performed on cells isolated
from at least four different donors, and results are expressed as the mean
(S.E.) peak in fluo-4 fluorescence of 26–145 cells. Statistical analysis was
performed using the ANOVA test followed by the Bonferroni post hoc test.
*, p  0.015; **, p  0.0005.
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treated with cyclosporine or in mature DCs the fluorescence
is distributed throughout the cytoplasm. These results indi-
cate that most of the transcription factor NFAT is targeted to
the nucleus in oscillating iDCs but that abrogation of Ca2
oscillations with 2-APB results in the preservation of NFATc1
within the cytoplasm. To determine whether this was specifi-
cally related to the transcription factor NFAT or a general
effect, we also followed the subcellular distribution of p65
(RelA), a component of the NF-B transcription complex (NF-
B1RelAIkB) detectable in the cytoplasm of iDCs that
translocates to the nucleus uponDCmaturation (12, 13, 26). As
shown in Fig. 4D, in LPS-maturedDCsNF-B is translocated to
the nucleus, whereas in iDCs it shows a cytoplasmic distribu-
tion. Blocking high frequency oscillations with 2-APB does not
result in the nuclear translocation of NF-B. Thus, the simple
abrogation of spontaneous Ca2 oscillations is not sufficient to
stimulate the cells to undergo maturation, whereas the oscilla-
tions appear to regulate nuclear targeting of NFAT and may be
intimately linked to the immature phenotype. The latter
hypothesis was tested by following the effect of abolishing the
high frequency oscillations on the transcription of several genes
characteristic ofmature DCs. As shown in Fig. 5A, iDCs exhibit
low transcription levels of CD80, CD86, CD83, interferon-,
and IL23A, genes that are characteristically transcribed in
matureDCs (1, 26, 31). Inhibition of high frequency Ca2 oscil-
lations with Xestospongin C or 2-APB caused a significant
(2–20-fold) increase in their levels of expression.
Finally we studied whether the high frequency oscillations
are linked to endocytosis, an essential phenotypic characteristic
of iDCs (2, 3), by comparing the capacity of iDCs, 2-APB-
FIGURE 3. Calcium influx in iDCs monitored by TIRF microscopy. Fluo-4 loaded iDCs were resuspended in Krebs-Ringer medium containing 2 mM Ca2 or
100MLa3andallowed toattach topoly-L-lysine-coatedglass coverslips.Onceattached, cellsweremonitoredbybrightfield (panelA)witha surface reflection
interference contrast filter to monitor glass coverslip/cell membrane attachment site (panel B) or by TIRF microscopy (panel C). Images in panel C show
pseudocolored ratiometric (F/Fo) changes in membrane-associated [Ca
2]i at four time points. Panel D shows the kymograph representation of the Ca
2
changes in50 s in3 selectedcells frompanel C.Panel E shows themean (S.E.) increase in fluo-4 fluorescence ratio (F/Fo) of iDCsbathed in2mMCa
2 containing
Krebs-Ringer medium (n 57 cells), in iDCs bathed in Krebs-Ringer medium containing 100 M La3 (n 45 cells), and in LPS-matured DCs (n 20 cells).
Experiments were performed on cells isolated from at least four different donors. **, statistical analysis was performed using the ANOVA test followed by the
Bonferroni post hoc test p 0.0002.
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treated iDCs, andmatureDCs to endocytose FITC-labeled dex-
tran. Fig. 5B shows that although 2-APB reduces the percentage
of FITC-positive cells by 40%, thus significantly reducing the
endocytic activity of iDCs, it does not result in a loss of endo-
cytosis comparable with that seen in mature DCs (loss of
80%). These results strongly suggest that abolishing the Ca2
oscillations generates a signal(s)
required for DC maturation.
DISCUSSION
Spontaneous Ca2 oscillations,
which are rhythmic changes in
[Ca2]i in the absence of stimula-
tion, have been reported in certain
types of excitable and non-excitable
cells such as mesenchymal stem
cells, endodermal cells, human astro-
cytoma cells, astrocytes, pancreatic
acinar cells, cardiac myocytes, oo-
cytes, and fibroblasts (19–21, 32–35),
although their intracellularmediators
and biological role(s) and the func-
tional consequence of their inhibition
have in many cases not been eluci-
dated. In the present study we show
that spontaneous Ca2 oscillations
also occur in human DCs and that
these Ca2 events are an exclusive
characteristic of cells in the imma-
ture stage. In fact, the addition of
LPS as well as maturation triggered
by other stimuli leads to the loss of
the spontaneous high frequency
Ca2 transients. A similar finding
concerning the loss of spontaneous
Ca2 oscillations induced by differ-
entiation was reported in human
mesenchymal stem cells upon dif-
ferentiation into adipocytes (19)
and in osteogenic cells upon differ-
entiation into osteoblasts (36, 37).
Interestingly, in stem cells Ca2
oscillations occur during the G1 to S
transition, suggesting their involve-
ment in cell cycle progression (38,
39). On the other hand, in vitro
monocyte-derived DCs do not ac-
tively proliferate but, rather, acquire
the biochemical and immunological
characteristics of naturally occur-
ring iDCs (5) indicating that in these
cells the oscillations are probably
not involved in cell division.
In immature dendritic cells, in-
tracellular Ca2 stores and InsP3 are
intimately connected with the high
frequency oscillations, as they were
completely abolished by depleting
stores with the Ca2-ATPase inhibitor thapsigargin (2 M) in
the presence of EGTA (0.5 mM). The lack of high frequency
Ca2 oscillations in mature LPS-treated DCs could not be
explained by different levels of expression of functional InsP3R
as mature DCs respond to ATP an InsP3-mobilizing agonist
(23) with a Ca2 transient of comparable magnitude in the
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mature and immature stage (results not shown). As to the intra-
cellular mediator(s) of the Ca2 oscillations, U73122, an inhib-
itor of phospholipase C (40), completely blocked Ca2 tran-
sients, whereas both 2-APB, a rather unspecific inhibitor of the
InsP3R also inhibiting Ca2 entry (41, 42), and Xestospongin C,
an inhibitor of InsP3R-mediated Ca2 release (43), significantly
decreased the frequency and magnitude of these events. The
differences in response to these compounds could be explained
by the contribution of Ca2 influx to the maintenance of the
Ca2 oscillations. To further address this question, we per-
formed intracellular Ca2 measurements in medium contain-
ing 2mMCa2 or in the presence of 100M La3 to block Ca2
entry. Under these conditions Ca2 fluctuations were still pres-
ent, but there was a reduction in the percentage of cells
showing high frequency (	4 transients/50 s) Ca2 tran-
sients. This result together with theTIRFCa2measurements
support the hypothesis that Ca2 influx is necessary to main-
tain the high frequency Ca2 oscillations characteristic of
immature dendritic cells through a refilling mechanism.
The most intriguing question arising from the observation
that monocyte-derived dendritic cells in the immature stage
show frequent Ca2 oscillations concerns the biological role(s)
of the oscillations. Inmacrophages, Ca2 oscillations have been
reported to accompany phagocytosis, suggesting a relationship
between Ca2 oscillations and uptake of foreign particles (44,
45). In vivo, immature DCs continuously sample their environ-
ment for foreign antigens, and indeed one of themain functions
of iDCs is antigen capture by endocytosis. We originally
FIGURE 4. Influence of Ca2 oscillations on the intracellular localization of NFAT andNF-B. A, shown is a representativeWestern blot of the cytoplasmic
fraction of iDCs treated as indicated and LPS (1 g/ml)-matured DC (mDCs). In each lane the proteins present in the cytoplasmic extract of 6 106 cells was
separated on 7.5% SDS-polyacrylamide gel and blotted onto nitrocellulose. The blot was cut into two; the upper portion (	60 kDa) was incubated with rabbit
anti-NFATc1 followed by peroxidase-conjugated anti-rabbit IgG. The lower portion was used as a control for protein loading and developed with -tubulin.
Immunopositive bands were visualized by chemiluminescence; indicates bands corresponding to NFAT. The experiment was repeated five times on DCs
from different donors. B, the intensity of the immunopositive bands from five experiments was quantified by densitometry using Bio-Rad GelDoc 2000; the
intensities were corrected for -tubulin content. Values are expressed as % intensity of immunopositive bands of mature DCs. Statistical analysis was per-
formed using the ANOVA test followed by the Bonferroni post hoc test. *, p 0.04; **, p 0.00005. C, shown is an immunofluorescence analysis of NFATc1
subcellular distribution in iDCs (untreated or treated with 2 M cyclosporine (CSA)) and mature DC. Cells were fixed with an ice-cold solution of acetone:
methanol (1:1) for 20 min at
20 °C. Cells were then incubated with rabbit anti-NFAT followed by Alexa fluor 488-labeled anti-rabbit IgG. Before mounting,
DAPI staining was performed to visualize nuclei. The scale bar indicates 25 m. Arrows indicate nuclear localization of NFAT in iDCs. D, NF-B subcellular
distribution in iDCs (untreated or incubated with 100M 2-APB for 45 min or with 1g/ml LPS for 60 min) is shown. Cells were fixed with an ice-cold solution
of acetone:methanol (1:1) for 20min at
20 °C. Cells were then incubatedwith rabbit anti- NF-B p65 polyclonal antibody followed by Alexa fluor 488-labeled
anti-rabbit IgG. Beforemounting,DAPI stainingwasperformed to visualize nuclei. The scale bar indicates 25m.Arrows indicatenuclear translocationofNF-B
in LPS-treated DCs.
FIGURE 5.Maturationmarkers of DCs after inhibition of oscillations. A, real-time PCR analysis of genes involved in DCmaturation in untreated cells or DCs
treated for 18 hwith Xestospongin C (1M), 2-APB (100M), TLR-7 agonist 3M-001 (3M), or LPS (1g/ml). Total RNAwas extracted from 1–2 106 cells, and
CD83, CD80, CD86, interferon-, and IL23A gene expression was evaluated by quantitative real-time PCR. Gene expression results are expressed as mean
(S.E.)-fold increase as comparedwith values obtained in iDCs treatedwithmedium. Pooled data are from experiments carried out on cells from five different
donors except for CD83 (DC3M-001), INF (DC2-APB, 3M-001, LPS), IL23A (DCXestoC, DC2-APB), where data from four donors were pooled, and CD83
(DC2-APB), where data from three donors were pooled. Statistical analysis was performed using the PROCMIXED SAS 9.2 statistical analysis program. *, p
0.0001; **, p 0.00025; ***, p 0.001. B, endocytosis of FITC-labeled dextran is shown. Cells treated as described for panel Awere plated in 12-well plate and
incubated at 37 °C for 30min with 0.5 mg/ml of FITC-labeled dextran. Negative controls were also incubated with FITC-labeled dextran but kept for 30min at
4 °C. Cells were washed 2 times with ice-cold phosphate-buffered saline and fixed with 1% paraformaldehyde, and the % of FITC-positive (ve) cells was
assessedby flowcytometry.Bar graphs represent themean (S.E.)%of fluorescent cells; fluorescent valueobtained for iDCwas considered100%. Results from
3–8 experiments from 3–8 different donors were pooled and averaged. Statistical analysis was performed using the ANOVA test followed by the Bonferroni
post hoc test. *, p 0.018; **, p 0.0003.
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hypothesized that the high frequency Ca2 oscillations may be
involved in activation of endocytosis, and blocking Ca2 oscil-
lations with 2-APB resulted in a significant but partial decrease
of FITC-dextran endocytosis, suggesting that the high fre-
quency oscillations may not be essential for endocytosis as
reported in embryonic stem cell-derived primitive endodermal
cells (20). Alternatively, the inhibitory effect of 2-APB may
reflect the fact that endocytosis is a Ca2-dependent event
requiring InsP3R activation and/or Ca2 influx (46, 47). On the
other hand, the involvement of Ca2 signaling in maturation
had been previously documented (26, 28), and it was shown
that DC maturation is enhanced by activation of ryanodine
receptor-mediated Ca2 release. The results obtained by real
time PCR strongly suggest that pharmacological interventions,
which decrease the high frequency oscillations, activate signals
that are necessary but not sufficient to induce full DC
maturation.
We next turned our attention to Ca2-sensitive transcrip-
tion factors as Ca2 oscillations have been shown to promote
the expression of specific genes in other cell systems (39, 48).
We focused our attention on NFAT, a calcineurin-dependent
transcription factor, as early work demonstrated that NFAT
has the remarkable capacity to sense dynamic changes in the
[Ca2]i and is especially tuned to detect high frequent Ca2
oscillations occurring within cells (48, 49). In fact, high fre-
quency oscillations have been shown to activateNFATby keep-
ing the transcription factor in the nucleus at high enough levels
to bind to enhancer sites long enough to allow initiation of
transcription. Because in our case only iDCs possess these high
frequency Ca2 fluctuations, NFAT should be active and trans-
located into the nucleus only in iDCs and not in LPS-matured
DCs. Western blot analysis of endogenous NFAT indeed
showed that the cytosolic fraction of iDCs contains consider-
able less immunopositive band compared with that present in
mature DCs; furthermore, by shutting off the Ca2 oscillations
with 2-APB, NFAT is retained in the cytoplasm. As opposed to
what was observed for NFAT, the transcription factor NF-B is
activated and translocated into the nucleus in LPS-matured
DCs but not in iDCs nor in 2-APB-treated DCs. Thus, simply
blocking the high frequency Ca2 oscillations or blocking
nuclear translocation of NFAT is not sufficient to induce either
nuclear translocation of NF-B or DC maturation.
Altogether these results indicate that the high frequency
Ca2 oscillations depend on the maturation stage of DCs, and
we suggest that they act as “frequency encoding” (as opposed to
amplitude encoding) signals, whereby through the activation of
NFAT, DCs maintain their immature phenotype. Our data do
not support recent results showing that LPS induces a transient
increase in [Ca2]i in DCs (50–52).We directly tested whether
the addition of LPS (1 g/ml) to iDCs causes an increase in the
cytoplasmic [Ca2]i but failed to obtain any response. Similarly,
no changes in the [Ca2]i on plasmamembrane microdomains
after the addition of LPS were observed by TIRF microscopy
(data not shown). The differences between our results and
those presented in Refs. 50–52 aremost likely due to the differ-
ent experimental models that were used; that is, humanmono-
cyte-derived DCs in this study versusmouse bone marrow-de-
rived DCs. In fact, as opposed to mouse DCs, immature human
DCs express very low levels of CD14, and thus, the CD14-de-
pendent Ca2 signaling pathways may be absent in our system.
Our possibility of using the TIRF microscope has enabled us to
directly monitor membrane-associated events, and our results
together with those of Matzner et al. (51) argue against a major
role of Ca2 influx in LPS-mediated Ca2 signaling.
In conclusion,we report that humanmonocyte-derived iDCs
exhibit spontaneous [Ca2]i oscillations that are linked to
InsP3R activation and to, a lesser extent, to Ca2 influx. These
high frequency events are lost duringmaturation and appear to
be an endogenous characteristic of the immature phenotype,
possibly activating nuclear translocation of NFAT and, thus,
enhancing the transcription of genes involved in maintaining
the cells immature. The results of the present investigation are
important because they point out novel aspects of intracellular
signaling in human DC and may open new areas of research
that could be developed in the future to help patients requiring
modulation of their immune response.
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II. Functional properties of RyR1 mutations linked to 
malignant hyperthermia and central core disease 
 
II.1 Introduction to publications 
 
Dominant point mutations in the gene encoding RYR1 have been linked to Malignant 
Hyperthermia (MH) and Central core disease (CCD). MH is a pharmacogenetic disorder 
with autosomal dominant inheritance and abnormal Ca
2+ 
homeostasis in skeletal muscle 
in response to triggering agents. CCD is a slowly progressive myopathy characterized by 
muscle weakness and hypotonia. CCD is characterized histologically by the presence of 
central cores running along longitudinal axis of the muscle fibre. 
In this section of my thesis we describe results obtained on EBV immortalize B- 
lymphocyte cell lines. The aim of these studies is to develop a parallel diagnostic tool 
aimed at identifying functional defects in RyR1 caused by mutations. In fact to date the 
“gold standard” for defining MH susceptibility is an invasive in vitro contracture test 
(IVST) and clinical histopathological examination of muscle fibres in the case of CCD. 
The study of the functional properties of RyR channels carrying mutations linked to 
neuromuscular disorders is important from a diagnostic point of view but also to 
understand the basic pathophysiological mechanism leading to these different diseases. In 
fact understanding the mechanisms leading to dysregulation of Ca2+ homeostasis is of 
fundamental importance if one is to develop a pharmacological treatment to improve the 
quality of life of affected patients.  
In this section, we investigated the Ca
2+
 homeostasis of EBV-transformed lymphocytes 
carrying 9 distinct RYR1 mutations (p.D544Y, p.R2336H, p.E2404K and p.D2730G, 
p.E1058K, p.R1679H, p.H382N, p.K1393R and p.R2508G) associated with MHS and 
CCD cases from Swiss and Swedish population. 
In order to assess the functional effects of these mutations we compared Ca
2+
 
homeostasis in EBV cells from patients and healthy donors (used as controls). 
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We determined if mutation affect the resting Ca
2+
 concentration, the size of thapsigargin-
sensitive stores and the channel sensitivity to RyR1 agonists.  
 
II.2 publications 
 
 
1. Soledad Levano*, Mirko Vukcevic*, Martine Singer, Anja Matter, Susan Treves,    
    Albert Urwyler and Thierry Girard. Increasing the Number of Diagnostic Mutations in  
    Malignant Hyperthermia 
    Hum Mutat. 2009 Apr; 30(4): 590-8. 
  *These authors contributed equally to this work 
 
2. Mirko Vukcevic*, Marcus Broman*, Gunilla Islander, Mikael Bodelsson, Eva   
    Ranklev-Twetman, Clemens R. Müller and Susan Treves. Functional Properties of 
    RyR1 Mutations Identified in Swedish Malignant Hyperthermia and Central Core  
    Disease Patients 
    Anesth Analg. 2010 Feb 8. [Epub ahead of print] 
   *These authors contributed equally to this work 
 
Human MutationRESEARCH ARTICLE
Increasing the Number of Diagnostic Mutations
in Malignant Hyperthermia
Soledad Levano,1,2 Mirko Vukcevic,1,2 Martine Singer,1,2 Anja Matter,1,2 Susan Treves,1,2 Albert Urwyler,1,2
and Thierry Girard1,2
1Department of Biomedicine, University Hospital Basel, Basel, Switzerland
2Department of Anesthesia, University Hospital Basel, Basel, Switzerland
Communicated by William Oetting
Received 21 February 2008; accepted revised manuscript 16 July 2008.
Published online 3 February 2009 in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/humu.20878
ABSTRACT: Malignant hyperthermia (MH) is an auto-
somal dominant disorder characterized by abnormal
calcium homeostasis in skeletal muscle in response to
triggering agents. Today, genetic investigations on ryano-
dine receptor type 1 (RYR1) gene and a1 subunit of the
dihydropyridine receptor (DHPR) (CACNA1S) gene
have improved the procedures associated with MH
diagnosis. In approximately 50% of MH cases a causative
RYR1 mutation was found. Molecular genetic testing
based on RYR1 mutations for MH diagnosis is challenging,
because the causative mutations, most of which are
private, are distributed throughout the RYR1 gene. A
more comprehensive genetic testing procedure is needed.
Therefore, we aim to expand the genetic information
related to MH and to evaluate the effect of mutations on
the MH phenotype. Performing an in-depth mutation
screening of the RYR1 transcript sequence in 36 unrelated
MH susceptible (MHS) patients, we identified 17 novel,
five rare, and eight non-disease-causing variants in 23
patients. The 13 remaining MHS patients presented no
known variants, neither in RYR1 nor in the CACNA1S
binding regions to RYR1. The 17 novel variants were
found to affect highly conserved amino acids and were
absent in 100 controls. Excellent genotype-phenotype
correlations were found by investigating 21 MHS
families—a total of 186 individuals. Epstein-Barr virus
(EBV) lymphoblastoid cells carrying four of these novel
mutations showed abnormal calcium homeostasis. The
results of this study contribute to the establishment of a
robust genetic testing procedure for MH diagnosis.
Hum Mutat 30, 590–598, 2009. & 2009 Wiley-Liss, Inc.
KEY WORDS: malignant hyperthermia; MH; ryanodine
receptor type 1; RYR1; MH diagnosis; in vitro contracture
testing; IVCT; mutation segregation; abnormal calcium
homeostasis
Introduction
Malignant hyperthermia (MH; MIM] 145600) is an autosomal
dominant pharmacogenetic disorder triggered by volatile haloge-
nated anesthetics and/or succinylcholine. An MH crisis reflects a
disturbance of skeletal muscle calcium homeostasis. Genetic
linkage studies mapped six different loci for MH, and two
candidate genes have been identified, namely the ryanodine
receptor type 1 gene (RYR1; MIM] 180901) located on
chromosome 19q13.1 [MacLennan et al., 1990] and the CACNA1S
gene (MIM] 114208), encoding the a1 subunit of the voltage-
gated dihydropyridine receptor (DHPR), located on chromosome
1q32 [Monnier et al., 1997; Robinson et al., 1997]. Both channels
are known to be involved in the regulation of calcium release from
the sarcoplasmic reticulum [Endo, 1989].
A number of studies in different populations reported that
mutations in the RYR1 gene account for approximately 50% of MH
cases, while 1% are linked to mutations in CACNA1S gene [Brandt
et al., 1999; Girard et al., 2001b; Monnier et al., 1997; Rueffert et al.,
2002; Sei et al., 2004; Stewart et al., 2001]. These studies are mostly
based on the mutation screening of the three previously identified
hotspot regions of RYR1 and of the CACNA1S binding region to
RYR1. In studies involving extensive mutation screening of the
genomic sequence of RYR1, a number of variants were also found
outside the hotspot regions [Galli et al., 2006; Ibarra et al., 2006;
Sambuughin et al., 2005; Tammaro et al., 2003]. Such in-depth
genetic analysis of the whole coding region seems to be essential, as
most of the mutations have been detected in single families or/and
specific populations. However, the cost of such analysis is high
because of the large size of the RYR1 gene, which comprises 106
exons and transcribes a 15-kb-long RNA molecule. As an alternative
approach, two reports recently described the genetic screening of
cDNA samples [Robinson et al., 2006; Sambuughin et al., 2005]. A
mutation screening of the RYR1 gene is a challenge, not only
because of its large size but also on account of sequence
heterogeneity. Several missense, nondisease variants, and multiple
silent polymorphisms are present, in addition to mutations
associated with MH. Recently, Robinson’s group reviewed all known
RYR1 mutations, which included 178 missense variants, of which 28
mutations have been functionally characterized [Robinson et al.,
2006]. Therefore, we selected automated sequencing technology as
an optimal method for the detection and differentiation of
single-nucleotide variations, providing more accurate information
in a highly polymorphic sequence like the RYR1 gene.
Testing for MH susceptibility can be performed using molecular
genetic methods [Urwyler et al., 2001]. However, only mutations
with a proven MH causative effect are to be used for diagnostic
investigations. According to the guidelines of the European MH
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Group (EMHG), novel mutations must be genetically and
functionally characterized, providing evidence of MH causality
prior to such use (www.emhg.org). In this context, we report a
comprehensive mutation study including detailed molecular
genetic examinations of all detected variants, genotype-phenotype
correlation analysis, and functional characterization of four
newly-identified MH-linked mutations.
Materials and Methods
Patient Selection and In Vitro Contracture Testing
Phenotyping
From the register of the Swiss MH Investigation Unit, 36 MH
families were selected that did not present any known causative RYR1
mutation when they were analyzed using restriction fragment length
polymorphisms (RFLP) [Girard et al., 2004]. Each family included at
least one individual who had experienced a MH crisis. Susceptibility
to MH was diagnosed on the basis of in vitro contracture testing
(IVCT), which is performed on muscle bundles exposed to increased
concentrations of halothane and caffeine. Contractures of Z2mN
following 2% halothane or 2mM caffeine are considered patholo-
gical. Depending on the contracture response measured after drug
treatment, patients are diagnosed as MH normal (MHN) if no
pathological contracture occurs, MH susceptible (MHS) if patholo-
gical contractures occur following administration of caffeine and
halothane, or MH equivocal (MHE) if either caffeine or halothane
lead to pathological contractures [European Malignant Hyperpyrexia
Group, 1984]. For patient safety, MHE individuals are clinically
treated as MH positive, although this group is scientifically classified
as a group of unclear MH diagnosis. To achieve a high confidence of
true-positive MH diagnosis, we selected one MHS patient per family
who presented a muscle contracture ofZ5mN at 2% halothane and/
or 2mM caffeine. For most of the MH families, relatives were
available for the mutation segregation and the genotype-phenotype
analyses. A random sample of 100 anonymous blood donors from
the general population was included. This study was approved by the
regional ethical committee (Ethikkomission beider Basel [EKBB]).
Isolation of Total RNA and Genomic DNA
Muscle biopsies, which were not exposed to either halothane or
caffeine, were used for RNA isolation using RNeasy Mini Kit
(Qiagen GmbH, Hilden, Germany) according to the manufac-
turer’s protocol. Genomic DNA was isolated either from whole
blood or untreated muscle tissue using QIAamp DNA mini kit
(Qiagen AG) according to the manufacturer’s protocol.
Mutation Screening
RYR1 Transcript
Total RNA was transcribed to cDNA using the first-strand cDNA
kit (Roche Diagnostics, Rotkreuz, Switzerland) according to the
manufacturer’s protocol. The 23 primer pairs for the amplification of
the whole RYR1 transcript were previously published by McCarthy’s
Group [Schulte am Esch et al., 2000]. One universal condition was
established and applied to 23 PCR reactions using Pwo Super Yield
DNA polymerase (Roche Diagnostics). The PCR products were
cleaned by ultrafiltration using a 96-well filter plate (Roche
Diagnostics) and sequenced in both directions by commercial
services (Microsynth Sequencing Group, Balgach, Switzerland). The
analyses of the sequences were performed using the Staden package
(www.mrc-lmb.cam.ac.uk/pubseq/staden_home.htlm) and the wild-
type human RYR1 transcript sequence (GenBank accession number
NM_000540.1) starting with 11 corresponding to A of the ATG
initiation codon. All observed variations in the cDNA sequence were
verified by additional analysis of genomic DNA.
CACNA1S Transcript
Using cDNA as a template, exons 14 to 18 and 25 to 27 of
CACNA1S were amplified by PCR. The PCR products were
cleaned as described above and sequenced using the BigDye
terminator cycle sequencing kit and the ABI Prism 3100 Avant
Genetic Analyzer (Applied Biosystems, Foster City, CA) according
to the manufacturer’s instructions. The sequences were analyzed
and compared with the wild-type sequence of CACNA1S
(NM_000069.1) as described above.
Molecular Genetic Analysis of Detected Mutations
The mutation segregation was systematically investigated in DNA
samples of available relatives. The isolated genomic DNA was
amplified by PCR using 1 Eppendorf Master Mix (Eppendorf
AG, Hamburg, Germany) and primer pairs flanking the RYR1
exons of interest. The mutation detection scanning was performed
by RFLP and denaturing high-performance liquid chromatography
(dHPLC) (Table 1). Using the same procedure, the mutation
occurrences in 100 DNA samples of random blood donors were
investigated to assess their possible polymorphic status.
Bioinformatic Tools
For the analysis of the conservative status across the evolution of
the gene, a protein multiple sequence alignment was performed
using ClustalW v1.82 (www.ebi.ac.uk/clustalw). Two open-source
programs (MUpro [www.ics.uci.edu/baldig/mutation.html] and
Pmut [http://mmb2.pcb.ub.es:8080/PMut]) available through web
servers were used to predict the effect of single amino acid
mutations on the RYR1 protein in silico. MUpro is a program based
on support vector machines that uses primary sequence informa-
tion to predict protein stability through single amino acid
mutations [Cheng et al., 2006]. The recommended value to use is
the predicted energy change (DDG). A negative DDG value
indicates that a given mutation decreases protein stability. The
web-based Pmut tool is based on the use of neural networks trained
with human mutational data, such as sequence-derived information
(structure, evolutionary conservation, data, and residue properties).
The prediction, whether a given mutation is pathological or neutral,
is described according to a pathological index ranging from 0 to 1,
where an index 40.5 indicates a pathological character.
Functional Assay
Changes in the intracellular Ca21 concentration in Epstein-Barr
virus (EBV)-immortalized lymphoblastoid cells from healthy
controls and in MHS patients carrying the mutation of interest
were monitored with the fluorescent Ca21 indicator fura-2/AM.
Experiments were carried out on populations of cells in a LS50
spectrofluorimeter (Perkin Elmer Instruments, Shelton, CT) at
371C, as previously described [Girard et al., 2001a], or at the
single-cell level by digital imaging microscopy, also at 371C, as
previously described [Ducreux et al., 2006]. In the latter case,
lymphoblastoid cells loaded with 5 mM fura-2 were allowed to
attach to poly-L-lysine–treated glass coverslips for 10 minutes
prior to the experiments. Individual cells were stimulated with a
12-way 100-mm-diameter quartz micromanifold computer-con-
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trolled microperfuser (ALA Scientific, Westbury, NY). Online
(340 nm, 380 nm, and ratio) measurements were recorded using a
fluorescent Axiovert S100 TV inverted microscope (Carl Zeiss
GmbH, Jena, Germany) equipped with a 40 oil-immersion
Plan-NEOFLUAR objective (0.17 NA; Carl Zeiss GmbH) and
filters (BP 340/380, FT 425, and BP 500/530). The cells were
analyzed using an Openlab (Improvision, Coventry, UK) imaging
system and the average pixel value for each cell was measured at
excitation wavelengths of 340 and 380 nm.
The presence of the mutation in the lymphoblastoid cell lines
was confirmed by PCR and automated sequencing.
Statistical Analysis
Statistical analyses were performed using the Student’s t-test for
paired samples, or analysis of variance (ANOVA) when more than
two groups were compared. Origin software (version 6.0; Microcal
Software, Inc., Northampton, MA) was used for statistical analysis
and to generate dose-response curves according to the Hill equation.
From these curves, the effective concentration 50% (EC50) was
calculated. ANOVA was used to compare EC50 values. If they were
significantly different, Dunnett’s multiple comparison test was used
for post-hoc analysis. P values below 5% were considered significant.
Results
Mutations in RYR1 and CACNA1S Transcripts
The entire coding region of RYR1 was analyzed in 36 unrelated
MHS patients. In 23 of these patients we found 22 variants (64%).
Of these 22 variants, 17 (78%) were novel, one was a rare causative
MH mutation (p.L4838V) [Oyamada et al., 2002], and four
were previously reported variants (p.L13R, p.R2676W, p.T2787S,
and p.K4876R) [Guis et al., 2004; Ibarra et al., 2006; Monnier et al.,
2005; Sambuughin et al., 2005]. All novel variants were found
in the heterozygous state and were characterized as single-nucleotide
changes, but one was an in-frame duplication of nine nucleotides
(Table 1). The 17 novel variants were absent in 100 control
DNA samples. The variants p.R2336H and p.E2280K were recurrent
in eight and two families, respectively (Table 1). Four MHS patients
of unrelated families were double-variant carriers (p.R1043C/
p.R2336H, p.E2880K/p.E3290K, p.R367/p.S3217P, and p.M226K/
p.T4288_A4290dup), and one MHS patient even presented quad-
ruple variants (p.S1352G/p.R2676W/p.T2787S/p.P4501L).
Eight noncausative variants were previously reported
(p.P1787L, p.A1832G, p.G2060C, p.V2550L, p.E3583Q, and
p.Q3756E) [Robinson et al., 2006] or were already described
as polymorphisms, p.S1342G (rs34694816:A4G) and p.I2321V
(rs34390345:A4G), in the NCBI SNP database (www.ncbi.
nlm.nih.gov/projects/SNP). Some of these variants not associated
with MH were present alone, in combination with each
other, or with novel variants described here. In this context, five
MHS patients were identified as double carriers, who belong
to Family S1 (p.L13R/p.I2321V), Family S17 (p.E2880K/
p.E3583Q), Family S21 (p.G2060C/p.L4838V), and Families
S24 and S25 (p.P1787L/p.G2060C). One MHS patient from
Family S4 presented p.R530H, together with p.G2060C and
p.E3583Q.
In addition, silent polymorphisms were also detected. With the
exception of 11 polymorphisms, 30 have been previously listed in
the SNP database. Regarding splicing variants of RYR1, we
observed splicing transcripts lacking exons 70 and 83 in all of our
samples. A similar observation was recently reported [Robinson
et al., 2006].
In the remaining 13 of the 36 selected MHS patients who
did not present any known RYR1 variants, we further analyzed
the sequence of the interacting region of CACNA1S to
RYR1. We found the silent polymorphism T2630C (rs7415038)
coding for p.F801. This polymorphism was present in all
samples.
Table 1. RYR1 Variants Detected in Our MHS Patients and the Methods Used for the Genetic Analysis in the Family Members and
Controls
Nucleotide change Amino acid change Exon Analysis methoda Family References
c.38T4G p.L13R 1 Seq S1 Ibarra et al. [2006]
c.677T4A p.M226K 8 dHPLC S2 This study
c.1100G4T p.R367L 11 dHPLC/RFLP S3 This study
c.1589G4A p.R530H 15 RFLP S4 This study
c.1630G4T p.D544Y 15 RFLP S5 This study
c.3127C4T p.R1043C 24 dHPLC/RFLP S6 This study
c.4055C4G p.A1352G 28 dHPLC/RFLP S7 This study
c.7007G4A p.R2336H 43 dHPLC/RFLP S6, S8–S14 This study
c.7210G4A p.E2404K 44 dHPLC/RFLP S15 This study
c.8026C4T p.R2676W 50 RFLP S7 Guis et al. [2004]
c.8189A4G p.D2730G 51 dHPLC/RFLP S16 This study
c.8360C4G p.T2787S 53 RFLP S7 Guis et al. [2004]
c.8638G4A p.E2880K 56 dHPLC S17, S18 This study
c.9649T4C p.S3217P 65 dHPLC S3 This study
c.9868G4A p.E3290K 66 dHPLC S18 This study
c.11314C4T p.R3772W 79 dHPLC S19 This study
c.11416G4A p.G3806R 80 dHPLC S20 This study
c.12861_12869dupCACGGCGGC p.T4288_A4290dup 91 dHPLC S2 This study
c.13502C4T p.P4501L 92 dHPLC/RFLP S7 This study
c.14512C4G p.L4838V 101 dHPLC/RFLP S21 Oyamada et al. [2002]
c.14627A4G p.K4876R 101 dHPLC S22 Monnier et al. [2005]
c.14813T4C p.I4938T 103 dHPLC/RFLP S23 This study
Numbering of the transcript sequence starts with 11 corresponding to A of the ATG initiation codon and corresponds to the GenBank accession number NM_000540.1. The
amino acid numbering corresponds to the GenBank accession number NP_000531.1.
aFor segregation analysis and DNA controls.
dHPLC, denaturing high-performance liquid chromatography; RFLP, restriction fragment length polymorphism.
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Localization and Predicted Effect of RYR1 Mutations
The detected variants were distributed along the whole coding
region of RYR1 (Fig. 1). Ten out of the 17 novel variants were
localized outside of the previously reported hotspot regions.
Similarly, 15 out of 17 variants were confined to different domains
of RYR1 according to the SwissPfam protein database (www.
sanger.ac.uk/cgi-bin/Pfam).
The 16 novel point mutations caused amino acid changes that
were highly conserved throughout the evolution of RYR1 and
among different human isoforms (Table 2). Using two different
prediction programs, the novel amino acid changes, when
analyzed individually, were predicted to affect the protein stability
and to have a pathological character. For five variants (p.A1352G,
p.R1043C, p.R2676W, p.E3290K, and p.K4876R), the predictions
generated using MUpro and Pmut were divergent (Table 2).
Functional Assay of Novel Mutations
To perform functional analysis, we needed to use a variant that was
present in at least two MHS patients. Although eight variants met this
criterion, available fresh blood samples allowed analysis of only four
novel mutations (p.D544Y, p.R2336H, p.E2404K, and p.D2730G).
The resting Ca21 concentration in cells from patients carrying one of
the novel mutations was significantly higher than that observed in
cells from control individuals (Fig. 2A). To assess whether the
mutations affected the amount of Ca21 present in intracellular stores,
we treated the cells with the sarcoplasmic/endoplasmic reticulum
Ca21-ATPase (SERCA) inhibitor thapsigargin in the presence of
0.5mM ethylene glycol tetraacetic acid (EGTA). As shown in Figure
2B, none of the mutations affected the amount of Ca21 released from
rapidly releasable stores. Next, we assessed whether the mutations
affected the sensitivity of RYR1 to pharmacological stimulation.
Figure 3 shows the dose-response curves to 4-chloro-m-cresol and
caffeine. The presence of all mutations shifted the dose-response
curves to lower agonist concentrations compared to that observed in
cells from control individuals. This shift in the dose-response curve
was statistically significant for all four mutations with at least 1 out of
the 2 agonists (Fig. 3).
Segregation and Phenotype-Genotype Analysis
A total of 186 individuals (including the 21 selected MHS
patients) from 213 members of 21 MH families were available for
the segregation analysis (Table 3). One MH family (Family S2)
with no available relatives carried two variants. As a consequence,
19 out of 22 variants were further investigated for segregation.
Few (30%, 15/51) MHE patients were carriers of the
novel variants (Table 3). Excluding MHE individuals, a high
overall concordance of 0.94 (95% confidence interval [CI],
0.89–0.98) was observed between the phenotype and genotype.
Of the 69 MHS individuals, 65 were carriers, corresponding to a
sensitivity of 0.94 (95% CI, 0.85–0.98), whereas 3 out of the
66 MHN individuals carried RYR1 variants, resulting in a
specificity of 0.95 (95% CI, 0.86–0.99). These numbers would
be substantially lower after inclusion of the MHE patients.
Although these patients must clinically be considered MH-
positive, they belong to a group with unclear MH diagnosis.
Therefore, we only considered unambiguous IVCT diagnoses for
the above calculations.
From the eight families (Families S6 and S8–S14) carrying
p.R2336H, a total of 80 individuals were investigated. The
p.R2336H segregation was observed in family members across
three- and two-generation pedigrees and was transmitted to 22
out of 26 MHS patients and to 3 out of 21 MHE patients. The 3
out of 4 MHS noncarriers for R2336H belong to the large Family
S11, with 10 MHS carriers (Supplementary Fig. S1; available
online at http://www.interscience.wiley.com/jpages/1059-7794/
suppmat). For two of these patients (Supplementary Fig. S1,
Patients S11-1 and S11-2) the mutation inheritance was initially
assumed to be maternal. However, the mother of Patient S11-2
was diagnosed as MHN and did not carry p.R2336H. Unfortu-
nately, neither the parents nor any grandparents were available for
analysis. The third MHS noncarrier (Supplementary Fig. S1;
Patient S11-3) was identified in a different branch not carrying
p.R2336H. The fourth MHS noncarrier (Supplementary Fig. S2;
Patient S14-1) was the husband of an MHS patient, who carries
the p.R2336H. The analysis of the full RYR1 transcript in these
four MHS patients revealed no novel variants. As expected, the
p.R2336H was not detected in any of the 34 MHN individuals.
The index patient of Family S6 coexpressed p.R2336H together
with p.R1043C. After genetic analysis, it was found that the
mother presented wild-type sequences whereas the father carried
both variants. This suggests that the variants lie on the same
chromosome. The second most frequent variant, p.E2880K, was
examined in two families (Families S17 and S18) comprising 11
relatives with five MHS patients. One of the three MHS patients
Figure 1. Location of the RYR1 variants found in this study along the protein sequence. Novel variants are indicated by filled triangles and
known variants by open triangles. The hatched boxes represent the three putative hotspot regions. Selected domains according to the
SwissPfam protein database are represented by thin horizontal bars and are described as the following: MIR5 domain in ryanodine and inositol
trisphosphate receptors (IP3R) and protein O-mannosyltransferases; RIH5 RYR and IP3R homology domains (this extracellular domain may form
a binding site for IP3); RYR5 ryanodine receptor domain; RIH associate5RyR and IP3R homology associated (this domain is found in RYR and
IP3R); and LC5 low complexity region.
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from Family S18, carrying p.E2880K, exhibited an additional
change of glutamic acid to lysine, namely p.E3290K. The single
MHN sister harbored no variants.
An MHS double carrier in Family S3 carried p.R367L and
p.S3217P, whereas his MHE mother was a carrier of only p.S3217P.
This suggests that the father, who was not available for analysis, is
a possible carrier of p.R367L.
Discordances were found in two families carrying p.P4501L and
p.I4938T, in which these variants were harbored by MHN patients.
In Family S7 (Supplementary Fig. S3; Patients S7-1 and S7-2) an
MHS father was a carrier for four variants (p.A1352G, p.P4501L,
p.R2676W, and p.T2787S), while both of his MHN siblings carried
solely p.P4501L. Another discordance was identified in Family S23
(Supplementary Fig. S4), in which Patient S23-1 carried p.I4938T,
while being diagnosed MHN by IVCT. In all MHN patients, the
IVCT results were unambiguous, with viable muscle samples
contracting to neither caffeine nor halothane.Ta
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Figure 2. Comparison of the resting Ca21 concentration and the
status of thapsigargin-sensitive Ca21 stores in lymphoblastoid cells
from control and MHS individuals carrying the novel RYR1 mutations.
(A) Resting fluorescent values and (B) change in fluorescence (peak
resting fluorescence ratio 340/380 nm) induced by addition of 400 nM
thapsigargin. Fluorescence measurements were performed on fura-2
loaded lymphoblastoid cells (1  106 cells/ml) in a Perkin Elmer LS50
spectrofluorimeter thermostatted at 371C and equipped with a
magnetic stirrer. Results represent the mean7standard error of the
mean (SEM) of the indicated number of experiments. P5 0.002,
P5 0.001, P5 0.0003.
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Discussion
The RYR1 gene is the major locus of MH susceptibility. As such,
this gene is the principal focus on the genetic research of this
pharmacogenetic disease. The advantage of molecular genetic
testing for MH susceptibility, as well as the pathophysiological
understanding of MH, has led to a continued search for new
mutations in MH families with formerly unknown genotypes.
Figure 3. Dose-dependent changes in intracellular Ca21 concentrations induced by pharmacological RyR1 activation in lymphoblastoid cells
from control individuals and patients carrying the indicated RYR1 mutations. Single-cell intracellular Ca21 measurements of fura-2-loaded cells
were measured before and after the addition of the indicated concentration of 4-chloro-m-cresol (A) or caffeine (B). The curves show the changes
in intracellular Ca21 concentrations expressed as change in fluorescence ratio (peak ratio 340/380 nm; resting ratio 340/380 nm). Results are
mean7standard error of the mean (SEM) of the change in fluorescence of 10 to 53 individual cells. The curves were generated using a sigmoidal
dose-response curve function included in Origin software. cmc5 4-chloro-m-cresol; solid lines5 controls; dashed lines5 patients.
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However, the hunt for the causative mutations in the RYR1 gene is
challenging because of its sequence heterogeneity and the presence
of numerous rare mutations distributed across the whole RYR1
gene [Robinson et al., 2006]. This demonstrates the importance of
investigating the entire gene rather than hotspot regions. The
analysis of the coding region at the genomic DNA level by current
protocols is time-consuming. However, a stepwise approach seems
reasonable for the clarification of the MH genetic status in affected
individuals. Taking these facts into consideration, we first examined
MH families by screening the frequent causative RYR1 mutations
[Girard et al., 2004] and further investigated those families without
RYR1 mutations by amplification of the RYR1 transcript sequences
and automated sequencing, as described in this study.
Novel Mutations and Their Frequencies
The strict selection criteria based on the IVCT data (contrac-
tures Z5mN) might have contributed to the high detection rate
of RYR1 variants (64%, 23/36). A high proportion of novel
variants (78%, 17/22) was expected, as the MH patients were
prescreened for RYR1 mutations [Girard et al., 2004].
Interestingly, variant p.R2336H was detected with the highest
frequency, suggesting it to be a common mutation, similar to
p.V2168M in the Swiss population [Girard et al., 2001b]. As
previously reported, the prevalence of a specific mutation is high
in some populations and low in others. While p.V2168M is the
most prevalent mutation in Switzerland [Girard et al., 2001b],
p.G2434R is more common in the United Kingdom [Robinson
et al., 2002], p.G341R in the Caucasian population living in France
[Quane et al., 1994], and p.R614C in German and French families
[Brandt et al., 1999; Monnier et al., 2005].
Although all variants except for two were detected in single MH
families, most of the variants were found in more than one MHS
patient and were absent in MHN patients. Furthermore, p.L13R
and p.K4876R, which we detected in single families, were each
recently reported in a Japanese [Ibarra et al., 2006], a French
[Monnier et al., 2005], and a North American family [Monnier
et al., 2005; Sambuughin et al., 2005]. Similarly, D2730G and
I4938T variants were previously described with different amino
acid alterations in single UK (I4938M) and Japanese (D2730M)
MH families [Ibarra et al., 2006; Shepherd et al., 2004].
Characterization of Novel RYR1 Mutations
Novel mutations localized along the transcript could certainly
affect the function of RYR1, taking into account the fact that the
RYR1 gene contains several ligand binding sites as well as
conserved domains according to the SwissPfam protein database
and previously reported findings [Dulhunty and Pouliquin, 2003].
The N-terminal region (216–572) has been reported to have a
similar structure as the IP3R core region and to be involved in the
regulation of Ca21 channel activity [Serysheva et al., 2005]. In this
region, we detected four novel variants (p.M226L, p.R367L,
p.R530H, and p.D544Y) that could affect channel regulation.
Furthermore, two sequence regions (1924–2446 and 2644–3223)
have been found to be critical for excitation-contraction (E-C)
coupling [Perez et al., 2003]. In these regions we found five novel
variants (p.R2336H, p.E2404K, p.D2730G, p.E2880K, and
p.S3217P) that could alter the coupling mechanism. In addition,
p.E2404K could be one of the glutamate residues belonging to a
region (1641–2437) rich in glutamate and aspartate residues, and
Table 3. Total Individuals Included in the Genetic Screening Analysis
Amino acid change Family
Available
generations MHSa MHNa MHEa Total IVCT No IVCTb
p.L13R S1 2 2/2 1/0 0/0 3
p.M226K S2 1 1/1 0/0 0/0 1
p.R367L S3 2 1/1 0/0 1/0 2
p.R530H S4 2 1/1 0/0 2/0 3
p.D544Y S5 3 4/4 2/0 1/0 8 4
p.R1043C S6 2 2/2 1/0 3/0 6
p.A1352G S7 2 1/1 2/0 4/4 7
p.R2336H S6 2 2/2 1/0 3/0 6
S8 2 2/2 0/0 0/0 3
S9 2 1/1 1/0 1/0 4
S10 1 2/2 1/0 1/0 4
S11 3 10/7 23/0 9/0 53
S12 2 1/1 1/0 2/1 4
S13 3 5/5 4/0 4/1 22
S14 2 3/2 3/0 1/1 7
p.E2404K S15 2 3/3 1/0 2/1 6
p.R2676W S7 2 1/1 2/0 4/4 7
p.D2730G S16 3 17/17 6/0 5/0 28 2
p.T2787S S7 2 1/1 2/0 4/4 7
p.E2880K S17 3 1/1 2/0 2/1 5 2
S18 1 3/3 1/0 0/0 4
p.S3217P S3 1/1 0/0 1/1 2
p.E3290K S18 1 3/1 1/0 0/0 4
p.R3772W S19 2 1/1 0/0 0/0 1
p.G3806R S20 2 5/5 12/0 9/3 29
p.T4288_A4290dup S2 1 1/1 0/0 0/0 1
p.P4501L S7 2 1/1 2/2 4/2 7
p.L4838V S21 2 1/1 0/0 0/0 1 1
p.K4876R S22 2 2/2 0/0 1/1 3
p.I4938T S23 2 2/2 5/1 3/2 11
aTotal genotyped/total carrier.
bAdditional patients were available, without IVCT diagnosis.
596 HUMAN MUTATION, Vol. 30, No. 4, 590–598, 2009
may be involved in the ion conduction and regulation of the
channel [Bhat et al., 1997].
Taking advantage of bioinformatics tools, the novel variants have
been shown to affect well-conserved amino acid residues. Further-
more, all novel variants were predicted to destabilize the protein
structure according to the results from MUpro. They are also
predicted to be pathological according to the results from Pmut.
Functional Assay of Novel Mutations
Alterations of intracellular calcium homeostasis in EBV cells
from carriers of four mutations are a strong indication of the
causative role in the susceptibility to MH. The four RYR1
mutations we functionally characterized significantly increased the
resting calcium concentration; such a finding is consistent with a
previous report [Ducreux et al., 2006]. These four mutations were
also found to significantly affect either 4-chloro-m-cresol or
caffeine dose-response curve to pharmacological activation. Only
one mutation (p.D2730G) showed a significant reduction in EC50
of both caffeine and 4-chloro-m-cresol. We do not have
experimental explanations for the different agonistic effects in
these four mutations, but this might be influenced by the different
conformational state induced by each mutation, depending on the
position and the property of the amino acid substitution. In this
regard, the sensitivity of RYR1 to a particular agonist would also
be affected differently. In mutation p.E2404K, there was no
significant reduction in the EC50 of 4-chloro-m-cresol compared
to cells from control individuals. It is interesting to note that
although this residue is conserved throughout evolution, the
cardiac RYR isoform (RYR2) has lysine in position 2404.
Phenotype-Genotype Correlations
We found an excellent overall concordance of 93% between
IVCT-phenotype and genotype in 186 individuals from 21 MHS
families. There were six discordant MHS individuals that did not
carry the familial variant. Contracture data from IVCT were not
different from mutation carriers and the probability of an
alternative RYR1 mutation was ruled out by sequencing the full
coding region. In four MHS patients the absence of p.R2336H was
clarified by analyzing their pedigrees. Thus, the MH susceptibility
of these noncarriers could be due to involvement of other genes,
or represent false-positive IVCT diagnoses. The two remaining
discordant MHS patients were noncarriers for p.E3290K, but
carriers for p.E2880K. This might suggest that the p.E2880K could
be the causative mutation in this family. An additive effect of the
p.E3290K on the RYR1 would be possible; however, single and
double MHS carriers presented similar IVCT data. The implica-
tions of this variant remain indeterminate, as unfortunately the
other 2 of the 4 brothers who manifested MH events, as well as the
parents, were unavailable for genetic testing. The absence of
p.E3290K in the healthy controls (n5 100) was confirmed.
We also identified three discordant MHN patients carrying the
familial variant. For patient safety, identification of RYR1
mutations in patients diagnosed MHN by IVCT is crucial. If the
mutation is confirmed to be causative for MH, the MH status of
these patients will need to be corrected. The MHN individual
presenting p.I4938Twas the only discordant patient in Family S23.
As his mother is MHE by IVCT, this might suggest a variable
penetrance of p.I4938T or the participation of additional genes in
this family. Although the causative effect of p.I4938T has yet to be
proven, a variant at this position (p.I4938M) was previously found
to be linked to MH [Shepherd et al., 2004]. The last two
discordant MHN individuals carried the variant p.P4501L. In this
family (Family S7) with four different variants, p.P4501L does not
segregate with the IVCT phenotype. In spite of the absence of
p.P4501L in healthy controls, this variant does not seem not be
linked to MH susceptibility.
Recently, allelic silencing was proposed as an explanation for
phenotype-genotype discordances in multiminicore disease [Zhou
et al., 2006]. However, discordances of our study population
cannot be explained by allelic silencing, as genotyping on genomic
and cDNA level was concordant.
Unfortunately, segregation analysis could not be performed in 3
out of the 22 identified variants, as additional family members
were not available. Of interest might be the case of the duplication
of nine nucleotides, as these residues are localized in a protein
region (4187–4381) suggested to be involved in calcium inactiva-
tion [Du et al., 2000]. To expand the characterization of novel
mutations and to clarify arising discordance, in-depth molecular
genetic analysis should be performed in all members of affected
families. However, enrollment of patients is one of the acute
problems in genetic studies. Multicenter and international
collaborations could overcome this limitation, and mutations
identified in single families within different populations could be
characterized in an international effort.
In summary, this study describes novel RYR1 variants expressed
in patients registered in our MH investigation unit and four of
these mutations (p.D544Y, p.R2336H, p.E2404K, and p.D2730G)
that were functionally tested and seem to have a causative effect.
These results expand the number of MH mutations to be of value
in the molecular genetic diagnosis of MH susceptibility.
Furthermore, the presented novel mutations contribute to the
update of the international mutation database of the RYR1 gene
and emphasize the importance of international collaboration to
characterize rare mutations. Finally, the identification and
characterization of novel MH causative mutations is important,
to increase our understanding of the molecular mechanisms
underlying MH susceptibility.
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Functional Properties of RYR1 Mutations Identified in
Swedish Patients with Malignant Hyperthermia and
Central Core Disease
Mirko Vukcevic, PhD,*§ Marcus Broman, MD,†§ Gunilla Islander, MD, PhD,†
Mikael Bodelsson, MD, PhD,† Eva Ranklev-Twetman, MD, PhD,† Clemens R. Mu¨ller, PhD,‡
Susan Treves, PhD*
BACKGROUND: A diagnosis of malignant hyperthermia susceptibility by in vitro contraction
testing can often only be performed at specialized laboratories far away from where patients live.
Therefore, we have designed a protocol for genetic screening of the RYR1-cDNA and for
functional testing of newly identified ryanodine receptor 1 (RYR1) gene variants in B lymphocytes
isolated from peripheral blood samples drawn at local primary care centers.
METHODS: B lymphocytes were isolated for the extraction of RYR1-mRNA and genomic DNA and
for establishment of lymphoblastoid B cell lines in 5 patients carrying yet unclassified mutations
in the RYR1. The B lymphoblastoid cell lines were used to study resting cytoplasmic calcium
concentration, the peak calcium transient induced by the sarco(endo)plasmic reticulum Ca-
ATPase inhibitor thapsigargin, and the dose-dependent calcium release induced by the ryanodine
receptor agonist 4-chloro-m-cresol.
RESULTS: It was possible to extract mRNA for cDNA synthesis and to create B lymphocyte clones
from all samples. All B lymphoblastoid cell lines carrying RYR1 candidate mutations showed
significantly increased resting cytoplasmic calcium levels as well as a shift to lower concentra-
tions of 4-chloro-m-cresol inducing calcium release compared with controls.
CONCLUSIONS: Peripheral blood samples are stable regarding RNA and DNA extraction and
establishment of lymphoblastoid B cell lines after transportation at ambient temperature over
large distances by ordinary mail. Functional tests on B cells harboring the newly identified amino
acid substitutions indicate that they alter intracellular Ca2 homeostasis and are most likely
causative of malignant hyperthermia. (Anesth Analg 2010;X:●●●–●●●)
In individuals who are genetically malignant hyperther-mia (MH) susceptible (MHS) (Online Mendelian Inher-itance in Man [OMIM] 145600), volatile anesthetics
and/or succinylcholine can induce a severe decompensa-
tion of muscle calcium homeostasis leading to a life-
threatening crisis including hyperthermia, tachycardia,
coagulation disturbances, generalized muscle rigidity, oli-
guria, and eventually death.1 The diagnosis of MHS is
traditionally made by an in vitro contraction test (IVCT).
This investigation is highly invasive, requiring an open
muscle biopsy from musculus quadriceps and specialized
testing equipment.2
The clinical presentation of central core disease (CCD)
(OMIM 117000) is highly variable and symptoms can vary
from clinically very mild to severe congenital myopathy
with hypotonia, skeletal abnormalities, and scoliosis.3,4
The ryanodine receptor 1 (RYR1) is encoded by the
RYR1 gene located on chromosome 19q13.1. The gene
comprises 159,000 base pairs that are distributed over 106
exons. The RYR1-cDNA has a length of 15,117 kb and
encodes a protein monomer of 5038 amino acids.5,6 More
than 200 sequence variants in the RYR1 gene have been
identified and linked to MHS, CCD, and other neuromus-
cular disorders, yet the functional impact of only a minority
of these amino acid substitutions has been elucidated
(www.emhg.org). The vast majority of these variants have
been found in individual patients and their families, and
only a few recurrent variants each account for 10% of the
MHS subjects.5,6
Ca2 is a second messenger in skeletal muscle cells. It is
stored in the sarcoplasmic reticulum, an organelle whose
function is intimately linked to regulating the myoplas-
mic Ca2 concentration,7–11 and is released via a process
known as excitation-contraction coupling. When the
dihydropyridine receptor (DHPR), the voltage sensor on
the plasmalemma, senses a change in membrane potential,
it undergoes a conformational change and directly interacts
with the RYR1 Ca2 channel, causing it to open. DHPR and
RYR1 form highly organized structures on their respective
membranes: 4 DHPR units on the transverse tubular mem-
brane face corresponding RYR1 tetramers located on the
junctional face membrane of the terminal cisternae.12
Because Ca2 can act as a second messenger in many
biological functions, its intracellular concentration is tightly
regulated and maintained in a typical resting mammalian
cell at about 60 to 120 nM, whereas the extracellular free
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Ca2 concentration is about 2 mM.8,9 Any alteration of
Ca2 homeostasis can affect the function of cells. In muscle
cells, genetic disturbances of Ca2 handling result in a
variety of neuromuscular disorders such as MHS, CCD,
some forms of multiminicore disease and centronuclear
myopathy, and Brody disease.4,6,13
Although the RYR1 is mainly expressed in striated
muscle cells, it is now well established that B lymphocytes
also express this calcium channel.14,15
The aim of this study was to develop an alternative
protocol for diagnostic studies on MHS individuals by
transporting blood samples instead of the patients them-
selves to the specialized testing center. This increases the
opportunity of MHS diagnosis even if a patient’s health
service provider is far away from the MH laboratory. We
designed a simple and practical protocol for the collection
of blood samples to be drawn at the patients’ local primary
care centers. Three venous peripheral blood samples of 5
mL each were collected in different test tubes for mRNA
and genomic DNA extraction and for establishment of B
lymphoblastoid cell lines. Genetic screening and functional
studies were successfully performed on these samples.
METHODS
Clinical Presentation
With Regional Ethics Committee approval, the patients
participating in the study were informed by telephone and
also signed a written consent to the study. All patients carried
1 candidate RYR1 mutation each: patient 1: p.Glu1058Lys,
patient 2: p.Arg1679His, patient 3: p.His382Asn, patient 4:
p.Lys1393Arg, and patient 5: p.Arg2508Gly. These patients
are from a cohort of 15 ScandinavianMHS patients, whowere
screened for the RYR1 total coding region in our previous
study16 and found to carry a novel or yet unclassified se-
quence variant.
Details of the clinical presentation of the patients with
the reported RYR1 amino acid substitutions are given in
Table 1 and in Appendix 1 (see Supplemental Digital
Content 1, http://links.lww.com/AA/A61).
For patients 1 to 4, the MH rank was assessed. The MH
rank describes the qualitative likelihood, from 1  almost
never to 6  almost certain, that an adverse anesthetic event
represents MH. This clinical grading scale requires the
anesthesiologist to judge whether specific clinical signs are
appropriate for the patient’s medical condition, anesthetic
technique, or surgical procedure.17 The MH rank scores are
presented in Table 1 and in Appendix 1 (see Supplemental
Digital Content 1, http://links.lww.com/AA/A61). Patient 5
has an established CCDdiagnosis and hismain symptoms are
scoliosis and muscle weakness in the lower extremities. A
microscopic histopathologic picture of his muscle tissue is
shown in Figure 1.
In Vitro Contraction Test
Patients 1 to 4 had experienced serious MH clinical reac-
tions and thereafter were tested by IVCT and classified as
MHS. The patient with CCD (patient 5) was tested by the
IVCT as part of standard diagnostic investigations to
establish his diagnosis and was also classified as MHS. All
IVCTs were performed at the National Swedish Malignant
Hyperthermia Laboratory of Lund University Hospital
according to the European Malignant Hyperthermia group
protocol.2 The results of the IVCTs are presented in Table 1
and in Appendix 1 (see Supplemental Digital Content 1,
http://links.lww.com/AA/A61).
Blood Sampling
The patients were provided with written information about
the sampling process. Peripheral venous blood samples
Figure 1. Histopathologic picture of the muscle biopsy taken from
musculus vastus lateralis showing cores and degradation of the
myosin around the cores in a nicotinamide adenine dinucleotide
stain from patient 5, whose main disability is muscle weakness in
his lower extremities and scoliosis. Cores are the light structures,
devoid of mitochondria inside the cells. The sequence variant
p.Arg2508Gly found has been reported previously in a Japanese
patient with central core disease.22
Table 1. Clinical Details, In Vitro Contraction Test (IVCT), and Genetic Results of the Malignant
Hyperthermia Susceptible (MHS) and Central Core Disease (CCD) Individuals Studied
Age at MH
crisis Gender Surgery
IVCT result,
caffeine (g)
IVCT result,
halothane (g)
MH
rank
Candidate mutation
and exon found on
cDNA and verified
on genomic DNA
Patient 1, 29 y Female Cesarean delivery 6.2 7.55 6 p.Glu1058Lys in exon 24
Patient 2, 39 y Male Nasal septoplasty 2.4 4.1 5 p.Arg1679His in exon 34
Patient 3, 29 y Female Explorative laparotomy 2.8 1.8 4 p.His382Asn in exon 12
Patient 4, 5 y Male Achilles tendon elongation 0.5 1.15 6 p.Lys1393Arg in exon 29
Patient 5 Male — 7.2 7.3 – p.Arg2508Gly in exon 47
Maximal contractures in IVCT at the threshold concentrations of caffeine (2.0 mmol/L) and halothane (0.44 mmol/L) and the RYR1 candidate mutations are given.
The MH rank describes the likelihood that the clinical adverse reaction is MH.17
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were drawn by the local family doctor in an EDTA tube, a
PAXgene tube (BD, Stockholm, Sweden), and a heparin
tube. The tubes were sent by normal mail without further
handling or cooling to the laboratory in Wu¨rzburg, Ger-
many, a distance up to 2000 km and a transportation time
up to 6 days. Because PAXgene tubes are not normally
available at Swedish primary care centers, they were pro-
vided to the patients.
Genetics
Total RNA was extracted from the PAXgene tubes accord-
ing to the manufacturer’s instructions, and genomic DNA
of leukocytes was extracted from the EDTA tubes accord-
ing to standard protocols. First-strand cDNA was synthe-
sized using SuperScript™ II (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. Because of the
size of the RYR1-mRNA, the first cDNA strand was syn-
thesized using 3 mixes of specific primers. The resulting
first strands were then amplified in 500 to 700 base pairs
overlapping fragments using a second set of primers
(primer sequences are available from the authors on re-
quest). Sequencing was performed by using the BigDye 1.1
kit on an ABI 3130 XL (Applied Biosystems, Darmstadt,
Germany). All cDNA sequence variants leading to amino
acid substitutions were confirmed on genomic DNA from
the same patient.16,18
Establishment of Epstein-Barr Virus
Immortalized B Lymphoblastoid Cell Lines
B lymphocytes were isolated from the blood collected in the
heparin tubes and transformed by the Epstein-Barr virus,
as previously described.18
Functional Tests
Changes in the intracellular Ca2 concentration ([Ca2]i) of
the B lymphoblastoid cells from patients carrying the
candidate mutations and from healthy controls were as-
sessed as previously described14,18 after loading cells with
the fluorescent Ca2 indicator fura-2/AM (5-M final
concentration). Experiments were performed on cell popu-
lations (1.0  106 cells/mL, final volume 1.5 mL) in a
thermostated LS-50 Perkin-Elmer (Waltham, MA) spec-
trofluorimeter equipped with a magnetic stirrer. The peak
increase of the Ca2 transient obtained after addition of a
given concentration of 4-chloro-m-cresol on the linear part
of the fura-2 calcium-sensitive curve was expressed as
percentage of the peak Ca2 released by maximal concen-
trations (1000 M) of 4-chloro-m-cresol. To assess the size of
the intracellular Ca2 stores, the area under the curve (AUC)
obtained after addition of 400 nM thapsigargin, which repre-
sents the total amount of Ca2 present in the rapidly releas-
able intracellular Ca2 stores, was also calculated.
Statistical Analysis
Statistical analysis was performed using Student t test for
paired samples or ANOVA when 2 groups were com-
pared. The Origin computer program (Microcal Software,
Northampton, MA) was used for statistical analysis and
dose-response curve generation. The AUC values were
calculated from the dose-response curves, whereas the 50%
effective concentration (EC50) and Rmax values were calcu-
lated from sigmoidal curve fitting of all data points. Results
are expressed as mean value (sem) of n results, where n is
the number of measurements.
Figure 2. Comparison of the resting [Ca2]i and of the thapsigargin-
induced Ca2 release in lymphoblastoid B cells from healthy controls
and 5 patients carrying the reported RYR1 candidate mutations. A, In
all cases, resting fluorescence was significantly higher (*P  10–11)
in patients’ cell lines compared with healthy controls. B, The
thapsigargin-induced Ca2 release measurements are given as area
under the curve (AUC) units; these were calculated by integrating the
differences of the fluorescence values (the peak ratio 340/380 nm
obtained after the addition of 400 nM thapsigargin  the resting
ratio 340/380 nm). All cell lines show the same magnitude of Ca2
content within the thapsigargin-sensitive intracellular Ca2 stores.
Fluorescence measurements were performed on fura-2–loaded cells
as described in the Methods section. Values are the mean (SEM) of
the indicated n independent measurements. P values were obtained
by performing the Student t test on values obtained from cells
carrying the indicated mutation compared with controls.
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RESULTS
After the sampling protocol as outlined in Methods section,
peripheral blood samples proved to be sufficiently stable
during transportation by ordinary mail at ambient tempera-
tures over a period of up to 6 days for RNA and DNA
extraction and establishment of lymphoblastoid B cell lines.
Genetic screening for the presence of RYR1mutations16 and
calcium measurements on B lymphocytes could success-
fully be performed on these samples.
We first examined the resting [Ca2]i of the B lympho-
cytes carrying the newly identified sequence variants and
compared it with the resting [Ca2]i of healthy controls
(Fig. 2). All cell lines carrying a candidate mutation showed
statistically significantly higher resting [Ca2]i compared
Figure 3. Dose-dependent 4-chloro-m-cresol–induced Ca2 release in lymphoblastoid B cells from control individuals and from patients carrying
candidate RYR1 mutations. A, Representative trace of the effect of 4-chloro-m-cresol on the [Ca2]i of B lymphoblastoid cells from a control
individual. Once the resting steady state was obtained, 600 M 4-chloro-m-cresol was added as indicated by the arrow. B, p.Glu1058Lys (solid
line) compared with control (dashed line). C, p.Arg1679His. D, p.His382Asn. E, p.Lys1393Arg. F, p.Arg2508Gly. Conditions as described in
Figure 2. The peak increase of the Ca2 transient, obtained after addition of a given concentration of 4-chloro-m-cresol on the linear part of
the fura-2 calcium-sensitive curve, was expressed as percentage of the peak Ca2 released by maximal concentrations (1000 M) of
4-chloro-m-cresol. Results are expressed as mean  SEM (n  4–9), where n indicates the number of independent measurements each
performed on 1.5  106 cells. Sigmoidal dose-response curves were generated using Origin software.
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with cell lines from healthy controls. However, the AUC
calculations of the Ca2 transient obtained after stimulating
the B lymphocytes with 400 nM thapsigargin were all
within the same range, irrespective of whether the cells
were obtained from controls or from individuals carrying
the indicated RYR1 candidate mutations (Fig. 2). These
results imply that none of the mutations affect the size of
the intracellular Ca2 stores in a way that could not be
compensated by the cells. Nevertheless, all the amino acid
substitutions affect Ca2 homeostasis because they cause a
small but significant increase in the resting Ca2, a result
that has been previously shown for B lymphocytes from
individuals with the MHS phenotype.15,19–21
We next determined whether the newly identified mu-
tations affect the sensitivity of Ca2 release induced by the
RYR1 agonist 4-chloro-m-cresol. Figure 3A shows the typi-
cal increase in cytoplasmic [Ca2]i obtained in control cells
after the addition of 600 M 4-chloro-m-cresol. The trace,
which represents the mean change in fluorescence of 1.5 
106 cells, shows that addition of the RYR1 agonist is
accompanied by a transient increase in the 340/380 nm
fluorescent ratio, which returns to resting levels within
about 10 minutes. We then constructed 4-chloro-m-cresol
dose-response curves by calculating the peak Ca2 released
by 4-chloro-m-cresol in a population (1.5  106 cells) of
fura-2–loaded lymphoblastoid B cells as a percentage of the
maximal amount that could be released by 1000 M
4-chloro-m-cresol. Results are given as means  sem. The
dose-response curves from the cell lines carrying each of
the candidate mutations showed a significant shift to the
left compared with the curves from the cell lines from
healthy controls. Table 2 shows the EC50 values for
4-chloro-m-cresol–induced Ca2 release.
DISCUSSION
In this study, we used a practical protocol to draw periph-
eral blood samples from MHS individuals at their local
primary care centers to screen and identify RYR1 variants
and to perform functional tests on the newly identified
candidate mutations. Blood samples were sent by ordinary
mail from different locations in Sweden to the laboratory in
Wu¨rzburg, Germany, from September to January, which is
autumn and winter in Northern Europe. Thus, the samples
were not exposed to extreme heat, which could have
compromised their viability.
Four of the substitutions described in the present report
were identified in MHS patients who had developed life-
threatening MH reactions during anesthesia (p.Glu1058Lys,
p.Arg1679His, p.His382Asn, and p.Lys1393Arg). None of
these substitutions have been reported in former patients. The
fifth substitution (p.Arg2508Gly), occurring in the patient
with CCD, has been identified before in a cohort of patients
with CCD from Japan.22
Patient 1 (p.Glu1058Lys) has shown signs of a mild
muscular disease (Appendix 1, see Supplemental Digital
Content 1, http://links.lww.com/AA/A61), but despite
intensive investigations, a definitive diagnosis has not been
established. Patients with myotonic muscle disease can
especially react to succinylcholine23 and thus one could
argue the reaction she experienced was not true MH.
However, her clinical reaction scores were high on the
Larach scale and she had symptoms that are not first line in
myotonic patients reacting to succinylcholine and inhala-
tion anesthetics.
In our previous study,16 the substitution p.Arg1679His
was found in 1 of 150 healthy anonymized German subjects
and p.Lys1393Arg in 1 of 100 Swedish subjects leaving the
possibility of rare polymorphisms. However, the population
prevalence of a genetic MH disposition has never been
studied. Therefore, these control subjects could likewise be as
yet unidentified MH carriers. Ideal controls would of course
be individuals with known IVCT status not MHS.
After the report by Sei et al.14 that B lymphocytes also
express a functional type 1 RYR, we and others have
exploited such a system to investigate the functional effect
of candidate mutations linked to MHS and CCD pheno-
types.15,18,20–22,24–27 These studies have revealed that most
MH-causing mutations disturb normal calcium homeostasis
by (1) shifting the sensitivity of pharmacologic RYR1 activa-
tion to lower agonist concentrations, and (2) by causing an
increase in the resting [Ca2]i.
15,20,21,24 Overall, the results
compared well with the IVCT data of the same subjects.
Likewise, the results of this study demonstrate a significant
alteration of intracellular Ca2 handling for all 5 candidate
mutations and compare well with other studies.28
Assessing Ca2 homeostasis in the immortalized B
lymphocyte system offers several advantages such as (1)
cells can be grown in large numbers, (2) are easy to handle,
and (3) can be assayed using a simple methodology such as
fluorimetric analysis of cells loadedwith the fluorescent Ca2
indicator fura-2 and stimulated with the RYR1 agonist
4-chloro-m-cresol. In this context, it should be emphasized
that this system is only useful for assessing RYR1 mutations
and not, for example, mutations found in the -1 subunit gene
encoding the DHPR, which has been found to harbor muta-
tions in a small number of MHS families29 because this
isoform of the voltage sensor is probably not expressed in B
lymphocytes. Furthermore, it has been estimated that up to
30% of MH families might not link to RYR1 and thus will not
benefit from this method.5,16
We conclude from our results that the RYR1 amino acid
substitutions studied are highly likely to be associated with
the MH status in these patients. According to the guidelines
of the European Malignant Hyperthermia Group,30 RYR1
mutations should only be regarded as causative of MH if
functional tests have been performed on tissues from at
Table 2. EC50 for 4-Chloro-m-Cresol (4-cmc)-
Induced Calcium Release from Immortalized B
Lymphoblastoid Cell Lines from Controls and
Patients with the Indicated RYR1 Candidate
Mutations
RYR1 mutant cell line EC50 4-cmc (M)
Control 717.8  65.0
p.Glu1058Lys 550.0  28.3*
p.Arg1679His 480.9  65.3*
p.His382Asn 615.9  52.2*
p.Lys1393Arg 435.7  27.5*
p.Arg2508Gly 501.3  39.3*
Results are means  SEM (of n experiments) compared with controls.
*P  0.05.
XXX 2010 • Volume X • Number X www.anesthesia-analgesia.org 5
least 2 unrelated individuals carrying the same candidate
mutation. This, however, is impeded by the rarity of most
RYR1 mutations.
We propose our protocol as a complementary approach
for the diagnosis of MH-suspected subjects living far away
from an MH diagnostic center.
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CHAPTER 3: GENERAL CONCLUSION AND 
PERSPECTIVES 
 
 
Calcium is as an important second messenger, directing cells in their response to different 
agonists. The cell in turn is equipped with a variety of proteins to decode the information 
contained within the Ca
2+
 signal, in order to respond to the different signals coming from 
the extracellular environment. In this thesis we identified novel aspects of Ca
2+
 signalling 
in dendritic cells. We not only show that DCs express functional RyR1s, important 
players in calcium homeostasis in excitable cells, but we also investigated the role of 
RyR1 in DC biology and the mechanism trough which this channel can be activated 
physiologically in these cells. Since the involvement of Ca
2+
 dependent events in DCs 
activation and maturation processes had been previously established, our first idea was to 
investigate downstream events induced by Ca
2+
 release by pharmacological stimulation 
of the RyR1. Our data demonstrate that activation of RyR1 in iDCs generates signals, 
which act in synergy with TLRs in promoting DC maturation.  Although DCs are not 
excitable cells they express the cardiac isoform of L-type Ca
2+
 channel on the plasma 
membrane and they use a Ca
2+
 induce Ca
2+
 release mechanism to activate Ca
2+
 release 
from the RyR1. One of the intriguing questions prompting our research was that since 
DCs as non-excitable cells why are they are equipped with such a machinery capable of 
responding to signals within milliseconds? The solution to this question may come from 
the following facts: DCs synthesize large quantities of MHC class II molecules which 
classically bind peptides derived from endocytosed proteins and present them on their 
surface for interaction with T cells in order to initiate a specific immune response. Those 
empty MHC II molecules are expressed on the surface as well as sequestered within 
intracellular compartments and these sequestered molecules apparently reside 
unproductively within the cell. We now propose a direct role of DHPR-RyR1 signalling 
in the rapid surface expression of MHC class II molecules. Since MHC II molecules are 
crucial for antigen presentation and thus for the activation of a specific immune response 
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we think that DHPR-RyR1 signalling in DCs is important for very early and rapid 
activation of the immune system. 
From our studies, several interesting points have emerged: firstly even if DCs are not 
excitable cells depolarizing the plasma membrane by addition of 100mM KCl leads to 
intracellular Ca
2+
 release. Thus plasma membrane depolarization in DCs could be a 
physiological route of DHPR-RyR1 activation in vivo. Secondly, since the main 
intracellular cation is potassium and by using necrotic cells extract we were able to 
activate DHPR-RyR1 signalling pathway, we postulate that cells dying within an 
inflamed tissue may release their K
+
 in the vicinity of DCs and so activate the DHPR-
RyR1 signalling pathway. Alternatively, if the interaction between T cells and DCs is 
strong enough, it can lead to activation of Ca
2+
 release from the intracellular stores of T 
cells and activation of Ca
2+
 influx. In T cells this is accompanied by efflux of K
+
 to 
repolarise the T cell membrane potential. This K
+
 could be released into the 
immunological synapse where molecules involved in cross signalling between T cells and 
DCs are concentrated and could be sensed by the DHPR on iDCs leading to activation of 
the RyR1 signalling pathway and bringing about the rapid release of MHC class II 
molecules onto the surface of iDCs. A schematic diagram outlining this hypothesis is 
depicted in (Fig.3-1). 
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Figure 3-1: Schematic diagram depicting the model of RyR1-dependent signalling 
pathways in DC. Local depolarization of dendritic cell plasma membrane and activation 
of DHPR-RyR1 signalling by local increases of K
+
 concentration released from dying 
cells or activated T cells into immunological synapse could cause the rapid release of re-
cycling MHC class II molecules on the surface of dendritic cells. 
 
A possible outlook from these results of the DHPR-RyR1 signalling pathway could be 
the development of drugs aimed at improving the immune system by increasing the 
efficiency of Ag presentation of DCs or at impairing the immune system in case of 
induction of autoimmune disorders. 
During our investigations of Ca
2+
 homeostasis in DCs we noticed that spontaneous 
oscillations of the intracellular Ca
2+
 are exhibited by immature DCs. In contrast DCs, 
which had undergone the maturation process had lost these high frequency oscillations. 
Since these events are exclusively connected with the immature phenotype we suggest 
that these fluctuations in intracellular Ca
2+
 may be involved in maintaining the cells in the 
immature stage. As to their biological role, our results indicate that they are associated 
with the translocation of the transcription factor NFAT into the nucleus. These results are 
important because they point out novel aspects of intracellular Ca
2+
 signalling in human 
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DC and may open new areas of research important to help patients requiring modulations 
of the immune system. 
 
The second part of my thesis focuses on the functional consequences of RYR1 mutations 
on Ca
2+
 homeostasis and the possible use of EBV-immortalized B-lymphocytes 
expressing endogenous RYR1 mutation linked to neuromuscular disorders to prove the 
functional effect of a mutation.  
Unfortunately, muscle biopsies are not always available or their size is not sufficient for 
both histological diagnosis and generation of cell lines. Since RyR1is also expressed in 
human B-lymphocytes we investigated whether EBV-immortalized B-lymphocytes could 
be used as a model system to study the functional impact of RYR1 mutations identified in 
patients with neuromuscular disorders. All the RYR1 mutations, which we functionally 
characterized in the present work, cause a significant increase of the resting Ca
2+
 
concentration underlying their probable causative pathological role. 
Furthermore the sensitivity of mutated RyR1 to pharmacological activation was increased 
in all mutations, also suggesting altered functional properties of these mutated RyR1. 
Thus the results from this study contribute to the establishment of a robust 
genetic/functional testing procedure for MH and we propose our protocol as a 
complementary approach for the diagnosis of MH.  
 
As an outlook from these studies, we may hypothesize that mutations in RYR1 associated 
with MH and CCD are also present in B-lymphocytes and DCs and one of the roles of 
these cells in the immune response is to release inflammatory cytokines thus one of the 
downstream events of RYR1 mutations may be on the levels of circulating cytokines 
which may ultimately be involved in the pathology of these diseases. Since activation of 
the RyR1 leads to release of IL-6 and IL-1 + IL-6 from muscle cells and B-cells, 
respectively and since mutation in RYR1 result in significantly different amounts of pro-
inflammatory cytokines released by B-lymphocytes and differentiated mytubes in vitro, it 
is possible that RYR1 mutations found in patients with CCD and MH may affect the 
amount of circulating pro-inflammatory cytokines without an underlining infection. One 
of our future aims and ongoing studies are to determine the levels of IL-1 and IL-6 in the 
 118 
serum of patients carrying RYR1 mutations. Our future work will also focus on the impact 
of RYR1 mutations on dendritic cell function and generally on the immune system. In 
order to study in greater detail the function of the RyR1 in cells of immune system, we 
think it is important to use an animal model in which a mutation linked to MH/CCD has 
been knocked-in.  
We think that the results of these future studies will show us if there is a gain of 
immunological function connected with RYR1 mutation. In addition such studies may 
provide answers if alterations of the immune function bears any role in the 
pathophysiology of ryanodinopathies. 
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